CLEVILAND ACADEM	Web
Last Name	KAISI
First Name	DE NADIA.
Specialty	Patholiesst
Party	Plaintiff
Date (format =99/99/9999)	10/28/03
Type of Document	Articles Depu
Type of Injury	hung cancer
Type of Case	medmal.
eDocument Name	(d/doe011501.pdf)



7/25/01

Hosted by The Nurenberg, Plevin Law Firm Copyright © 1999-2001 CATA

http://cata.nphm.com/database/add_doc_page.asp

in the second second

-24

約:

October 28, 2003

Page 1	Page 3
1 IN THE COURT OF COMMON PLEAS 2 OF CUYAHOGA COUNTY, OHIO	
2 OF CUYAHOGA COUNTY, OHIO	2 (Thereupon, KAISI Deposition
	3 Exhibits 1 and 2 were marked for
· · · · · · · · · · · · · · · · · · ·	4 purposes of identification.)
of the Estate of	5
5 DANIEL P. GILL, deceased,	6
6 Plaintiff,	
7 vs Case No. 457639	, , , ,
Judge Russo	8 for examination, as provided by the Ohio Rules
8	9 of Civil Procedure, being by me first duly
ROGER A. MANSNERUS, M.D.,	10 sworn, as hereinafter certified, was deposed and
9 et al.,	11 said as follows:
10 Defendants.	12 EXAMINATION OF NADIA KAISI, M.D.
	13 BY MR. MISHKIND:
12 DEPOSITION OF NADIA KAISI, M.D.	14 Q. Would you please state your name for
13 TUESDAY, OCTOBER 28, 2003	
14	15 the record.
15 Deposition of NADIA KAISI, M.D., a Witness	16 A. Nadia Kaisi, also known as Nadia
16 herein, called by counsel on behalf of the	17 Al-Kaisi, A-L-K-A-I-S-I.
17 Plaintiff for examination under the statute,	18 Q. Do you prefer to be referred to as
18 taken before me, Vivian L. Gordon, a Registered	19 Dr. Kaisi or Dr. Al-Kaisi?
19 Diplomate Reporter and Notary Public in and for	20 A. Kaisi is fine,
20 the State of Ohio, pursuant to agreement of	21 Q. Dr. Kaisi?
21 counsel, at the offices of Parma Community	
22 General Hospital, 7007 Powers Avenue, Parma,	
23 Ohio, commencing at 1:30 o'clock p.m. on the day	23 Q. You are a pathologist; is that
24 and date above set forth.	24 correct?
25	25 A. Yes.
Page 2	Page 4
	Page 4
1 APPEARANCES:	1 Q. You have been identified as an expert
1 APPEARANCES: 2 On behalf of the Plaintiff	-
1 APPEARANCES: 2 On behalf of the Plaintiff 3 Becker & Mishkind	1 Q. You have been identified as an expert
1 APPEARANCES: 2 On behalf of the Plaintiff	1 Q. You have been identified as an expert 2 on behalf of Dr. Mansnerus and that's why I am 3 here to talk with you today. You understand
1 APPEARANCES: 2 On behalf of the Plaintiff 3 Becker & Mishkind 4 HOWARD D. MISHKIND, ESQ.	1 Q. You have been identified as an expert 2 on behalf of Dr. Mansnerus and that's why I am 3 here to talk with you today. You understand 4 that, don't you?
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes.
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes. Q. Have you had your deposition taken
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes. Q. Have you had your deposition taken 7 before?
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 241-2600 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes. Q. Have you had your deposition taken before? A. Yes.
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 241-2600 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes. Q. Have you had your deposition taken before? A. Yes. Q. Tell me how many times.
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 241-2600 On behalf of the Defendant 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes. Q. Have you had your deposition taken before? A. Yes. Q. Tell me how many times. A. Probably 12, 15 times.
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 241-2600 On behalf of the Defendant Reminger & Reminger 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes. Q. Have you had your deposition taken before? A. Yes. Q. Tell me how many times. A. Probably 12, 15 times. Q. So you generally know the routine in
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 241-2600 On behalf of the Defendant Reminger & Reminger ROBERT D. WARNER, ESQ. 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes. Q. Have you had your deposition taken before? A. Yes. Q. Tell me how many times. A. Probably 12, 15 times. Q. So you generally know the routine in
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 241-2600 On behalf of the Defendant Reminger & Reminger ROBERT D. WARNER, ESQ. 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes. Q. Have you had your deposition taken before? A. Yes. Q. Tell me how many times. A. Probably 12, 15 times. Q. So you generally know the routine in terms of I'm going to be asking you questions
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 241-2600 On behalf of the Defendant Reminger & Reminger ROBERT D. WARNER, ESQ. 1400 Midland Building 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes. Q. Have you had your deposition taken before? A. Yes. Q. Tell me how many times. A. Probably 12, 15 times. Q. So you generally know the routine in terms of I'm going to be asking you questions about your background and questions about your
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 241-2600 On behalf of the Defendant Reminger & Reminger ROBERT D. WARNER, ESQ. 1400 Midland Building Cleveland, Ohio 44115 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes. Q. Have you had your deposition taken before? A. Yes. Q. Tell me how many times. A. Probably 12, 15 times. Q. So you generally know the routine in terms of I'm going to be asking you questions about your background and questions about your opinions that you hold in this case. Do you
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 241-2600 On behalf of the Defendant Reminger & Reminger ROBERT D. WARNER, ESQ. 1400 Midland Building Cleveland, Ohio 44115 687-1311 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes. Q. Have you had your deposition taken before? A. Yes. Q. Tell me how many times. A. Probably 12, 15 times. Q. So you generally know the routine in terms of I'm going to be asking you questions about your background and questions about your opinions that you hold in this case. Do you understand that?
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 241-2600 On behalf of the Defendant Reminger & Reminger ROBERT D. WARNER, ESQ. 1400 Midland Building Cleveland, Ohio 44115 687-1311 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes. Q. Have you had your deposition taken before? A. Yes. Q. Tell me how many times. A. Probably 12, 15 times. A. Probably 12, 15 times. G. So you generally know the routine in terms of I'm going to be asking you questions about your background and questions about your opinions that you hold in this case. Do you understand that? A. Yes.
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 241-2600 On behalf of the Defendant Reminger & Reminger ROBERT D. WARNER, ESQ. 1400 Midland Building Cleveland, Ohio 44115 687-1311 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes. Q. Have you had your deposition taken before? A. Yes. Q. Tell me how many times. A. Probably 12, 15 times. A. Probably 12, 15 times. G. So you generally know the routine in terms of I'm going to be asking you questions about your background and questions about your opinions that you hold in this case. Do you understand that? A. Yes. Q. Even though you have had your
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 241-2600 On behalf of the Defendant Reminger & Reminger ROBERT D. WARNER, ESQ. 1400 Midland Building Cleveland, Ohio 44115 687-1311 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes. Q. Have you had your deposition taken before? A. Yes. Q. Tell me how many times. A. Probably 12, 15 times. A. Probably 12, 15 times. G. So you generally know the routine in terms of I'm going to be asking you questions about your background and questions about your opinions that you hold in this case. Do you understand that? A. Yes. Q. Even though you have had your deposition taken 12 to 15 times before, you and
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 241-2600 On behalf of the Defendant Reminger & Reminger ROBERT D. WARNER, ESQ. 1400 Midland Building Cleveland, Ohio 44115 687-1311 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes. Q. Have you had your deposition taken before? A. Yes. Q. Tell me how many times. A. Probably 12, 15 times. A. Probably 12, 15 times. Q. So you generally know the routine in terms of I'm going to be asking you questions about your background and questions about your opinions that you hold in this case. Do you understand that? A. Yes. Q. Even though you have had your
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 241-2600 On behalf of the Defendant Reminger & Reminger ROBERT D. WARNER, ESQ. 1400 Midland Building Cleveland, Ohio 44115 687-1311 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes. Q. Have you had your deposition taken before? A. Yes. Q. Tell me how many times. A. Probably 12, 15 times. A. Probably 12, 15 times. G. So you generally know the routine in terms of I'm going to be asking you questions about your background and questions about your opinions that you hold in this case. Do you understand that? A. Yes. Q. Even though you have had your deposition taken 12 to 15 times before, you and
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 241-2600 On behalf of the Defendant Reminger & Reminger ROBERT D. WARNER, ESQ. 1400 Midland Building Cleveland, Ohio 44115 687-1311 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes. Q. Have you had your deposition taken before? A. Yes. Q. Tell me how many times. A. Probably 12, 15 times. A. Probably 12, 15 times. G. So you generally know the routine in terms of I'm going to be asking you questions about your background and questions about your opinions that you hold in this case. Do you understand that? A. Yes. Q. Even though you have had your deposition taken 12 to 15 times before, you and I have never met; correct? A. Right.
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 241-2600 On behalf of the Defendant Reminger & Reminger ROBERT D. WARNER, ESQ. 1400 Midland Building Cleveland, Ohio 44115 687-1311 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes. Q. Have you had your deposition taken before? A. Yes. Q. Tell me how many times. A. Probably 12, 15 times. A. Probably 12, 15 times. Q. So you generally know the routine in terms of I'm going to be asking you questions about your background and questions about your opinions that you hold in this case. Do you understand that? A. Yes. Q. Even though you have had your deposition taken 12 to 15 times before, you and I have never met; correct? A. Right. Q. Let me just give you a couple
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 241-2600 On behalf of the Defendant Reminger & Reminger ROBERT D. WARNER, ESQ. 1400 Midland Building Cleveland, Ohio 44115 687-1311 687-1311 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes. Q. Have you had your deposition taken before? A. Yes. Q. Tell me how many times. A. Probably 12, 15 times. A. Probably 12, 15 times. Q. So you generally know the routine in terms of I'm going to be asking you questions about your background and questions about your opinions that you hold in this case. Do you understand that? A. Yes. Q. Even though you have had your deposition taken 12 to 15 times before, you and I have never met; correct? A. Right. Q. Let me just give you a couple precautions so that we can try to move the
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 241-2600 On behalf of the Defendant Reminger & Reminger ROBERT D. WARNER, ESQ. 1400 Midland Building Cleveland, Ohio 44115 687-1311 687-1311 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes. Q. Have you had your deposition taken before? A. Yes. Q. Tell me how many times. A. Probably 12, 15 times. A. Probably 12, 15 times. Q. So you generally know the routine in terms of I'm going to be asking you questions about your background and questions about your opinions that you hold in this case. Do you understand that? A. Yes. Q. Even though you have had your deposition taken 12 to 15 times before, you and I have never met; correct? A. Right. Q. Let me just give you a couple precautions so that we can try to move the deposition along as smoothly as possible.
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 241-2600 On behalf of the Defendant Reminger & Reminger ROBERT D. WARNER, ESQ. 1400 Midland Building Cleveland, Ohio 44115 687-1311 687-1311 	1Q. You have been identified as an expert2on behalf of Dr. Mansnerus and that's why I am3here to talk with you today. You understand4that, don't you?5A. Yes.6Q. Have you had your deposition taken7before?8A. Yes.9Q. Tell me how many times.10A. Probably 12, 15 times.11Q. So you generally know the routine in12terms of I'm going to be asking you questions13about your background and questions about your14opinions that you hold in this case. Do you15understand that?16A. Yes.17Q. Even though you have had your18deposition taken 12 to 15 times before, you and19I have never met; correct?20A. Right.21Q. Let me just give you a couple22precautions so that we can try to move the23deposition along as smoothly as possible.24I'll wait until you are done with an
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 241-2600 On behalf of the Defendant Reminger & Reminger ROBERT D. WARNER, ESQ. 1400 Midland Building Cleveland, Ohio 44115 687-1311 687-1311 	 Q. You have been identified as an expert on behalf of Dr. Mansnerus and that's why I am here to talk with you today. You understand that, don't you? A. Yes. Q. Have you had your deposition taken before? A. Yes. Q. Tell me how many times. A. Probably 12, 15 times. A. Probably 12, 15 times. Q. So you generally know the routine in terms of I'm going to be asking you questions about your background and questions about your opinions that you hold in this case. Do you understand that? A. Yes. Q. Even though you have had your deposition taken 12 to 15 times before, you and I have never met; correct? A. Right. Q. Let me just give you a couple precautions so that we can try to move the deposition along as smoothly as possible.
 APPEARANCES: On behalf of the Plaintiff Becker & Mishkind HOWARD D. MISHKIND, ESQ. Skylight Office Tower Suite 660 1220 W. 2nd Street Cleveland, Ohio 44113 241-2600 On behalf of the Defendant Reminger & Reminger ROBERT D. WARNER, ESQ. 1400 Midland Building Cleveland, Ohio 44115 687-1311 687-1311 	1Q. You have been identified as an expert2on behalf of Dr. Mansnerus and that's why I am3here to talk with you today. You understand4that, don't you?5A. Yes.6Q. Have you had your deposition taken7before?8A. Yes.9Q. Tell me how many times.10A. Probably 12, 15 times.11Q. So you generally know the routine in12terms of I'm going to be asking you questions13about your background and questions about your14opinions that you hold in this case. Do you15understand that?16A. Yes.17Q. Even though you have had your18deposition taken 12 to 15 times before, you and19I have never met; correct?20A. Right.21Q. Let me just give you a couple22precautions so that we can try to move the23deposition along as smoothly as possible.24I'll wait until you are done with an

1 (Pages 1 to 4)

Page 5	Dage 7
raye J	Page 7
1 Also, wait until I am done with my question	1 report on my computer, on my PC. These are the
2 before you start answering it so that we aren't	2 notes that I have made.
3 overlapping each other, okay?	3 Q. That was going to be my next question
4 A. Okay. 5 Q. Occasionally Mr. Warner may object to	4 as to whether or not the report, which is
5 Q. Occasionally Mr. Warner may object to 6 a question. The court reporter will take the	5 Exhibit 2, whether that was typed by yourself or6 whether you had someone else do it for you?
7 objection down, but that doesn't mean that you	7 A. I usually type my reports.
8 then won't proceed to answer the question. But	8 Q. And in this case, did you prepare the
9 if he objects to a question, wait until he	9 report yourself?
10 finishes his objection and then go ahead and	10 A. Yes.
11 answer the question, okay?	11 Q. So as you reviewed the case, you
12 A. Okay.	12 prepared your report. Was it a work in progress
13 Q. If you don't understand my question,	13 or did you review the entire case and then
14 tell me that you don't understand. I'll try to	14 prepare the report?
15 rephrase it or I'll have Vivian read it back to	15 A. I think I reviewed all the documents
16 you. Is that fair, as well?	16 that I refer to in my report and then typed the
17 A. Yes. 18 Q. I have had marked as an exhibit	17 report.
19 Q. Thave had marked as an exhibit 19 Plaintiff's Exhibit 2 with your name on it and	18 Q. Can you tell me from looking at your 19 report when it was that you prepared this
20 I'm going to hand this to you.	19 report when it was that you prepared this 20 report?
21 Is this, in fact, the report that you	21 A. I just noticed that the date was
22 authored to Mr. Warner in connection with your	22 missing here, so
23 opinions in this case?	23 MR. WARNER: Objection. There is a
24 A. Yes.	24 date at the bottom.
25 Q. Is this the only report that you have	25 A. January 9th, 2003.
Page 6	Page 8
Page 6	-
 authored in this case? A. Yes. Q. In looking through the material that 	1 Q. Do you know what that January 9, 2003
 authored in this case? A. Yes. Q. In looking through the material that you have with you today, I do not see any notes 	 Q. Do you know what that January 9, 2003 represents? A. Probably a fax. I usually fax my reports and then follow up with a signed copy in
 authored in this case? A. Yes. Q. In looking through the material that you have with you today, I do not see any notes written 	 Q. Do you know what that January 9, 2003 represents? A. Probably a fax. I usually fax my reports and then follow up with a signed copy in the mail. So it's probably the day I faxed it
 authored in this case? A. Yes. Q. In looking through the material that you have with you today, I do not see any notes written (Telephone interruption.) 	 Q. Do you know what that January 9, 2003 represents? A. Probably a fax. I usually fax my reports and then follow up with a signed copy in the mail. So it's probably the day I faxed it to Mr. Warner's office.
 authored in this case? A. Yes. Q. In looking through the material that you have with you today, I do not see any notes written (Telephone interruption.) Q. In looking through your file or the 	 Q. Do you know what that January 9, 2003 represents? A. Probably a fax. I usually fax my reports and then follow up with a signed copy in the mail. So it's probably the day I faxed it to Mr. Warner's office. Q. And again, understand, this is my
 authored in this case? A. Yes. Q. In looking through the material that you have with you today, I do not see any notes written (Telephone interruption.) Q. In looking through your file or the material that you have with you, I do not see 	 Q. Do you know what that January 9, 2003 represents? A. Probably a fax. I usually fax my reports and then follow up with a signed copy in the mail. So it's probably the day I faxed it to Mr. Warner's office. Q. And again, understand, this is my only opportunity to talk to you before you
 authored in this case? A. Yes. Q. In looking through the material that you have with you today, I do not see any notes written (Telephone interruption.) Q. In looking through your file or the material that you have with you, I do not see any written notes or any typed notes. Was my 	 Q. Do you know what that January 9, 2003 represents? A. Probably a fax. I usually fax my reports and then follow up with a signed copy in the mail. So it's probably the day I faxed it to Mr. Warner's office. Q. And again, understand, this is my only opportunity to talk to you before you testify. I just want to make certain that, is
 authored in this case? A. Yes. Q. In looking through the material that you have with you today, I do not see any notes written (Telephone interruption.) Q. In looking through your file or the material that you have with you, I do not see any written notes or any typed notes. Was my perusal of your file accurate in terms of there 	 Q. Do you know what that January 9, 2003 represents? A. Probably a fax. I usually fax my reports and then follow up with a signed copy in the mail. So it's probably the day I faxed it to Mr. Warner's office. Q. And again, understand, this is my only opportunity to talk to you before you testify. I just want to make certain that, is it your testimony that that stamp on the bottom
 authored in this case? A. Yes. Q. In looking through the material that you have with you today, I do not see any notes written (Telephone interruption.) Q. In looking through your file or the material that you have with you, I do not see any written notes or any typed notes. Was my 	 Q. Do you know what that January 9, 2003 represents? A. Probably a fax. I usually fax my reports and then follow up with a signed copy in the mail. So it's probably the day I faxed it to Mr. Warner's office. Q. And again, understand, this is my only opportunity to talk to you before you testify. I just want to make certain that, is it your testimony that that stamp on the bottom of the report in the lower left-hand corner was
 authored in this case? A. Yes. Q. In looking through the material that you have with you today, I do not see any notes written (Telephone interruption.) Q. In looking through your file or the material that you have with you, I do not see any written notes or any typed notes. Was my perusal of your file accurate in terms of there not being any notes? 	 Q. Do you know what that January 9, 2003 represents? A. Probably a fax. I usually fax my reports and then follow up with a signed copy in the mail. So it's probably the day I faxed it to Mr. Warner's office. Q. And again, understand, this is my only opportunity to talk to you before you testify. I just want to make certain that, is it your testimony that that stamp on the bottom of the report in the lower left-hand corner was placed by you as opposed to perhaps someone at
 authored in this case? A. Yes. Q. In looking through the material that you have with you today, I do not see any notes written (Telephone interruption.) Q. In looking through your file or the material that you have with you, I do not see any written notes or any typed notes. Was my perusal of your file accurate in terms of there not being any notes? A. That's correct. (Telephone interruption.) Q. Let's try that one more time. Am I 	 Q. Do you know what that January 9, 2003 represents? A. Probably a fax. I usually fax my reports and then follow up with a signed copy in the mail. So it's probably the day I faxed it to Mr. Warner's office. Q. And again, understand, this is my only opportunity to talk to you before you testify. I just want to make certain that, is it your testimony that that stamp on the bottom of the report in the lower left-hand corner was placed by you as opposed to perhaps someone at Mr. Warner's office?
 authored in this case? A. Yes. Q. In looking through the material that you have with you today, I do not see any notes written (Telephone interruption.) Q. In looking through your file or the material that you have with you, I do not see any written notes or any typed notes. Was my perusal of your file accurate in terms of there not being any notes? A. That's correct. (Telephone interruption.) Q. Let's try that one more time. Am I correct in my statement that there aren't any 	 Q. Do you know what that January 9, 2003 represents? A. Probably a fax. I usually fax my reports and then follow up with a signed copy in the mail. So it's probably the day I faxed it to Mr. Warner's office. Q. And again, understand, this is my only opportunity to talk to you before you testify. I just want to make certain that, is it your testimony that that stamp on the bottom of the report in the lower left-hand corner was placed by you as opposed to perhaps someone at Mr. Warner's office?
 authored in this case? A. Yes. Q. In looking through the material that you have with you today, I do not see any notes written (Telephone interruption.) Q. In looking through your file or the material that you have with you, I do not see any written notes or any typed notes. Was my perusal of your file accurate in terms of there not being any notes? A. That's correct. (Telephone interruption.) Q. Let's try that one more time. Am I correct in my statement that there aren't any written or typed notes in the file? 	 Q. Do you know what that January 9, 2003 represents? A. Probably a fax. I usually fax my reports and then follow up with a signed copy in the mail. So it's probably the day I faxed it to Mr. Warner's office. Q. And again, understand, this is my only opportunity to talk to you before you testify. I just want to make certain that, is it your testimony that that stamp on the bottom of the report in the lower left-hand corner was placed by you as opposed to perhaps someone at Mr. Warner's office? A. I did not place that stamp. Q. Do you know who placed that stamp? A. No.
 authored in this case? A. Yes. Q. In looking through the material that you have with you today, I do not see any notes written (Telephone interruption.) Q. In looking through your file or the material that you have with you, I do not see any written notes or any typed notes. Was my perusal of your file accurate in terms of there not being any notes? A. That's correct. (Telephone interruption.) Q. Let's try that one more time. Am I correct in my statement that there aren't any written or typed notes in the file? A. That's correct. 	 Q. Do you know what that January 9, 2003 represents? A. Probably a fax. I usually fax my reports and then follow up with a signed copy in the mail. So it's probably the day I faxed it to Mr. Warner's office. Q. And again, understand, this is my only opportunity to talk to you before you testify. I just want to make certain that, is it your testimony that that stamp on the bottom of the report in the lower left-hand corner was placed by you as opposed to perhaps someone at Mr. Warner's office? A. I did not place that stamp. Q. Do you know who placed that stamp? A. No. Q. And there is nowhere on this report
 authored in this case? A. Yes. Q. In looking through the material that you have with you today, I do not see any notes written (Telephone interruption.) Q. In looking through your file or the material that you have with you, I do not see any written notes or any typed notes. Was my perusal of your file accurate in terms of there not being any notes? A. That's correct. (Telephone interruption.) Q. Let's try that one more time. Am I correct in my statement that there aren't any written or typed notes in the file? A. That's correct. Q. Did you at the time that you reviewed 	 Q. Do you know what that January 9, 2003 represents? A. Probably a fax. I usually fax my reports and then follow up with a signed copy in the mail. So it's probably the day I faxed it to Mr. Warner's office. Q. And again, understand, this is my only opportunity to talk to you before you testify. I just want to make certain that, is it your testimony that that stamp on the bottom of the report in the lower left-hand corner was placed by you as opposed to perhaps someone at Mr. Warner's office? A. I did not place that stamp. Q. Do you know who placed that stamp? A. No. Q. And there is nowhere on this report indicating the date that it was faxed, if, in
 authored in this case? A. Yes. Q. In looking through the material that you have with you today, I do not see any notes written (Telephone interruption.) Q. In looking through your file or the material that you have with you, I do not see any written notes or any typed notes. Was my perusal of your file accurate in terms of there not being any notes? A. That's correct. (Telephone interruption.) Q. Let's try that one more time. Am I correct in my statement that there aren't any written or typed notes in the file? A. That's correct. Q. Did you at the time that you reviewed the case make any notes? 	 Q. Do you know what that January 9, 2003 represents? A. Probably a fax. I usually fax my reports and then follow up with a signed copy in the mail. So it's probably the day I faxed it to Mr. Warner's office. Q. And again, understand, this is my only opportunity to talk to you before you testify. I just want to make certain that, is it your testimony that that stamp on the bottom of the report in the lower left-hand corner was placed by you as opposed to perhaps someone at Mr. Warner's office? A. I did not place that stamp. Q. Do you know who placed that stamp? A. No. Q. And there is nowhere on this report indicating the date that it was faxed, if, in fact, it was faxed to Mr. Warner; correct?
 authored in this case? A. Yes. Q. In looking through the material that you have with you today, I do not see any notes written (Telephone interruption.) Q. In looking through your file or the material that you have with you, I do not see any written notes or any typed notes. Was my perusal of your file accurate in terms of there not being any notes? A. That's correct. (Telephone interruption.) Q. Let's try that one more time. Am I correct in my statement that there aren't any written or typed notes in the file? A. That's correct. Q. Did you at the time that you reviewed the case make any notes? A. No, I don't believe so. 	 Q. Do you know what that January 9, 2003 represents? A. Probably a fax. I usually fax my reports and then follow up with a signed copy in the mail. So it's probably the day I faxed it to Mr. Warner's office. Q. And again, understand, this is my only opportunity to talk to you before you testify. I just want to make certain that, is it your testimony that that stamp on the bottom of the report in the lower left-hand corner was placed by you as opposed to perhaps someone at Mr. Warner's office? A. I did not place that stamp. Q. Do you know who placed that stamp? A. No. Q. And there is nowhere on this report indicating the date that it was faxed, if, in fact, it was faxed to Mr. Warner; correct? A. That's correct. Unless this is the
 authored in this case? A. Yes. Q. In looking through the material that you have with you today, I do not see any notes written (Telephone interruption.) Q. In looking through your file or the material that you have with you, I do not see any written notes or any typed notes. Was my perusal of your file accurate in terms of there not being any notes? A. That's correct. (Telephone interruption.) Q. Let's try that one more time. Am I correct in my statement that there aren't any written or typed notes in the file? A. That's correct. Q. Did you at the time that you reviewed the case make any notes? A. No, I don't believe so. When you say you don't believe so, 	 Q. Do you know what that January 9, 2003 represents? A. Probably a fax. I usually fax my reports and then follow up with a signed copy in the mail. So it's probably the day I faxed it to Mr. Warner's office. Q. And again, understand, this is my only opportunity to talk to you before you testify. I just want to make certain that, is it your testimony that that stamp on the bottom of the report in the lower left-hand corner was placed by you as opposed to perhaps someone at Mr. Warner's office? A. I did not place that stamp. Q. Do you know who placed that stamp? A. No. Q. And there is nowhere on this report indicating the date that it was faxed, if, in faxed stamp, you know, when you fax that report,
 authored in this case? A. Yes. Q. In looking through the material that you have with you today, I do not see any notes written (Telephone interruption.) Q. In looking through your file or the material that you have with you, I do not see any written notes or any typed notes. Was my perusal of your file accurate in terms of there not being any notes? A. That's correct. (Telephone interruption.) Q. Let's try that one more time. Am I correct in my statement that there aren't any written or typed notes in the file? A. That's correct. Q. Did you at the time that you reviewed the case make any notes? A. No, I don't believe so. When you say you don't believe so, just in fairness to you, I want to make certain 	 Q. Do you know what that January 9, 2003 represents? A. Probably a fax. I usually fax my reports and then follow up with a signed copy in the mail. So it's probably the day I faxed it to Mr. Warner's office. Q. And again, understand, this is my only opportunity to talk to you before you testify. I just want to make certain that, is it your testimony that that stamp on the bottom of the report in the lower left-hand corner was placed by you as opposed to perhaps someone at Mr. Warner's office? A. I did not place that stamp. Q. Do you know who placed that stamp? A. No. Q. And there is nowhere on this report indicating the date that it was faxed, if, in faxed stamp, you know, when you fax that report, when you fax a paper, then it usually prints on
 authored in this case? A. Yes. Q. In looking through the material that you have with you today, I do not see any notes written (Telephone interruption.) Q. In looking through your file or the material that you have with you, I do not see any written notes or any typed notes. Was my perusal of your file accurate in terms of there not being any notes? A. That's correct. (Telephone interruption.) Q. Let's try that one more time. Am I correct in my statement that there aren't any written or typed notes in the file? A. That's correct. Q. Did you at the time that you reviewed the case make any notes? A. No, I don't believe so. Q. When you say you don't believe so, just in fairness to you, I want to make certain that your answer is unequivocal in terms of I 	 Q. Do you know what that January 9, 2003 represents? A. Probably a fax. I usually fax my reports and then follow up with a signed copy in the mail. So it's probably the day I faxed it to Mr. Warner's office. Q. And again, understand, this is my only opportunity to talk to you before you testify. I just want to make certain that, is it your testimony that that stamp on the bottom of the report in the lower left-hand corner was placed by you as opposed to perhaps someone at Mr. Warner's office? A. I did not place that stamp. Q. Do you know who placed that stamp? A. No. Q. And there is nowhere on this report indicating the date that it was faxed, if, in faxed stamp, you know, when you fax that report, when you fax a paper, then it usually prints on the report.
 authored in this case? A. Yes. Q. In looking through the material that you have with you today, I do not see any notes written (Telephone interruption.) Q. In looking through your file or the material that you have with you, I do not see any written notes or any typed notes. Was my perusal of your file accurate in terms of there not being any notes? A. That's correct. (Telephone interruption.) Q. Let's try that one more time. Am I correct in my statement that there aren't any written or typed notes in the file? A. That's correct. Q. Did you at the time that you reviewed the case make any notes? A. No, I don't believe so. Q. When you say you don't believe so, just in fairness to you, I want to make certain 	 Q. Do you know what that January 9, 2003 represents? A. Probably a fax. I usually fax my reports and then follow up with a signed copy in the mail. So it's probably the day I faxed it to Mr. Warner's office. Q. And again, understand, this is my only opportunity to talk to you before you testify. I just want to make certain that, is it your testimony that that stamp on the bottom of the report in the lower left-hand corner was placed by you as opposed to perhaps someone at Mr. Warner's office? A. I did not place that stamp. Q. Do you know who placed that stamp? A. No. Q. And there is nowhere on this report indicating the date that it was faxed, if, in faxed stamp, you know, when you fax that report, when you fax a paper, then it usually prints on the report. Q. You are guessing that that's the fax
 authored in this case? A. Yes. Q. In looking through the material that you have with you today, I do not see any notes written (Telephone interruption.) Q. In looking through your file or the material that you have with you, I do not see any written notes or any typed notes. Was my perusal of your file accurate in terms of there not being any notes? A. That's correct. (Telephone interruption.) Q. Let's try that one more time. Am I correct in my statement that there aren't any written or typed notes in the file? A. That's correct. Q. Did you at the time that you reviewed the case make any notes? A. No, I don't believe so. Q. When you say you don't believe so, just in fairness to you, I want to make certain that your answer is unequivocal in terms of I 	 Q. Do you know what that January 9, 2003 represents? A. Probably a fax. I usually fax my reports and then follow up with a signed copy in the mail. So it's probably the day I faxed it to Mr. Warner's office. Q. And again, understand, this is my only opportunity to talk to you before you testify. I just want to make certain that, is it your testimony that that stamp on the bottom of the report in the lower left-hand corner was placed by you as opposed to perhaps someone at Mr. Warner's office? A. I did not place that stamp. Q. Do you know who placed that stamp? A. No. Q. And there is nowhere on this report indicating the date that it was faxed, if, in faxed stamp, you know, when you fax that report, when you fax a paper, then it usually prints on the report. Q. You are guessing that that's the fax

2 (Pages 5 to 8)

October 28, 2003

Page 9	Page 11
 A. Yes. Q. In fact, you don't know what that date of January 9, 2003 represents; true? A. That's true. Q. And as you look at this report, recognizing that there is no date on this report, are you able to tell me when this report was prepared? A. I can from looking at the records, if you want me to go into these letters that Mr. Warner had sent me. Q. Well, let me ask you this. You received some material from Mr. Warner before preparing this report; correct? A. Yes. Q. And the material that you received from Mr. Warner before preparing this report came with a cover letter; true? A. Yes. Q. And that cover letter was dated what? A. December 19th, 2002. Q. So can we agree that you didn't prepare your report before December 19th, 2002? A. Yes. Q. Is the material that you reviewed for 	 sending it to Mr. Warner, it appears as if you received some additional material; true? A. Yes. Q. Did any of that additional material from the standpoint of your opinions in this case have any significance? A. As to my report and my opinions that I expressed in my report? Q. Yes. A. I don't think so. Q. And just for the record, is it fair to say that the material that you received after preparing your report, that the material that you received were depositions? A. Yes. Q. And it appears as if you received That's true. Q. It appears as if you have received why don't you tell me which depositions you received. Maybe it would be easier. A. Dr. Levitan's deposition, and Dr. Steele's deposition. Q. Did you read each of those
Page 10 1 purposes of your report referenced in your 2 undated report, which is Exhibit 2? 3 A. Yes. I think the first letter I 4 received from Mr. Warner was December 9th, which 5 accompanied the slides, the glass slides. 6 Q. Okay. 7 A. And that's what I usually do is I 8 review the slides before I review any of the 9 medical records. 10 And then the second cover letter was 11 dated December 19th from Mr. Warner which 12 accompanied the medical records and the reports, 13 the expert witness reports, which I reviewed 14 after that, and my report was sometime after the 15 review of the medical records. 16 Q. But suffice if to say, you don't know 17 exactly when you prepared your report; correct? 18 A. That's correct. 19 Q. Do you normally put a date on your 20 reports? 21 A. Yes. 22 Q. In this case, is it fair to say that 23 you just don't know why the date was omitted? 24 A. I think It was an oversight. 25 Q. After preparing this report and	 Page 12 depositions from cover to cover? A. No, I did not read them from cover to cover. Q. Did you read them sufficiently enough that you are familiar with what those doctors said in their depositions? A. Yes, I think so. Q. But you made no notes; true? A. That's true. Q. When is the last time you reviewed this material prior to us getting together today? A. I think it was at the time I received the depositions. Q. Other than the depositions that you have identified and the material that is referenced in Exhibit 2, which includes the slides, have you reviewed any other material in connection with this case, ma'am? A. No. Q. As you sit here right now, do you anticipate reviewing any other material prior to testifying that you believe to be relevant or material to the opinions that you intend to provide in this case?

3 (Pages 9 to 12)

	Page 13		Page 15
	_		
1	A. Not unless Mr. Warner provides me		Q. Tell me the names of the other two full time.
2 3	with additional material.	2 3	
4	Q. As you sit here right now, do you have any understanding that Mr. Warner is	2 4	A. Edward Cottle, C-O-T-T-L-E, and Angelina Bautista, B-A-U-T-I-S-T-A. These are
5	intending to provide you with any additional	5	the two full-time pathologists.
6	material?	6	Q. And the other one that is short.
7	A. No.	7	A. Caroline Steinetz, S-T-E-I-N-E-T-Z.
8	Q. In looking at your report, it appears	8	Q. Do all three and a half of you work
9	as if you do not intend to provide opinions with	9	exclusively at Parma?
10	regard to Dr. Mansnerus' care of Mr. Gill; is	10	A. No. The three of us work exclusively
11	that true?	11	at Parma, but Dr. Steinetz works at other
12	A. That's correct.	12	hospitals, as well; mostly Marymount and Parma.
13	Q. So you won't be taking the stand and	13	Sometimes at UH, as well.
14	saying that you have an opinion that	14	Q. You are not board certified in
15	Dr. Mansnerus complied with the standard of	15	internal medicine; true?
16	care; true?	16	A. True.
17	A. That's true.	17	Q. You are not board certified in
18	Q. Your focus is with regard to the	18	oncology; correct?
19 20	issue of staging of the lung cancer and	19	A. Correct.
20	providing potential opinions as relate to any	20	Q. You don't hold yourself out as an
22	alteration in the outcome of this case; is that a fair statement?	21 22	expert in the area of oncology; correct?
23	A. Yes.	23	A. As it relates to pathology. Part of pathology is related to oncology, but not as a
24	Q. And obviously we are going to talk	24	
25	about those opinions shortly.	25	Q. So you are looking at slides or other
	about those opinions storay.		c. so you are looking as sides of outer
	Page 14		Page 16
	Page 14		Page 16
1	Exhibit 1 is your CV; is that true?	1	specimens from the standpoint of evaluating
2	Exhibit 1 is your CV; is that true? A. Yes.	2	specimens from the standpoint of evaluating staging and assisting potentially with treatment
2 3	Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few	2 3	specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating
2 3 4	Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few background questions and then some specifics	2 3 4	specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating cancer patients?
2 3 4 5	Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few background questions and then some specifics about your CV for a few minutes.	2 3 4 5	specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating cancer patients? A. Well, I do not see cancer patients
2 3 4	Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few background questions and then some specifics about your CV for a few minutes. We are here at Parma Hospital today.	2 3 4 5 6	specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating cancer patients? A. Well, I do not see cancer patients routinely, if that's your question.
2 3 4 5 6	Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few background questions and then some specifics about your CV for a few minutes. We are here at Parma Hospital today. What is your position here at the hospital?	2 3 4 5 6 7	specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating cancer patients? A. Well, I do not see cancer patients routinely, if that's your question. Q. When is the last time that you had
2 3 4 5 6 7	Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few background questions and then some specifics about your CV for a few minutes. We are here at Parma Hospital today.	2 3 4 5 6	specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating cancer patients? A. Well, I do not see cancer patients routinely, if that's your question. Q. When is the last time that you had any hands-on involvement in terms of treating a
2 3 4 5 6 7 8	Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few background questions and then some specifics about your CV for a few minutes. We are here at Parma Hospital today. What is your position here at the hospital? A. I'm an associate pathologist.	2 3 4 5 6 7 8	specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating cancer patients? A. Well, I do not see cancer patients routinely, if that's your question. Q. When is the last time that you had any hands-on involvement in terms of treating a patient that had a suspicion of lung cancer?
2 3 4 5 6 7 8 9 10 11	Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few background questions and then some specifics about your CV for a few minutes. We are here at Parma Hospital today. What is your position here at the hospital? A. I'm an associate pathologist. Q. Whom are you employed by?	2 3 4 5 6 7 8 9	specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating cancer patients? A. Well, I do not see cancer patients routinely, if that's your question. Q. When is the last time that you had any hands-on involvement in terms of treating a
2 3 4 5 6 7 8 9 10 11 12	 Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few background questions and then some specifics about your CV for a few minutes. We are here at Parma Hospital today. What is your position here at the hospital? A. I'm an associate pathologist. Q. Whom are you employed by? A. Cottle Pathology Services, Inc. 	2 3 4 5 6 7 8 9 10	 specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating cancer patients? A. Well, I do not see cancer patients routinely, if that's your question. Q. When is the last time that you had any hands-on involvement in terms of treating a patient that had a suspicion of lung cancer? A. Actually seeing the patient and
2 3 4 5 6 7 8 9 10 11 12 13	Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few background questions and then some specifics about your CV for a few minutes. We are here at Parma Hospital today. What is your position here at the hospital? A. I'm an associate pathologist. Q. Whom are you employed by? A. Cottle Pathology Services, Inc. Q. How long have you been employed by that group? A. A little over three years.	2 3 4 5 6 7 8 9 10 11	 specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating cancer patients? A. Well, I do not see cancer patients routinely, if that's your question. Q. When is the last time that you had any hands-on involvement in terms of treating a patient that had a suspicion of lung cancer? A. Actually seeing the patient and examining him physically? Q. Yes. A. When I was a resident.
2 3 4 5 6 7 8 9 10 11 12 13 14	Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few background questions and then some specifics about your CV for a few minutes. We are here at Parma Hospital today. What is your position here at the hospital? A. I'm an associate pathologist. Q. Whom are you employed by? A. Cottle Pathology Services, Inc. Q. How long have you been employed by that group? A. A little over three years. Q. How many other pathologists are there	2 3 4 5 6 7 8 9 10 11 12 13 14	specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating cancer patients? A. Well, I do not see cancer patients routinely, if that's your question. Q. When is the last time that you had any hands-on involvement in terms of treating a patient that had a suspicion of lung cancer? A. Actually seeing the patient and examining him physically? Q. Yes.
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few background questions and then some specifics about your CV for a few minutes. We are here at Parma Hospital today. What is your position here at the hospital? A. I'm an associate pathologist. Q. Whom are you employed by? A. Cottle Pathology Services, Inc. Q. How long have you been employed by that group? A. A little over three years. Q. How many other pathologists are there in that group?	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating cancer patients? A. Well, I do not see cancer patients routinely, if that's your question. Q. When is the last time that you had any hands-on involvement in terms of treating a patient that had a suspicion of lung cancer? A. Actually seeing the patient and examining him physically? Q. Yes. A. When I was a resident. Q. That would have been how long ago? A. That was 1986-87.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few background questions and then some specifics about your CV for a few minutes. We are here at Parma Hospital today. What is your position here at the hospital? A. I'm an associate pathologist. Q. Whom are you employed by? A. Cottle Pathology Services, Inc. Q. How long have you been employed by that group? A. A little over three years. Q. How many other pathologists are there in that group? A. We are a total of three and a half;	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating cancer patients? A. Well, I do not see cancer patients routinely, if that's your question. Q. When is the last time that you had any hands-on involvement in terms of treating a patient that had a suspicion of lung cancer? A. Actually seeing the patient and examining him physically? Q. Yes. A. When I was a resident. Q. That would have been how long ago? A. That was 1986-87. Q. And I take it also that you don't
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few background questions and then some specifics about your CV for a few minutes. We are here at Parma Hospital today. What is your position here at the hospital? A. I'm an associate pathologist. Q. Whom are you employed by? A. Cottle Pathology Services, Inc. Q. How long have you been employed by that group? A. A little over three years. Q. How many other pathologists are there in that group? A. We are a total of three and a half; three full time and one part time.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating cancer patients? A. Well, I do not see cancer patients routinely, if that's your question. Q. When is the last time that you had any hands-on involvement in terms of treating a patient that had a suspicion of lung cancer? A. Actually seeing the patient and examining him physically? Q. Yes. A. When I was a resident. Q. That would have been how long ago? A. That was 1986-87. Q. And I take it also that you don't hold yourself out as an expert in the area of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few background questions and then some specifics about your CV for a few minutes. We are here at Parma Hospital today. What is your position here at the hospital? A. I'm an associate pathologist. Q. Whom are you employed by? A. Cottle Pathology Services, Inc. Q. How long have you been employed by that group? A. A little over three years. Q. How many other pathologists are there in that group? A. We are a total of three and a half; three full time and one part time. Q. I was going to ask you how the fourth 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating cancer patients? A. Well, I do not see cancer patients routinely, if that's your question. Q. When is the last time that you had any hands-on involvement in terms of treating a patient that had a suspicion of lung cancer? A. Actually seeing the patient and examining him physically? Q. Yes. A. When I was a resident. Q. That would have been how long ago? A. That was 1986-87. Q. And I take it also that you don't hold yourself out as an expert in the area of radiology or radiological interpretation?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few background questions and then some specifics about your CV for a few minutes. We are here at Parma Hospital today. What is your position here at the hospital? A. I'm an associate pathologist. Q. Whom are you employed by? A. Cottle Pathology Services, Inc. Q. How long have you been employed by that group? A. A little over three years. Q. How many other pathologists are there in that group? A. We are a total of three and a half; three full time and one part time. Q. I was going to ask you how the fourth one became a half person. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating cancer patients? A. Well, I do not see cancer patients routinely, if that's your question. Q. When is the last time that you had any hands-on involvement in terms of treating a patient that had a suspicion of lung cancer? A. Actually seeing the patient and examining him physically? Q. Yes. A. When I was a resident. Q. That would have been how long ago? A. That was 1986-87. Q. And I take it also that you don't hold yourself out as an expert in the area of radiology or radiological interpretation? A. Well, I do have, of course I do have
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few background questions and then some specifics about your CV for a few minutes. We are here at Parma Hospital today. What is your position here at the hospital? A. I'm an associate pathologist. Q. Whom are you employed by? A. Cottle Pathology Services, Inc. Q. How long have you been employed by that group? A. A little over three years. Q. How many other pathologists are there in that group? A. We are a total of three and a half; three full time and one part time. Q. I was going to ask you how the fourth one became a half person. A. She is a little short. Just kidding. 	2 3 4 5 6 7 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating cancer patients? A. Well, I do not see cancer patients routinely, if that's your question. Q. When is the last time that you had any hands-on involvement in terms of treating a patient that had a suspicion of lung cancer? A. Actually seeing the patient and examining him physically? Q. Yes. A. When I was a resident. Q. That would have been how long ago? A. That was 1986-87. Q. And I take it also that you don't hold yourself out as an expert in the area of radiology or radiological interpretation? A. Well, I do have, of course I do have knowledge of radiology as it relates to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 9 20 21	 Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few background questions and then some specifics about your CV for a few minutes. We are here at Parma Hospital today. What is your position here at the hospital? A. I'm an associate pathologist. Q. Whom are you employed by? A. Cottle Pathology Services, Inc. Q. How long have you been employed by that group? A. A little over three years. Q. How many other pathologists are there in that group? A. We are a total of three and a half; three full time and one part time. Q. I was going to ask you how the fourth one became a half person. A. She is a little short. Just kidding. Q. Tell me, including yourself, there 	2 3 4 5 6 7 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating cancer patients? A. Well, I do not see cancer patients routinely, if that's your question. Q. When is the last time that you had any hands-on involvement in terms of treating a patient that had a suspicion of lung cancer? A. Actually seeing the patient and examining him physically? Q. Yes. A. When I was a resident. Q. That would have been how long ago? A. That was 1986-87. Q. And I take it also that you don't hold yourself out as an expert in the area of radiology or radiological interpretation? A. Well, I do have, of course I do have knowledge of radiology as it relates to pathology and how it correlates with the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few background questions and then some specifics about your CV for a few minutes. We are here at Parma Hospital today. What is your position here at the hospital? A. I'm an associate pathologist. Q. Whom are you employed by? A. Cottle Pathology Services, Inc. Q. How long have you been employed by that group? A. A little over three years. Q. How many other pathologists are there in that group? A. We are a total of three and a half; three full time and one part time. Q. I was going to ask you how the fourth one became a half person. A. She is a little short. Just kidding. Q. Tell me, including yourself, there 	2 3 4 5 6 7 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating cancer patients? A. Well, I do not see cancer patients routinely, if that's your question. Q. When is the last time that you had any hands-on involvement in terms of treating a patient that had a suspicion of lung cancer? A. Actually seeing the patient and examining him physically? Q. Yes. A. When I was a resident. Q. That would have been how long ago? A. That was 1986-87. Q. And I take it also that you don't hold yourself out as an expert in the area of radiology or radiological interpretation? A. Well, I do have, of course I do have knowledge of radiology as it relates to pathology and how it correlates with the pathology, but I am not an expert in radiology.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 9 20 21 22 23	 Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few background questions and then some specifics about your CV for a few minutes. We are here at Parma Hospital today. What is your position here at the hospital? A. I'm an associate pathologist. Q. Whom are you employed by? A. Cottle Pathology Services, Inc. Q. How long have you been employed by that group? A. A little over three years. Q. How many other pathologists are there in that group? A. We are a total of three and a half; three full time and one part time. Q. I was going to ask you how the fourth one became a half person. A. She is a little short. Just kidding. Q. Tell me, including yourself, there are three full time or including yourself there 	2 3 4 5 6 7 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating cancer patients? A. Well, I do not see cancer patients routinely, if that's your question. Q. When is the last time that you had any hands-on involvement in terms of treating a patient that had a suspicion of lung cancer? A. Actually seeing the patient and examining him physically? Q. Yes. A. When I was a resident. Q. That would have been how long ago? A. That was 1986-87. Q. And I take it also that you don't hold yourself out as an expert in the area of radiology or radiological interpretation? A. Well, I do have, of course I do have knowledge of radiology as it relates to pathology and how it correlates with the pathology, but I am not an expert in radiology. Q. Your education in terms of medical
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 20 21 22 23 24	 Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few background questions and then some specifics about your CV for a few minutes. We are here at Parma Hospital today. What is your position here at the hospital? A. I'm an associate pathologist. Q. Whom are you employed by? A. Cottle Pathology Services, Inc. Q. How long have you been employed by that group? A. A little over three years. Q. How many other pathologists are there in that group? A. We are a total of three and a half; three full time and one part time. Q. I was going to ask you how the fourth one became a half person. A. She is a little short. Just kidding. Q. Tell me, including yourself, there are three full time or including yourself there are four? A. Including myself there are three full 	2 3 4 5 6 7 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating cancer patients? A. Well, I do not see cancer patients routinely, if that's your question. Q. When is the last time that you had any hands-on involvement in terms of treating a patient that had a suspicion of lung cancer? A. Actually seeing the patient and examining him physically? Q. Yes. A. When I was a resident. Q. That would have been how long ago? A. That was 1986-87. Q. And I take it also that you don't hold yourself out as an expert in the area of radiology or radiological interpretation? A. Well, I do have, of course I do have knowledge of radiology as it relates to pathology and how it correlates with the pathology, but I am not an expert in radiology. Q. Your education in terms of medical school took place where?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 9 20 21 22 23	 Exhibit 1 is your CV; is that true? A. Yes. Q. I want to ask you just a few background questions and then some specifics about your CV for a few minutes. We are here at Parma Hospital today. What is your position here at the hospital? A. I'm an associate pathologist. Q. Whom are you employed by? A. Cottle Pathology Services, Inc. Q. How long have you been employed by that group? A. A little over three years. Q. How many other pathologists are there in that group? A. We are a total of three and a half; three full time and one part time. Q. I was going to ask you how the fourth one became a half person. A. She is a little short. Just kidding. Q. Tell me, including yourself, there are three full time or including yourself there 	2 3 4 5 6 7 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 specimens from the standpoint of evaluating staging and assisting potentially with treatment modalities as opposed to actually treating cancer patients? A. Well, I do not see cancer patients routinely, if that's your question. Q. When is the last time that you had any hands-on involvement in terms of treating a patient that had a suspicion of lung cancer? A. Actually seeing the patient and examining him physically? Q. Yes. A. When I was a resident. Q. That would have been how long ago? A. That was 1986-87. Q. And I take it also that you don't hold yourself out as an expert in the area of radiology or radiological interpretation? A. Well, I do have, of course I do have knowledge of radiology as it relates to pathology and how it correlates with the pathology, but I am not an expert in radiology. Q. Your education in terms of medical

4 (Pages 13 to 16)

5 (Pages 17 to 20)

F	
Dawa (7	
Page 17	Page 19
1 Iraq.	1 types, yes.
2 Q. And that's where you were born; true?	2 Q. So when one looks under a microscope,
3 A. Yes.	3 one can look for the type of configuration of
4 MR. MISHKIND: Off the record.	4 the cell in terms of trying to define whether or
5 (Discussion off the record.)	5 not it's a squamous cell carcinoma or one of the
6 Q. Before your affiliation with the	6 other nonsmall cell carcinomas; correct?
7 pathology group that you mentioned, where did	7 A. There are several criteria that we
8 you practice?	8 look at and take into consideration to try to
9 A. University Hospitals of Cleveland.	9 classify the tumor and to classify the nonsmall
10 Q. And how many years did you practice	10 cell cancer into the different subcategories,
11 there?	11 like squamous cell carcinoma, adenocarcinoma,
12 A. From 1986 to July 2000.	12 merkel undifferentiated carcinoma,
13 Q. What was your position at UH?	13 neuroendocrine carcinomas and otherwise.
14 A. The first year I was there from 1986	14 Q. Did Mr. Gill have squamous cell
15 to 1987 I did a fellowship in surgical pathology	15 carcinoma?
16 and cytopathology. Then I became a staff	
17 pathologist and held various administrative	
18 positions, like the director of histology,19 director of cytology, as outlined in my CV.	18 a component that was poorly differentiated
	19 nonsmall cell; i.e., the tumor cells did not
	20 express any specific differentiation. There
	21 were four slides that had squamous
22 Q. Cytology.	22 differentiation and there were four slides that
23 A. Cytology is the study of the cells.	23 had that glandular or adenocarcinoma
24 Q. And histology is study of blood?	24 differentiation.
25 A. Of the tissue.	25 Q. So as we look through the medical
Page 18	Page 20
	Page 20
1 Q. It's no mystery that we are talking	1 records, we may see different references to the
1 Q. It's no mystery that we are talking 2 about nonsmall cell lung cancer in this case;	 records, we may see different references to the descriptive terms of his nonsmall cell
1 Q. It's no mystery that we are talking 2 about nonsmall cell lung cancer in this case; 3 correct?	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma?
 Q. It's no mystery that we are talking about nonsmall cell lung cancer in this case; correct? A. What do you mean it's no mystery? 	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct.
 Q. It's no mystery that we are talking about nonsmall cell lung cancer in this case; correct? A. What do you mean it's no mystery? Q. Well, Mr. Gill had, when it was 	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it
 Q. It's no mystery that we are talking about nonsmall cell lung cancer in this case; correct? A. What do you mean it's no mystery? Q. Well, Mr. Gill had, when it was diagnosed, he had a diagnosis in terms of the 	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it referred to as adenosquamous carcinoma, which is
 Q. It's no mystery that we are talking about nonsmall cell lung cancer in this case; correct? A. What do you mean it's no mystery? Q. Well, Mr. Gill had, when it was diagnosed, he had a diagnosis in terms of the primary tumor falling within the category of 	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it referred to as adenosquamous carcinoma, which is sort of a combination of adenocarcinoma and
 Q. It's no mystery that we are talking about nonsmall cell lung cancer in this case; correct? A. What do you mean it's no mystery? Q. Well, Mr. Gill had, when it was diagnosed, he had a diagnosis in terms of the primary tumor falling within the category of nonsmall cell carcinoma; true? 	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it referred to as adenosquamous carcinoma, which is sort of a combination of adenocarcinoma and squamous cell carcinoma?
 Q. It's no mystery that we are talking about nonsmall cell lung cancer in this case; correct? A. What do you mean it's no mystery? Q. Well, Mr. Gill had, when it was diagnosed, he had a diagnosis in terms of the primary tumor falling within the category of nonsmall cell carcinoma; true? A. Well, if you are asking me if I agree 	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it referred to as adenosquamous carcinoma, which is sort of a combination of adenocarcinoma and squamous cell carcinoma? A. That's correct.
 Q. It's no mystery that we are talking about nonsmall cell lung cancer in this case; correct? A. What do you mean it's no mystery? Q. Well, Mr. Gill had, when it was diagnosed, he had a diagnosis in terms of the primary tumor falling within the category of nonsmall cell carcinoma; true? A. Well, if you are asking me if I agree from reviewing the slides on Mr. Gill that he 	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it referred to as adenosquamous carcinoma, which is sort of a combination of adenocarcinoma and squamous cell carcinoma? A. That's correct. Q. And that would be different from
 Q. It's no mystery that we are talking about nonsmall cell lung cancer in this case; correct? A. What do you mean it's no mystery? Q. Well, Mr. Gill had, when it was diagnosed, he had a diagnosis in terms of the primary tumor falling within the category of nonsmall cell carcinoma; true? A. Well, if you are asking me if I agree from reviewing the slides on Mr. Gill that he had nonsmall cell lung cancer, the answer is 	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it referred to as adenosquamous carcinoma, which is sort of a combination of adenocarcinoma and squamous cell carcinoma? A. That's correct. Q. And that would be different from poorly differentiated nonsmall cell carcinoma;
 Q. It's no mystery that we are talking about nonsmall cell lung cancer in this case; correct? A. What do you mean it's no mystery? Q. Well, Mr. Gill had, when it was diagnosed, he had a diagnosis in terms of the primary tumor falling within the category of nonsmall cell carcinoma; true? A. Well, if you are asking me if I agree from reviewing the slides on Mr. Gill that he had nonsmall cell lung cancer, the answer is yes, I do. 	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it referred to as adenosquamous carcinoma, which is sort of a combination of adenocarcinoma and squamous cell carcinoma? A. That's correct. Q. And that would be different from poorly differentiated nonsmall cell carcinoma; true?
 Q. It's no mystery that we are talking about nonsmall cell lung cancer in this case; correct? A. What do you mean it's no mystery? Q. Well, Mr. Gill had, when it was diagnosed, he had a diagnosis in terms of the primary tumor falling within the category of nonsmall cell carcinoma; true? A. Well, if you are asking me if 1 agree from reviewing the slides on Mr. Gill that he had nonsmall cell lung cancer, the answer is yes, I do. Q. There are different categories of 	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it referred to as adenosquamous carcinoma, which is sort of a combination of adenocarcinoma and squamous cell carcinoma? A. That's correct. Q. And that would be different from poorly differentiated nonsmall cell carcinoma; true? A. Not necessarily. Poorly
 Q. It's no mystery that we are talking about nonsmall cell lung cancer in this case; correct? A. What do you mean it's no mystery? Q. Well, Mr. Gill had, when it was diagnosed, he had a diagnosis in terms of the primary tumor falling within the category of nonsmall cell carcinoma; true? A. Well, if you are asking me if I agree from reviewing the slides on Mr. Gill that he had nonsmall cell lung cancer, the answer is yes, I do. Q. There are different categories of lung cancer; correct? 	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it referred to as adenosquamous carcinoma, which is sort of a combination of adenocarcinoma and squamous cell carcinoma? A. That's correct. Q. And that would be different from poorly differentiated nonsmall cell carcinoma; true? A. Not necessarily. Poorly differentiated nonsmall cell carcinomas can have
1Q.It's no mystery that we are talking2about nonsmall cell lung cancer in this case;3correct?4A.What do you mean it's no mystery?5Q.Well, Mr. Gill had, when it was6diagnosed, he had a diagnosis in terms of the7primary tumor falling within the category of8nonsmall cell carcinoma; true?9A.10from reviewing the slides on Mr. Gill that he11had nonsmall cell lung cancer, the answer is12yes, I do.13Q.14lung cancer; correct?15A.Yes.	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it referred to as adenosquamous carcinoma, which is sort of a combination of adenocarcinoma and squamous cell carcinoma? A. That's correct. Q. And that would be different from poorly differentiated nonsmall cell carcinoma; true? A. Not necessarily. Poorly differentiated nonsmall cell carcinomas can have signs of either adeno or squamous
1Q.It's no mystery that we are talking2about nonsmall cell lung cancer in this case;3correct?4A.What do you mean it's no mystery?5Q.Well, Mr. Gill had, when it was6diagnosed, he had a diagnosis in terms of the7primary tumor falling within the category of8nonsmall cell carcinoma; true?9A.9A.10from reviewing the slides on Mr. Gill that he11had nonsmall cell lung cancer, the answer is12yes, I do.13Q.14lung cancer; correct?15A.16Q.16Q.	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it referred to as adenosquamous carcinoma, which is sort of a combination of adenocarcinoma and squamous cell carcinoma? A. That's correct. Q. And that would be different from poorly differentiated nonsmall cell carcinoma; true? A. Not necessarily. Poorly differentiated nonsmall cell carcinomas can have signs of either adeno or squamous differentiatedno. So the poorly differentiated
 Q. It's no mystery that we are talking about nonsmall cell lung cancer in this case; correct? A. What do you mean it's no mystery? Q. Well, Mr. Gill had, when it was diagnosed, he had a diagnosis in terms of the primary tumor falling within the category of nonsmall cell carcinoma; true? A. Well, if you are asking me if 1 agree from reviewing the slides on Mr. Gill that he had nonsmall cell lung cancer, the answer is yes, I do. Q. There are different categories of lung cancer; correct? A. Yes. Q. Those that would fall outside of the area of nonsmall cell are grouped in what title, 	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it referred to as adenosquamous carcinoma, which is sort of a combination of adenocarcinoma and squamous cell carcinoma? A. That's correct. Q. And that would be different from poorly differentiated nonsmall cell carcinoma; true? A. Not necessarily. Poorly differentiated nonsmall cell carcinomas can have signs of either adeno or squamous differentiated no. So the poorly differentiated aspect of it is another characterization of the
 Q. It's no mystery that we are talking about nonsmall cell lung cancer in this case; correct? A. What do you mean it's no mystery? Q. Well, Mr. Gill had, when it was diagnosed, he had a diagnosis in terms of the primary tumor falling within the category of nonsmall cell carcinoma; true? A. Well, if you are asking me if 1 agree from reviewing the slides on Mr. Gill that he had nonsmall cell lung cancer, the answer is yes, I do. Q. There are different categories of lung cancer; correct? A. Yes. Q. Those that would fall outside of the area of nonsmall cell are grouped in what title, what category? 	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it referred to as adenosquamous carcinoma, which is sort of a combination of adenocarcinoma and squamous cell carcinoma? A. That's correct. Q. And that would be different from poorly differentiated nonsmall cell carcinoma; true? A. Not necessarily. Poorly differentiated nonsmall cell carcinomas can have signs of either adeno or squamous differentiation. So the poorly differentiated aspect of it is another characterization of the tumor. So adenosquamous carcinomas and nonsmall
1Q.It's no mystery that we are talking2about nonsmall cell lung cancer in this case;3correct?4A.What do you mean it's no mystery?5Q.Well, Mr. Gill had, when it was6diagnosed, he had a diagnosis in terms of the7primary tumor falling within the category of8nonsmall cell carcinoma; true?9A.9A.10from reviewing the slides on Mr. Gill that he11had nonsmall cell lung cancer, the answer is12yes, I do.13Q.14lung cancer; correct?15A.16Q.17area of nonsmall cell are grouped in what title,18what category?19A.19A.10The ones that fall outside the	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it referred to as adenosquamous carcinoma, which is sort of a combination of adenocarcinoma and squamous cell carcinoma? A. That's correct. Q. And that would be different from poorly differentiated nonsmall cell carcinoma; true? A. Not necessarily. Poorly differentiated nonsmall cell carcinomas can have signs of either adeno or squamous differentiated nonsmall cell carcinomas and nonsmall gect of it is another characterization of the tumor. So adenosquamous carcinomas and nonsmall cell lung cancers can be poorly differentiated
1Q.It's no mystery that we are talking2about nonsmall cell lung cancer in this case;3correct?4A.What do you mean it's no mystery?5Q.Well, Mr. Gill had, when it was6diagnosed, he had a diagnosis in terms of the7primary tumor falling within the category of8nonsmall cell carcinoma; true?9A.9A.10from reviewing the slides on Mr. Gill that he11had nonsmall cell lung cancer, the answer is12yes, I do.13Q.14lung cancer; correct?15A.16Q.17area of nonsmall cell are grouped in what title,18what category?19A.10nonsmall cell?	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it referred to as adenosquamous carcinoma, which is sort of a combination of adenocarcinoma and squamous cell carcinoma? A. That's correct. Q. And that would be different from poorly differentiated nonsmall cell carcinoma; true? A. Not necessarily. Poorly differentiated nonsmall cell carcinomas can have signs of either adeno or squamous differentiation. So the poorly differentiated aspect of it is another characterization of the tumor. So adenosquamous carcinomas and nonsmall cell lung cancers can be poorly differentiated
1Q.It's no mystery that we are talking2about nonsmall cell lung cancer in this case;3correct?4A.What do you mean it's no mystery?5Q.Well, Mr. Gill had, when it was6diagnosed, he had a diagnosis in terms of the7primary tumor falling within the category of8nonsmall cell carcinoma; true?9A.9A.10from reviewing the slides on Mr. Gill that he11had nonsmall cell lung cancer, the answer is12yes, I do.13Q.14lung cancer; correct?15A.16Q.17Those that would fall outside of the17area of nonsmall cell are grouped in what title,18what category?19A.14Q.15Yes.	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it referred to as adenosquamous carcinoma, which is sort of a combination of adenocarcinoma and squamous cell carcinoma? A. That's correct. Q. And that would be different from poorly differentiated nonsmall cell carcinoma; true? A. Not necessarily. Poorly differentiated nonsmall cell carcinomas can have signs of either adeno or squamous differentiation. So the poorly differentiated aspect of it is another characterization of the tumor. So adenosquamous carcinomas and nonsmall cell lung cancers can be poorly differentiated or well differentiated or moderately well differentiated.
1Q.It's no mystery that we are talking2about nonsmall cell lung cancer in this case;3correct?4A.What do you mean it's no mystery?5Q.Well, Mr. Gill had, when it was6diagnosed, he had a diagnosis in terms of the7primary tumor falling within the category of8nonsmall cell carcinoma; true?9A.9A.10from reviewing the slides on Mr. Gill that he11had nonsmall cell lung cancer, the answer is12yes, I do.13Q.14lung cancer; correct?15A.16Q.17Those that would fall outside of the17area of nonsmall cell are grouped in what title,18what category?19A.10Yes.21Q.22A.23A.24A.25A.26Yes.27A.28A.29Are the small cells.	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it referred to as adenosquamous carcinoma, which is sort of a combination of adenocarcinoma and squamous cell carcinoma? A. That's correct. Q. And that would be different from poorly differentiated nonsmall cell carcinoma; true? A. Not necessarily. Poorly differentiated nonsmall cell carcinomas can have signs of either adeno or squamous differentiation. So the poorly differentiated aspect of it is another characterization of the tumor. So adenosquamous carcinomas and nonsmall cell lung cancers can be poorly differentiated or well differentiated or moderately well differentiated. Q. We will talk more about that in a
1Q.It's no mystery that we are talking2about nonsmall cell lung cancer in this case;3correct?4A.What do you mean it's no mystery?5Q.Well, Mr. Gill had, when it was6diagnosed, he had a diagnosis in terms of the7primary tumor falling within the category of8nonsmall cell carcinoma; true?9A.9A.9A.10from reviewing the slides on Mr. Gill that he11had nonsmall cell lung cancer, the answer is12yes, I do.13Q.14lung cancer; correct?15A.16Q.17area of nonsmall cell are grouped in what title,18what category?19A.19A.10res.21Q.22A.23Q.24And within the nonsmall cell there	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it referred to as adenosquamous carcinoma, which is sort of a combination of adenocarcinoma and squamous cell carcinoma? A. That's correct. Q. And that would be different from poorly differentiated nonsmall cell carcinoma; true? A. Not necessarily. Poorly differentiated nonsmall cell carcinomas can have signs of either adeno or squamous differentiation. So the poorly differentiated aspect of it is another characterization of the tumor. So adenosquamous carcinomas and nonsmall cell lung cancers can be poorly differentiated or well differentiated or moderately well differentiated.
1Q.It's no mystery that we are talking2about nonsmall cell lung cancer in this case;3correct?4A.What do you mean it's no mystery?5Q.Well, Mr. Gill had, when it was6diagnosed, he had a diagnosis in terms of the7primary tumor falling within the category of8nonsmall cell carcinoma; true?9A.9A.10from reviewing the slides on Mr. Gill that he11had nonsmall cell lung cancer, the answer is12yes, I do.13Q.14lung cancer; correct?15A.16Q.17rhose that would fall outside of the17area of nonsmall cell are grouped in what title,18what category?19A.10Yes.21Q.22A.23Q.24Are the small cells.25Q.26And within the nonsmall cell there2724283729303030313032313334343434343535363637363836393630363436353636363736363637<	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it referred to as adenosquamous carcinoma, which is sort of a combination of adenocarcinoma and squamous cell carcinoma? A. That's correct. Q. And that would be different from poorly differentiated nonsmall cell carcinoma; true? A. Not necessarily. Poorly differentiated nonsmall cell carcinomas can have signs of either adeno or squamous differentiation. So the poorly differentiated aspect of it is another characterization of the tumor. So adenosquamous carcinomas and nonsmall cell lung cancers can be poorly differentiated or well differentiated or moderately well differentiated. Q. We will talk more about that in a little bit. But just to sort of talk in general about what we know the ultimate diagnosis on
1Q.It's no mystery that we are talking2about nonsmall cell lung cancer in this case;3correct?4A.What do you mean it's no mystery?5Q.Well, Mr. Gill had, when it was6diagnosed, he had a diagnosis in terms of the7primary tumor falling within the category of8nonsmall cell carcinoma; true?9A.9A.9A.10from reviewing the slides on Mr. Gill that he11had nonsmall cell lung cancer, the answer is12yes, I do.13Q.14lung cancer; correct?15A.16Q.17area of nonsmall cell are grouped in what title,18what category?19A.19A.10res.21Q.22A.23Q.24And within the nonsmall cell there	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it referred to as adenosquamous carcinoma, which is sort of a combination of adenocarcinoma and squamous cell carcinoma? A. That's correct. Q. And that would be different from poorly differentiated nonsmall cell carcinoma; true? A. Not necessarily. Poorly differentiated nonsmall cell carcinomas can have signs of either adeno or squamous differentiation. So the poorly differentiated aspect of it is another characterization of the tumor. So adenosquamous carcinomas and nonsmall cell lung cancers can be poorly differentiated or well differentiated or moderately well differentiated. Q. We will talk more about that in a little bit. But just to sort of talk in general
1Q.It's no mystery that we are talking2about nonsmall cell lung cancer in this case;3correct?4A.What do you mean it's no mystery?5Q.Well, Mr. Gill had, when it was6diagnosed, he had a diagnosis in terms of the7primary tumor falling within the category of8nonsmall cell carcinoma; true?9A.9A.10from reviewing the slides on Mr. Gill that he11had nonsmall cell lung cancer, the answer is12yes, I do.13Q.14lung cancer; correct?15A.16Q.17Those that would fall outside of the17area of nonsmall cell are grouped in what title,18what category?19A.10Yes.21Q.22A.23Q.24are various types of nonsmall cell; correct?	 records, we may see different references to the descriptive terms of his nonsmall cell carcinoma? A. That's correct. Q. I think at one point I see it referred to as adenosquamous carcinoma, which is sort of a combination of adenocarcinoma and squamous cell carcinoma? A. That's correct. Q. And that would be different from poorly differentiated nonsmall cell carcinoma; true? A. Not necessarily. Poorly differentiated nonsmall cell carcinomas can have signs of either adeno or squamous differentiation. So the poorly differentiated aspect of it is another characterization of the tumor. So adenosquamous carcinomas and nonsmall cell lung cancers can be poorly differentiated or well differentiated or moderately well differentiated. Q. We will talk more about that in a little bit. But just to sort of talk in general about what we know the ultimate diagnosis on

October 28, 2003

Page 21	Page 23
 and ask you whether there are any lectures that you have given of the 17 that are referenced that would be relevant to the issue of staging or diagnosis of nonsmall cell carcinoma? A. Can I take a look at my CV? MR. MISHKIND: Rob, I think you may have the same, just to make it easy for her. Q. For the record, it's on page five. And if you have the same version, the invited guest lectures on page five and six total 17. A. I don't see anything related to the lung in these lectures, but the lectures that I do give related to the diagnosis of lung cancer is in the invited seminars and workshops which are mostly at our national meetings, the American Society of Clinical Pathologists national meetings. Q. What page would that be on your CV? A. Well, it starts, the lung lectures start on page 11. I think the fourth item, pulmonary cytology workshop, there are several of them in different years, different locations. Q. Now, the one that I am focusing in on, the first pulmonary cytology workshop that 	 A. I have all of the abstracts and the material that I was giving to the participants. The kodachromes that I used for the presentation, I have it, but it's not it's part of my kodachrome collection that I use to lecture at the medical school and at University Hospitals, so it's not one. I usually mix and match, depending on the subject and the audience. Q. In terms of the printed material, though, that you gave back in 1994 and it looks like you continued to do that periodically over the years did that printed material change at all or was it pretty much the same from year to year? A. I may have updated the references, but the basic material is pretty much the same. Q. So you would have a file that would have your printed material that you presented to the American Society of Clinical Pathologists; true? A. Yes. Q. And that would have some relevance to the issues that we are talking about in this
 Page 22 and that was at the American Society of Clinical Pathologists, the national meeting in Seattle in April of 1994, was that a presentation that you were one of a number of presenters? A. Well, this was solely my presentation. Q. Did you provide any written material or slide presentations, power point or anything of that nature? A. Yes. There is an abstract that we provide to the participants at the time of the meeting. There is a set of kodachromes and case histories that we provide to the participants ptior to the meeting, and during the meeting there are a set of kodachrome slides. At that time I did not use the power point presentation, so they were 35 millimeter transparencies. Q. If someone like Howard Mishkind wanted to acquire a copy of the material that was disseminated at that presentation, what would I have to do? A. You can ask me. Q. It's something that you have in your 	 Page 24 A. Mostly in the area of the diagnosis of lung cancer, yes. Q. If you would be so kind as to provide copies of the printed material, not necessarily the slides, but the printed material to Mr. Warner, and I'll make a request on the record that Mr. Warner provide me with a copy of that. A. Okay. Q. Doctor, it looks like the last time that you presented at the cytology workshop was 1998; is that true? A. 1999. Which is on page 12. Q. My CV that was faxed to me actually ended on page 11. So you have got a page 12. A. I'm sorry. Q. It's not your fault. MR. MISHKIND: Rob, what I would like to do is MR. WARNER: We can get you copies. MR. MISHKIND: Just for the record, my CV ended at page 11 and the original has 12 pages. MR. WARNER: When we leave, we will go down to the copy center.

6 (Pages 21 to 24)

October 28, 2003

Page 25	Page 27
1 MR. MISHKIND: And we will just	1 subspecialty?
2 substitute page 12 to Exhibit 1.	
3 Q. Doctor, besides the invited workshops	2 A. By training and certification I am a 3 board anatomic and clinical pathologist. My
4 or seminars, if I look back through your CV,	4 specialty areas are surgical pathology and
5 there is a number of abstracts. There are a	
6 number of peer reviewed articles and educational	
7 publications in your bibliography. Do any of	6 expertise in these subspecialties is breast 7 pathology and lung pathology. I still do look
8 them have any relevance to the topic of nonsmall	
9 cell lung cancer?	
10 A. Well, some of them have relevance to	
11 the diagnosis of lung cancer in general, even	
12 though the specific tumors that are described or	
13 reported were neuroendocrine carcinoma or	
14 carcinoid tumors, but they do enter into the	13 provided with to interpret. I was at UH at the 14 time that the breast center was founded and
15 category of lung cancers.	15 started and I developed my interest that way.
16 Q. Would the references be voluminous or	
17 could you very quickly look through and tell me	
18 number 10 or number 11 would have something	
19 touching on the topic of lung cancer?	18 directors. And for several years I was in charge19 of reviewing all the lung pathology material for
20 A. Sure. Many of the lectures that I	20 conferences and be the person to answer
21 gave at University Hospitals of Cleveland do	21 questions of the physicians, pulmonologists.
22 relate to lung cancer; again mostly in the	22 A few years actually before I left
23 diagnosis aspect of it.	
24 And these are not listed separately	, b
25 as such, but they are under the teaching	
23 as such, but they are under the teaching	25 responsibility gradually to one of our younger
Page 26	Page 28
 responsibilities at University Hospitals of Cleveland which is on page five of the 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you
2 Cleveland which is on page five of the 3 educational publications. On page seven, number	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology?
 Cleveland which is on page five of the educational publications. On page seven, number four, it relates to pulmonary blastoma, which is 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver.
 2 Cleveland which is on page five of the 3 educational publications. On page seven, number 4 four, it relates to pulmonary blastoma, which is 5 a different type of lung tumor than the one we 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver. Q. Is Dr. DeShriver still at UH?
 2 Cleveland which is on page five of the 3 educational publications. On page seven, number 4 four, it relates to pulmonary blastoma, which is 5 a different type of lung tumor than the one we 6 are discussing today. 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver. Q. Is Dr. DeShriver still at UH? A. No.
 2 Cleveland which is on page five of the 3 educational publications. On page seven, number 4 four, it relates to pulmonary blastoma, which is 5 a different type of lung tumor than the one we 6 are discussing today. 7 Under the peer reviewed articles on 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver. Q. Is Dr. DeShriver still at UH? A. No. Q. Where is she at now?
 2 Cleveland which is on page five of the 3 educational publications. On page seven, number 4 four, it relates to pulmonary blastoma, which is 5 a different type of lung tumor than the one we 6 are discussing today. 7 Under the peer reviewed articles on 8 page seven, there is number two, bronchial 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver. Q. Is Dr. DeShriver still at UH? A. No. Q. Where is she at now? A. I don't know.
 2 Cleveland which is on page five of the 3 educational publications. On page seven, number 4 four, it relates to pulmonary blastoma, which is 5 a different type of lung tumor than the one we 6 are discussing today. 7 Under the peer reviewed articles on 8 page seven, there is number two, bronchial 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver. Q. Is Dr. DeShriver still at UH? A. No. Q. Where is she at now? A. I don't know. Q. When you are looking at lung or
 2 Cleveland which is on page five of the 3 educational publications. On page seven, number 4 four, it relates to pulmonary blastoma, which is 5 a different type of lung tumor than the one we 6 are discussing today. 7 Under the peer reviewed articles on 8 page seven, there is number two, bronchial 9 carcinoid tumor. 10 Number 14 on page eight. I think 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver. Q. Is Dr. DeShriver still at UH? A. No. Q. Where is she at now? A. I don't know. Q. When you are looking at lung or breast pathology, you are normally looking at
 2 Cleveland which is on page five of the 3 educational publications. On page seven, number 4 four, it relates to pulmonary blastoma, which is 5 a different type of lung tumor than the one we 6 are discussing today. 7 Under the peer reviewed articles on 8 page seven, there is number two, bronchial 9 carcinoid tumor. 10 Number 14 on page eight. I think 11 that's it. 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver. Q. Is Dr. DeShriver still at UH? A. No. Q. Where is she at now? A. I don't know. Q. When you are looking at lung or breast pathology, you are normally looking at surgical specimens; true?
 2 Cleveland which is on page five of the 3 educational publications. On page seven, number 4 four, it relates to pulmonary blastoma, which is 5 a different type of lung tumor than the one we 6 are discussing today. 7 Under the peer reviewed articles on 8 page seven, there is number two, bronchial 9 carcinoid tumor. 10 Number 14 on page eight. I think 11 that's it. 12 Q. On the last page of your CV that I 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver. Q. Is Dr. DeShriver still at UH? A. No. Q. Where is she at now? A. I don't know. Q. When you are looking at lung or breast pathology, you are normally looking at surgical specimens; true? A. Yes.
 2 Cleveland which is on page five of the 3 educational publications. On page seven, number 4 four, it relates to pulmonary blastoma, which is 5 a different type of lung tumor than the one we 6 are discussing today. 7 Under the peer reviewed articles on 8 page seven, there is number two, bronchial 9 carcinoid tumor. 10 Number 14 on page eight. I think 11 that's it. 12 Q. On the last page of your CV that I 13 didn't have until a moment ago, there is a book 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver. Q. Is Dr. DeShriver still at UH? A. No. Q. Where is she at now? A. I don't know. Q. When you are looking at lung or breast pathology, you are normally looking at surgical specimens; true? A. Yes. Q. And in looking at surgical specimens,
 2 Cleveland which is on page five of the 3 educational publications. On page seven, number 4 four, it relates to pulmonary blastoma, which is 5 a different type of lung tumor than the one we 6 are discussing today. 7 Under the peer reviewed articles on 8 page seven, there is number two, bronchial 9 carcinoid tumor. 10 Number 14 on page eight. I think 11 that's it. 12 Q. On the last page of your CV that I 13 didn't have until a moment ago, there is a book 14 chapter that you wrote? 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver. Q. Is Dr. DeShriver still at UH? A. No. Q. Where is she at now? A. I don't know. Q. When you are looking at lung or breast pathology, you are normally looking at surgical specimens; true? A. Yes. Q. And in looking at surgical specimens, you are providing some input to the clinician as
 2 Cleveland which is on page five of the 3 educational publications. On page seven, number 4 four, it relates to pulmonary blastoma, which is 5 a different type of lung tumor than the one we 6 are discussing today. 7 Under the peer reviewed articles on 8 page seven, there is number two, bronchial 9 carcinoid tumor. 10 Number 14 on page eight. I think 11 that's it. 12 Q. On the last page of your CV that I 13 didn't have until a moment ago, there is a book 14 chapter that you wrote? 15 A. Yes. 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver. Q. Is Dr. DeShriver still at UH? A. No. Q. Where is she at now? A. I don't know. Q. When you are looking at lung or breast pathology, you are normally looking at surgical specimens; true? A. Yes. Q. And in looking at surgical specimens, you are providing some input to the clinician as to what the patient's prognosis is based upon
 2 Cleveland which is on page five of the 3 educational publications. On page seven, number 4 four, it relates to pulmonary blastoma, which is 5 a different type of lung tumor than the one we 6 are discussing today. 7 Under the peer reviewed articles on 8 page seven, there is number two, bronchial 9 carcinoid tumor. 10 Number 14 on page eight. I think 11 that's it. 12 Q. On the last page of your CV that I 13 didn't have until a moment ago, there is a book 14 chapter that you wrote? 15 A. Yes. 16 Q. Does that have anything to do with 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver. Q. Is Dr. DeShriver still at UH? A. No. Q. Where is she at now? A. I don't know. Q. When you are looking at lung or breast pathology, you are normally looking at surgical specimens; true? A. Yes. Q. And in looking at surgical specimens, you are providing some input to the clinician as to what the patient's prognosis is based upon the cell structure and other findings that you
 2 Cleveland which is on page five of the 3 educational publications. On page seven, number 4 four, it relates to pulmonary blastoma, which is 5 a different type of lung tumor than the one we 6 are discussing today. 7 Under the peer reviewed articles on 8 page seven, there is number two, bronchial 9 carcinoid tumor. 10 Number 14 on page eight. I think 11 that's it. 12 Q. On the last page of your CV that I 13 didn't have until a moment ago, there is a book 14 chapter that you wrote? 15 A. Yes. 16 Q. Does that have anything to do with 17 lung cancer? 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver. Q. Is Dr. DeShriver still at UH? A. No. Q. Where is she at now? A. I don't know. Q. When you are looking at lung or breast pathology, you are normally looking at surgical specimens; true? A. Yes. Q. And in looking at surgical specimens, you are providing some input to the clinician as to what the patient's prognosis is based upon the cell structure and other findings that you make on that surgical specimen; correct?
 2 Cleveland which is on page five of the 3 educational publications. On page seven, number 4 four, it relates to pulmonary blastoma, which is 5 a different type of lung tumor than the one we 6 are discussing today. 7 Under the peer reviewed articles on 8 page seven, there is number two, bronchial 9 carcinoid tumor. 10 Number 14 on page eight. I think 11 that's it. 12 Q. On the last page of your CV that I 13 didn't have until a moment ago, there is a book 14 chapter that you wrote? 15 A. Yes. 16 Q. Does that have anything to do with 17 lung cancer? 18 A. No. It was on GYN cytology. I was 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver. Q. Is Dr. DeShriver still at UH? A. No. Q. Where is she at now? A. I don't know. Q. When you are looking at lung or breast pathology, you are normally looking at surgical specimens; true? A. Yes. Q. And in looking at surgical specimens, you are providing some input to the clinician as to what the patient's prognosis is based upon the cell structure and other findings that you make on that surgical specimen; correct? A. Yes.
 2 Cleveland which is on page five of the 3 educational publications. On page seven, number 4 four, it relates to pulmonary blastoma, which is 5 a different type of lung tumor than the one we 6 are discussing today. 7 Under the peer reviewed articles on 8 page seven, there is number two, bronchial 9 carcinoid tumor. 10 Number 14 on page eight. I think 11 that's it. 12 Q. On the last page of your CV that I 13 didn't have until a moment ago, there is a book 14 chapter that you wrote? 15 A. Yes. 16 Q. Does that have anything to do with 17 lung cancer? 18 A. No. It was on GYN cytology. I was 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver. Q. Is Dr. DeShriver still at UH? A. No. Q. Where is she at now? A. I don't know. Q. When you are looking at lung or breast pathology, you are normally looking at surgical specimens; true? A. Yes. Q. And in looking at surgical specimens, you are providing some input to the clinician as to what the patient's prognosis is based upon the cell structure and other findings that you make on that surgical specimen; correct? A. Yes. Q. So you may assist in terms of
 2 Cleveland which is on page five of the 3 educational publications. On page seven, number 4 four, it relates to pulmonary blastoma, which is 5 a different type of lung tumor than the one we 6 are discussing today. 7 Under the peer reviewed articles on 8 page seven, there is number two, bronchial 9 carcinoid tumor. 10 Number 14 on page eight. I think 11 that's it. 12 Q. On the last page of your CV that I 13 didn't have until a moment ago, there is a book 14 chapter that you wrote? 15 A. Yes. 16 Q. Does that have anything to do with 17 lung cancer? 18 A. No. It was on GYN cytology. I was 19 asked to write a book on pulmonary cytology but 20 I declined. 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver. Q. Is Dr. DeShriver still at UH? A. No. Q. Where is she at now? A. I don't know. Q. When you are looking at lung or breast pathology, you are normally looking at surgical specimens; true? A. Yes. Q. And in looking at surgical specimens, you are providing some input to the clinician as to what the patient's prognosis is based upon the cell structure and other findings that you make on that surgical specimen; correct? A. Yes. Q. So you may assist in terms of Staging, in particular with lung cancer, staging
 2 Cleveland which is on page five of the 3 educational publications. On page seven, number 4 four, it relates to pulmonary blastoma, which is 5 a different type of lung tumor than the one we 6 are discussing today. 7 Under the peer reviewed articles on 8 page seven, there is number two, bronchial 9 carcinoid tumor. 10 Number 14 on page eight. I think 11 that's it. 12 Q. On the last page of your CV that I 13 didn't have until a moment ago, there is a book 14 chapter that you wrote? 15 A. Yes. 16 Q. Does that have anything to do with 17 lung cancer? 18 A. No. It was on GYN cytology. I was 19 asked to write a book on pulmonary cytology but 20 I declined. 21 Q. Why is that? 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver. Q. Is Dr. DeShriver still at UH? A. No. Q. Where is she at now? A. I don't know. Q. When you are looking at lung or breast pathology, you are normally looking at surgical specimens; true? A. Yes. Q. And in looking at surgical specimens, you are providing some input to the clinician as to what the patient's prognosis is based upon the cell structure and other findings that you make on that surgical specimen; correct? A. Yes. Q. So you may assist in terms of staging, in particular with lung cancer, staging what the stage is of the lung cancer so that a
 2 Cleveland which is on page five of the 3 educational publications. On page seven, number 4 four, it relates to pulmonary blastoma, which is 5 a different type of lung tumor than the one we 6 are discussing today. 7 Under the peer reviewed articles on 8 page seven, there is number two, bronchial 9 carcinoid tumor. 10 Number 14 on page eight. I think 11 that's it. 12 Q. On the last page of your CV that I 13 didn't have until a moment ago, there is a book 14 chapter that you wrote? 15 A. Yes. 16 Q. Does that have anything to do with 17 lung cancer? 18 A. No. It was on GYN cytology. I was 19 asked to write a book on pulmonary cytology but 20 I declined. 21 Q. Why is that? 22 A. Because at the time I did not think I 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver. Q. Is Dr. DeShriver still at UH? A. No. Q. Where is she at now? A. I don't know. Q. When you are looking at lung or Dreast pathology, you are normally looking at surgical specimens; true? A. Yes. Q. And in looking at surgical specimens, you are providing some input to the clinician as to what the patient's prognosis is based upon the cell structure and other findings that you make on that surgical specimen; correct? A. Yes. Q. So you may assist in terms of staging, in particular with lung cancer, staging what the stage is of the lung cancer so that a clinical decision can be made as to what type of
 2 Cleveland which is on page five of the 3 educational publications. On page seven, number 4 four, it relates to pulmonary blastoma, which is 5 a different type of lung tumor than the one we 6 are discussing today. 7 Under the peer reviewed articles on 8 page seven, there is number two, bronchial 9 carcinoid tumor. 10 Number 14 on page eight. I think 11 that's it. 12 Q. On the last page of your CV that I 13 didn't have until a moment ago, there is a book 14 chapter that you wrote? 15 A. Yes. 16 Q. Does that have anything to do with 17 lung cancer? 18 A. No. It was on GYN cytology. I was 19 asked to write a book on pulmonary cytology but 20 I declined. 21 Q. Why is that? 22 A. Because at the time I did not think I 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver. Q. Is Dr. DeShriver still at UH? A. No. Q. Where is she at now? A. I don't know. Q. When you are looking at lung or breast pathology, you are normally looking at surgical specimens; true? A. Yes. Q. And in looking at surgical specimens, you are providing some input to the clinician as to what the patient's prognosis is based upon the cell structure and other findings that you make on that surgical specimen; correct? A. Yes. Q. So you may assist in terms of staging, in particular with lung cancer, staging what the stage is of the lung cancer so that a clinical decision can be made as to what type of adjunctive treatment may be appropriate for that
 2 Cleveland which is on page five of the 3 educational publications. On page seven, number 4 four, it relates to pulmonary blastoma, which is 5 a different type of lung tumor than the one we 6 are discussing today. 7 Under the peer reviewed articles on 8 page seven, there is number two, bronchial 9 carcinoid tumor. 10 Number 14 on page eight. I think 11 that's it. 12 Q. On the last page of your CV that I 13 didn't have until a moment ago, there is a book 14 chapter that you wrote? 15 A. Yes. 16 Q. Does that have anything to do with 17 lung cancer? 18 A. No. It was on GYN cytology. I was 19 asked to write a book on pulmonary cytology but 20 I declined. 21 Q. Why is that? 22 A. Because at the time I did not think I 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver. Q. Is Dr. DeShriver still at UH? A. No. Q. Where is she at now? A. I don't know. Q. When you are looking at lung or Dreast pathology, you are normally looking at surgical specimens; true? A. Yes. Q. And in looking at surgical specimens, you are providing some input to the clinician as to what the patient's prognosis is based upon the cell structure and other findings that you make on that surgical specimen; correct? A. Yes. Q. So you may assist in terms of staging, in particular with lung cancer, staging what the stage is of the lung cancer so that a clinical decision can be made as to what type of
 2 Cleveland which is on page five of the 3 educational publications. On page seven, number 4 four, it relates to pulmonary blastoma, which is 5 a different type of lung tumor than the one we 6 are discussing today. 7 Under the peer reviewed articles on 8 page seven, there is number two, bronchial 9 carcinoid tumor. 10 Number 14 on page eight. I think 11 that's it. 12 Q. On the last page of your CV that I 13 didn't have until a moment ago, there is a book 14 chapter that you wrote? 15 A. Yes. 16 Q. Does that have anything to do with 17 lung cancer? 18 A. No. It was on GYN cytology. I was 19 asked to write a book on pulmonary cytology but 20 I declined. 21 Q. Why is that? 22 A. Because at the time I did not think I 23 could devote the time necessary to write a book. 24 Q. Do you have an area within pathology 	 more junior pathologists there at UH. Q. Who was it at UH that had asked you to head up the lung pathology? A. Dr. Katherine DeShriver. Q. Is Dr. DeShriver still at UH? A. No. Q. Where is she at now? A. I don't know. Q. When you are looking at lung or breast pathology, you are normally looking at surgical specimens; true? A. Yes. Q. And in looking at surgical specimens, you are providing some input to the clinician as to what the patient's prognosis is based upon the cell structure and other findings that you make on that surgical specimen; correct? A. Yes. Q. So you may assist in terms of staging, in particular with lung cancer, staging what the stage is of the lung cancer so that a clinical decision can be made as to what type of adjunctive treatment may be appropriate for that

7 (Pages 25 to 28)

October 28, 2003

Daga 20	Dara 94
Page 29	Page 31
1 Q. And also having some prognostic	1 negligence cases.
2 indicators as to how long the patient	2 Q. Sure. You understand in this case,
3 statistically may live; correct?	3 there are allegations that Dr. Mansnerus did not
4 A. Yes. These are findings that are	4 comply with the standard of care. You
5 related to the staging, basically, and the	5 understand that?
6 histologic type of the tumor.	6 A. Right.
7 Q. You are not typically asked to	
8 provide an opinion as to when the patient	8 for Dr. Mansnerus as to whether he did or didn't
9 progressed from Stage 1 to Stage 2 to Stage 3 to	9 meet the standard of care; correct?
10 Stage 4, are you?	10 A. That's correct.
11 A. You mean in my daily practice of	11 Q. But this case involves issues of
12 pathology	12 medical negligence where there is a plaintiff
13 Q. Yes.	13 and a defendant.
14 A at Parma Hospital? Not as a	14 A. Yes.
15 written report, but as discussions in tumor	15 Q. And Dr. Mansnerus is the defendant.
16 conferences on specific patients.	16 In that context, have you testified in a
17 Q. But on a day-to-day basis, when you	17 courtroom where there were allegations of
18 provide an opinion that someone is Stage 4,	18 malpractice on the part of a physician?
19 nonsmall cell poorly differentiated	19 A. Yes.
	20 Q. Of the four to five times that you
21 configuration is, your concern is more of giving	21 have testified, how many times have you
22 that information to the clinician as opposed to	22 testified in court in that capacity?
23 determining when that patient progressed from	23 A. Either once or twice.
24 Stage 3 to Stage 4; true?	24 Q. The other times that you have
25 A. That's true.	25 testified in a courtroom, what was the capacity
Page 30	Date 20
	Page 32
·	Page 32
1 Q. Before I move away entirely from your	1 of your appearance?
1 Q. Before I move away entirely from your 2 CV, is there anything else in your CV by way of	
1 Q. Before I move away entirely from your	1 of your appearance?
1 Q. Before I move away entirely from your 2 CV, is there anything else in your CV by way of 3 presentations, lectures, book chapters, invited	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor.
1 Q. Before I move away entirely from your 2 CV, is there anything else in your CV by way of 3 presentations, lectures, book chapters, invited 4 presentations that touch on the topic of lung	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you
1 Q. Before I move away entirely from your 2 CV, is there anything else in your CV by way of 3 presentations, lectures, book chapters, invited 4 presentations that touch on the topic of lung	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or
 Q. Before I move away entirely from your CV, is there anything else in your CV by way of presentations, lectures, book chapters, invited presentations that touch on the topic of lung cancer, other than what we have talked about? A. I don't think so. 	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or were they all civil cases?
 Q. Before I move away entirely from your CV, is there anything else in your CV by way of presentations, lectures, book chapters, invited presentations that touch on the topic of lung cancer, other than what we have talked about? A. I don't think so. Q. I'm going to focus your attention now 	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or were they all civil cases? A. I think they were all civil cases.
 Q. Before I move away entirely from your CV, is there anything else in your CV by way of presentations, lectures, book chapters, invited presentations that touch on the topic of lung cancer, other than what we have talked about? A. I don't think so. Q. I'm going to focus your attention now on your medical/legal experience and ask you 	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or were they all civil cases? A. I think they were all civil cases. Q. The other three times that you have
 Q. Before I move away entirely from your CV, is there anything else in your CV by way of presentations, lectures, book chapters, invited presentations that touch on the topic of lung cancer, other than what we have talked about? A. I don't think so. Q. I'm going to focus your attention now on your medical/legal experience and ask you some questions about that, okay? 	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or were they all civil cases? A. I think they were all civil cases. Q. The other three times that you have testified in court were not malpractice cases or
 Q. Before I move away entirely from your CV, is there anything else in your CV by way of presentations, lectures, book chapters, invited presentations that touch on the topic of lung cancer, other than what we have talked about? A. I don't think so. Q. I'm going to focus your attention now on your medical/legal experience and ask you some questions about that, okay? A. Okay. 	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or were they all civil cases? A. I think they were all civil cases. Q. The other three times that you have testified in court were not malpractice cases or what you may refer to as medical/legal cases?
 Q. Before I move away entirely from your CV, is there anything else in your CV by way of presentations, lectures, book chapters, invited presentations that touch on the topic of lung cancer, other than what we have talked about? A. I don't think so. Q. I'm going to focus your attention now on your medical/legal experience and ask you some questions about that, okay? A. Okay. Q. You said that you have testified 12 	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or were they all civil cases? A. I think they were all civil cases. Q. The other three times that you have testified in court were not malpractice cases or what you may refer to as medical/legal cases? I m sorry, say it again.
 Q. Before I move away entirely from your CV, is there anything else in your CV by way of presentations, lectures, book chapters, invited presentations that touch on the topic of lung cancer, other than what we have talked about? A. I don't think so. Q. I'm going to focus your attention now on your medical/legal experience and ask you some questions about that, okay? A. Okay. Q. You said that you have testified 12 to 15 times; true? 	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or were they all civil cases? A. I think they were all civil cases. Q. The other three times that you have testified in court were not malpractice cases or what you may refer to as medical/legal cases? A. I'm sorry, say it again. Q. Sure. Let me make it easier for you
 Q. Before I move away entirely from your CV, is there anything else in your CV by way of presentations, lectures, book chapters, invited presentations that touch on the topic of lung cancer, other than what we have talked about? A. I don't think so. Q. I'm going to focus your attention now on your medical/legal experience and ask you some questions about that, okay? A. Okay. Q. You said that you have testified 12 to 15 times; true? A. Depositions taken. 	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or were they all civil cases? A. I think they were all civil cases. Q. The other three times that you have testified in court were not malpractice cases or what you may refer to as medical/legal cases? A. I'm sorry, say it again. Q. Sure. Let me make it easier for you so that we are speaking the same language. I'll
 Q. Before I move away entirely from your CV, is there anything else in your CV by way of presentations, lectures, book chapters, invited presentations that touch on the topic of lung cancer, other than what we have talked about? A. I don't think so. Q. I'm going to focus your attention now on your medical/legal experience and ask you some questions about that, okay? A. Okay. Q. You said that you have testified 12 to 15 times; true? A. Depositions taken. Q. Depositions. 	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or were they all civil cases? A. I think they were all civil cases. Q. The other three times that you have testified in court were not malpractice cases or what you may refer to as medical/legal cases? A. I'm sorry, say it again. Q. Sure. Let me make it easier for you so that we are speaking the same language. I'll come at it from a different direction.
 Q. Before I move away entirely from your CV, is there anything else in your CV by way of presentations, lectures, book chapters, invited presentations that touch on the topic of lung cancer, other than what we have talked about? A. I don't think so. Q. I'm going to focus your attention now on your medical/legal experience and ask you some questions about that, okay? A. Okay. Q. You said that you have testified 12 to 15 times; true? A. Depositions taken. Q. Depositions. 	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or were they all civil cases? A. I think they were all civil cases. Q. The other three times that you have testified in court were not malpractice cases or what you may refer to as medical/legal cases? A. I'm sorry, say it again. Q. Sure. Let me make it easier for you so that we are speaking the same language. I'll come at it from a different direction. The four to five times that you have
 Q. Before I move away entirely from your CV, is there anything else in your CV by way of presentations, lectures, book chapters, invited presentations that touch on the topic of lung cancer, other than what we have talked about? A. I don't think so. Q. I'm going to focus your attention now on your medical/legal experience and ask you some questions about that, okay? A. Okay. Q. You said that you have testified 12 to 15 times; true? A. Depositions taken. Q. Depositions. A. Approximately. Q. Have you ever testified in a 	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or were they all civil cases? A. I think they were all civil cases. Q. The other three times that you have testified in court were not malpractice cases or what you may refer to as medical/legal cases? A. I'm sorry, say it again. Q. Sure. Let me make it easier for you so that we are speaking the same language. I'll come at it from a different direction. The four to five times that you have
 Q. Before I move away entirely from your CV, is there anything else in your CV by way of presentations, lectures, book chapters, invited presentations that touch on the topic of lung cancer, other than what we have talked about? A. I don't think so. Q. I'm going to focus your attention now on your medical/legal experience and ask you some questions about that, okay? A. Okay. Q. You said that you have testified 12 to 15 times; true? A. Depositions taken. Q. Have you ever testified in a courtroom? 	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or were they all civil cases? A. I think they were all civil cases. Q. The other three times that you have testified in court were not malpractice cases or what you may refer to as medical/legal cases? A. I'm sorry, say it again. Q. Sure. Let me make it easier for you so that we are speaking the same language. I'll come at it from a different direction. The four to five times that you have testified in the courtroom, how many of those times that you have testified in the courtroom
 Q. Before I move away entirely from your CV, is there anything else in your CV by way of presentations, lectures, book chapters, invited presentations that touch on the topic of lung cancer, other than what we have talked about? A. I don't think so. Q. I'm going to focus your attention now on your medical/legal experience and ask you some questions about that, okay? A. Okay. Q. You said that you have testified 12 to 15 times; true? A. Depositions taken. Q. Have you ever testified in a courtroom? A. Yes. 	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or were they all civil cases? A. I think they were all civil cases. Q. The other three times that you have testified in court were not malpractice cases or what you may refer to as medical/legal cases? A. I'm sorry, say it again. Q. Sure. Let me make it easier for you so that we are speaking the same language. I'll come at it from a different direction. The four to five times that you have
 Q. Before I move away entirely from your CV, is there anything else in your CV by way of presentations, lectures, book chapters, invited presentations that touch on the topic of lung cancer, other than what we have talked about? A. I don't think so. Q. I'm going to focus your attention now on your medical/legal experience and ask you some questions about that, okay? A. Okay. Q. You said that you have testified 12 to 15 times; true? A. Depositions taken. Q. Have you ever testified in a courtroom? 	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or were they all civil cases? A. I think they were all civil cases. Q. The other three times that you have testified in court were not malpractice cases or what you may refer to as medical/legal cases? A. I'm sorry, say it again. Q. Sure. Let me make it easier for you so that we are speaking the same language. I'll come at it from a different direction. The four to five times that you have testified in the courtroom, how many of those
 Q. Before I move away entirely from your CV, is there anything else in your CV by way of presentations, lectures, book chapters, invited presentations that touch on the topic of lung cancer, other than what we have talked about? A. I don't think so. Q. I'm going to focus your attention now on your medical/legal experience and ask you some questions about that, okay? A. Okay. Q. You said that you have testified 12 to 15 times; true? A. Depositions taken. Q. Have you ever testified in a courtroom? A. Yes. 	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or were they all civil cases? A. I think they were all civil cases. Q. The other three times that you have testified in court were not malpractice cases or what you may refer to as medical/legal cases? A. I'm sorry, say it again. Q. Sure. Let me make it easier for you so that we are speaking the same language. I'll come at it from a different direction. The four to five times that you have testified in the courtroom, how many of those times that you have testified in the courtroom have you been retained by the attorney representing a hospital or a doctor?
 Q. Before I move away entirely from your CV, is there anything else in your CV by way of presentations, lectures, book chapters, invited presentations that touch on the topic of lung cancer, other than what we have talked about? A. I don't think so. Q. I'm going to focus your attention now on your medical/legal experience and ask you some questions about that, okay? A. Okay. Q. You said that you have testified 12 to 15 times; true? A. Depositions taken. Q. Have you ever testified in a courtroom? A. Yes. Q. How many times? A. Four or five times. 	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or were they all civil cases? A. I think they were all civil cases. Q. The other three times that you have testified in court were not malpractice cases or what you may refer to as medical/legal cases? A. I'm sorry, say it again. Q. Sure. Let me make it easier for you so that we are speaking the same language. I'll come at it from a different direction. The four to five times that you have testified in the courtroom, how many of those times that you have testified in the courtroom have you been retained by the attorney representing a hospital or a doctor? A. All of them.
 Q. Before I move away entirely from your CV, is there anything else in your CV by way of presentations, lectures, book chapters, invited presentations that touch on the topic of lung cancer, other than what we have talked about? A. I don't think so. Q. I'm going to focus your attention now on your medical/legal experience and ask you some questions about that, okay? A. Okay. Q. You said that you have testified 12 to 15 times; true? A. Depositions taken. Q. Have you ever testified in a courtroom? A. Yes. Q. How many times? A. Four or five times. Q. Have you ever testified in a 	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or were they all civil cases? A. I think they were all civil cases. Q. The other three times that you have testified in court were not malpractice cases or what you may refer to as medical/legal cases? A. I'm sorry, say it again. Q. Sure. Let me make it easier for you so that we are speaking the same language. I'll come at it from a different direction. The four to five times that you have testified in the courtroom, how many of those times that you have testified in the courtroom have you been retained by the attorney representing a hospital or a doctor? A. All of them. Q. Can you explain to me when I asked
 Q. Before I move away entirely from your CV, is there anything else in your CV by way of presentations, lectures, book chapters, invited presentations that touch on the topic of lung cancer, other than what we have talked about? A. I don't think so. Q. I'm going to focus your attention now on your medical/legal experience and ask you some questions about that, okay? A. Okay. Q. You said that you have testified 12 to 15 times; true? A. Depositions taken. Q. Have you ever testified in a courtroom? A. Yes. Q. How many times? A. Four or five times. Q. Have you ever testified in a courtroom as an expert witness in a medical 	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or were they all civil cases? A. I think they were all civil cases. Q. The other three times that you have testified in court were not malpractice cases or what you may refer to as medical/legal cases? A. I'm sorry, say it again. Q. Sure. Let me make it easier for you so that we are speaking the same language. I'll come at it from a different direction. The four to five times that you have testified in the courtroom, how many of those times that you have testified in the courtroom have you been retained by the attorney representing a hospital or a doctor? A. All of them. Q. Can you explain to me when I asked you about the four to five times why you
 Q. Before I move away entirely from your CV, is there anything else in your CV by way of presentations, lectures, book chapters, invited presentations that touch on the topic of lung cancer, other than what we have talked about? A. I don't think so. Q. I'm going to focus your attention now on your medical/legal experience and ask you some questions about that, okay? A. Okay. Q. You said that you have testified 12 to 15 times; true? A. Depositions taken. Q. Have you ever testified in a courtroom? A. Yes. Q. How many times? A. Four or five times. Q. Have you ever testified in a courtroom as an expert witness in a medical negligence case? 	 1 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or were they all civil cases? A. I think they were all civil cases. Q. The other three times that you have testified in court were not malpractice cases or what you may refer to as medical/legal cases? A. I'm sorry, say it again. Q. Sure. Let me make it easier for you so that we are speaking the same language. I'll come at it from a different direction. The four to five times that you have testified in the courtroom, how many of those times that you have testified in the courtroom have you been retained by the attorney representing a hospital or a doctor? A. All of them. Q. Can you explain to me when I asked you about the four to five times why you separated out one to two times that you were
 Q. Before I move away entirely from your CV, is there anything else in your CV by way of presentations, lectures, book chapters, invited presentations that touch on the topic of lung cancer, other than what we have talked about? A. I don't think so. Q. I'm going to focus your attention now on your medical/legal experience and ask you some questions about that, okay? A. Okay. Q. You said that you have testified 12 to 15 times; true? A. Depositions taken. Q. Have you ever testified in a courtroom? A. Yes. Q. How many times? A. Four or five times. Q. Have you ever testified in a courtroom as an expert witness in a medical negligence case? A. You mean medical/legal case? I don't 	 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or were they all civil cases? A. I think they were all civil cases. Q. The other three times that you have testified in court were not malpractice cases or what you may refer to as medical/legal cases? A. I'm sorry, say it again. Q. Sure. Let me make it easier for you so that we are speaking the same language. I'll come at it from a different direction. The four to five times that you have testified in the courtroom, how many of those times that you have testified in the courtroom have you been retained by the attorney representing a hospital or a doctor? A. All of them. Q. Can you explain to me when I asked you about the four to five times that you were testifying in a malpractice case as opposed to
 Q. Before I move away entirely from your CV, is there anything else in your CV by way of presentations, lectures, book chapters, invited presentations that touch on the topic of lung cancer, other than what we have talked about? A. I don't think so. Q. I'm going to focus your attention now on your medical/legal experience and ask you some questions about that, okay? A. Okay. Q. You said that you have testified 12 to 15 times; true? A. Depositions taken. Q. Have you ever testified in a courtroom? A. Yes. Q. How many times? A. Four or five times. Q. Have you ever testified in a courtroom as an expert witness in a medical negligence case? 	 1 of your appearance? A. Mostly determining the stage of the tumor and the rate of progression of the tumor. Q. Were any of these times that you testified in court, were they criminal cases or were they all civil cases? A. I think they were all civil cases. Q. The other three times that you have testified in court were not malpractice cases or what you may refer to as medical/legal cases? A. I'm sorry, say it again. Q. Sure. Let me make it easier for you so that we are speaking the same language. I'll come at it from a different direction. The four to five times that you have testified in the courtroom, how many of those times that you have testified in the courtroom have you been retained by the attorney representing a hospital or a doctor? A. All of them. Q. Can you explain to me when I asked you about the four to five times why you separated out one to two times that you were

8 (Pages 29 to 32)

October 28, 2003

Page 33	Page 35
 A. Well, the one time that I do remember the details was regarding the interpretation of PAP smears by a lab. And as is obvious from my answer, I can't really remember the other case. But I know that there are two other cases that did not involve the interpretation of pathologic material and I can't remember whether there is it's probably not five, it's probably just four cases, more like four. Q. But even though there may not have been an issue of interpretation of the pathological material, were all of these cases medical/legal cases? A. Yes. Q. And all of the cases you had been retained by a defense attorney to come in and testify; true? A. Yes. Q. When is the last time you testified in a courtroom, either in Cleveland or anywhere else? A. Yes. Q. Was that here in Cleveland? A. Yes. Q. Do you remember what firm, what law 	 you want on the list? Q. If you have the name of the attorney, the name of the case. These are matters that you have already testified on, so it wouldn't be an issue of disclosing something that you haven't been identified in. If you have given depositions or you have testified in court, then we don't have to worry about somebody saying that you were a confidential consultant, okay? A. Okay. Q. When are you scheduled next to testify in a courtroom? A. In November. Q. And that would again be for? A. I think it's the Gill case. MR. WARNER: This case is continued. THE WITNESS: So the November 20th date is off? MR. WARNER: Is off. Cancel it on your calendar. (Discussion off the record.) Q. Putting aside the Gill case, do you know when you are next set to testify? A. I am not scheduled. Q. The 12 to 15 times that you have
 Page 34 1 firm had retained you to testify? A. No. Q. Do you remember the subject matter of 4 that case that was one year ago? A. Yes. It was a breast cancer patient. Q. Did the breast cancer patient die? A. No. She was alive at the time of 8 trial. Q. And was your opinion essentially that 10 an earlier diagnosis would probably not have led 11 to a different outcome? A. Yes. Q. You don't remember the name of the 14 law firm? A. No. Q. Do you keep any records of your 17 medical/legal cases? A. Yes. Q. That's something that you would have 20 on your computer? 21 A. Yes. Q. I'm going to request that you provide 23 me with a list of the medical/legal cases that 24 you have been involved in. 25 A. Sure. What kind of information do 	 Page 36 given depositions, have all of those cases been where you have been retained as an expert by a party in litigation? A. Well, one time I was a defendant. Q. Have you been a defendant on more than one occasion? A. No. Q. How long ago was that, ma'am? A. I was a fellow at University Hospitals, so it was in 1987. Q. How did that case wind up? A. This was a famous case, the Moskovitz case. Q. Yes, I recognize the name. A. At the time I was a resident at Mt. Sinai Hospital when the alleged malpractice occurred, and I was a resident involved in the frozen section, but not in the actual interpretation of any of the tissue. So I was named and when it was found out that I had nothing to do with actually interpreting any of the pathology material, my name was dropped in the case. Q. Chuck Kampinski is the one that took your deposition?

9 (Pages 33 to 36)

October 28, 2003

Page 37	Dama 30
Fage 37	Page 39
1 A. Yes.	1 including Mr. Warner, on medical malpractice
2 Q. Let's put aside that experience.	2 cases?
3 Other than that experience where you were named,	3 A. You mean by Reminger & Reminger?
4 you have been able to avoid the unfortunate	4 Q. Yes.
5 experience of being named as a defendant at any	5 A. Yes.
6 other time in your career?	6 Q. Mr. Warner, how many times has he
7 A. Well, I don't know if I was able to	7 asked you and you have agreed to serve as an
8 avoid it, but thank God, I have not been named.	8 expert on behalf of one of his doctors?
9 Q. Avoiding it or otherwise, you haven't	9 A. Four or five times.
10 been named?	10 Q. Would this be the fifth or the sixth
11 A. No.	11 or would this be would that all be
12 Q. The other times that you have given	12 encompassing with the Gill case?
13 deposition testimony, I want to talk about	13 A. That's probably additional. But
14 those. They have been in situations where you	14 that's not an accurate number.
15 have been retained as an expert witness; is that	15 Q. These are your best estimates?
16 true?	16 A. Yes.
17 A. Yes.	17 Q. So that if we added Gill, your best
18 Q. I take it all of them have had to do	18 estimate would be this is now the fifth or sixth
19 with pathology issues?	19 time that you have been an expert for
20 A. Mostly pathology issues. Sometimes	20 Mr. Warner?
21 it was related to the proximate cause of death.	21 A. Probably.
22 Q. Have you ever testified in deposition	22 Q. What about other lawyers at
23 in a nonsmall cell lung cancer case?	23 Reminger & Reminger?
24 A. I don't remember so.	24 A. I have reviewed maybe a couple other
25 Q. Of the 11 to 14 times, excluding the	25 cases for some other Reminger & Reminger
Page 38	Page 40
	Page 40
1 one time that you were a defendant, how many of	1 lawyers.
 one time that you were a defendant, how many of those cases where you were serving as an expert, 	 lawyers. Q. Do you remember the name of any of
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing 	 lawyers. Q. Do you remember the name of any of the attorneys?
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them.
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at the request of an attorney representing a doctor 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them. Q. How many cases have you reviewed for
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at the request of an attorney representing a doctor or a hospital? 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them. Q. How many cases have you reviewed for Jim Malone?
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at the request of an attorney representing a doctor or a hospital? A. I think all of these cases. 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them. Q. How many cases have you reviewed for Jim Malone? A. One.
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at the request of an attorney representing a doctor or a hospital? A. I think all of these cases. Q. So is it fair to say that your 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them. Q. How many cases have you reviewed for Jim Malone? A. One. Q. Any other lawyers that names come to
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at the request of an attorney representing a doctor or a hospital? A. I think all of these cases. Q. So is it fair to say that your testifying experience in terms of depositions, 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them. Q. How many cases have you reviewed for Jim Malone? A. One. Q. Any other lawyers that names come to mind?
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at the request of an attorney representing a doctor or a hospital? A. I think all of these cases. Q. So is it fair to say that your testifying experience in terms of depositions, as well as courtroom testimony, has been 100 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them. Q. How many cases have you reviewed for Jim Malone? A. One. Q. Any other lawyers that names come to mind? A. There is a woman lawyer that I can't
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at the request of an attorney representing a doctor or a hospital? A. I think all of these cases. Q. So is it fair to say that your testifying experience in terms of depositions, as well as courtroom testimony, has been 100 percent at the request of an attorney 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them. Q. How many cases have you reviewed for Jim Malone? A. One. Q. Any other lawyers that names come to mind? M. There is a woman lawyer that I can't remember her name.
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at the request of an attorney representing a doctor or a hospital? A. I think all of these cases. Q. So is it fair to say that your testifying experience in terms of depositions, as well as courtroom testimony, has been 100 percent at the request of an attorney representing either a doctor or a hospital? 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them. Q. How many cases have you reviewed for Jim Malone? A. One. Q. Any other lawyers that names come to mind? M. There is a woman lawyer that I can't remember her name. Q. Marilena?
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at the request of an attorney representing a doctor or a hospital? A. I think all of these cases. Q. So is it fair to say that your testifying experience in terms of depositions, as well as courtroom testimony, has been 100 percent at the request of an attorney representing either a doctor or a hospital? A. As far as giving depositions and 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them. Q. How many cases have you reviewed for Jim Malone? A. One. Q. Any other lawyers that names come to mind? M. There is a woman lawyer that I can't remember her name. Q. Marilena? A. No. Sue.
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at the request of an attorney representing a doctor or a hospital? A. I think all of these cases. Q. So is it fair to say that your testifying experience in terms of depositions, as well as courtroom testimony, has been 100 percent at the request of an attorney representing either a doctor or a hospital? A. As far as giving depositions and court testimony, yes. 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them. Q. How many cases have you reviewed for Jim Malone? A. One. Q. Any other lawyers that names come to mind? M. There is a woman lawyer that I can't remember her name. Q. Marilena? A. No. Sue. Q. Sue Seacrist?
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at the request of an attorney representing a doctor or a hospital? A. I think all of these cases. Q. So is it fair to say that your testifying experience in terms of depositions, as well as courtroom testimony, has been 100 percent at the request of an attorney representing either a doctor or a hospital? A. As far as giving depositions and court testimony, yes. Q. How many cases a year are presented 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them. Q. How many cases have you reviewed for Jim Malone? A. One. Q. Any other lawyers that names come to mind? M. There is a woman lawyer that I can't remember her name. Q. Marilena? A. No. Sue. Q. Sue Seacrist? A. Sue Seacrist, yes.
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at the request of an attorney representing a doctor or a hospital? A. I think all of these cases. Q. So is it fair to say that your testifying experience in terms of depositions, as well as courtroom testimony, has been 100 percent at the request of an attorney representing either a doctor or a hospital? A. As far as giving depositions and court testimony, yes. Q. How many cases a year are presented to you, new cases for you to take a look at by 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them. Q. How many cases have you reviewed for Jim Malone? A. One. Q. Any other lawyers that names come to mind? A. There is a woman lawyer that I can't remember her name. Q. Marilena? A. No. Sue. Q. Sue Seacrist? A. Sue Seacrist, yes. Q. How many cases have you reviewed for
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at the request of an attorney representing a doctor or a hospital? A. I think all of these cases. Q. So is it fair to say that your testifying experience in terms of depositions, as well as courtroom testimony, has been 100 percent at the request of an attorney representing either a doctor or a hospital? A. As far as giving depositions and court testimony, yes. Q. How many cases a year are presented to you, new cases for you to take a look at by an attorney like Mr. Warner or some other 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them. Q. How many cases have you reviewed for Jim Malone? A. One. Q. Any other lawyers that names come to mind? A. There is a woman lawyer that I can't remember her name. Q. Marilena? A. No. Sue. Q. Sue Seacrist? A. Sue Seacrist, yes. Q. How many cases have you reviewed for
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at the request of an attorney representing a doctor or a hospital? A. I think all of these cases. Q. So is it fair to say that your testifying experience in terms of depositions, as well as courtroom testimony, has been 100 percent at the request of an attorney representing either a doctor or a hospital? A. As far as giving depositions and court testimony, yes. Q. How many cases a year are presented to you, new cases for you to take a look at by an attorney like Mr. Warner or some other lawyer? 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them. Q. How many cases have you reviewed for Jim Malone? A. One. Q. Any other lawyers that names come to mind? A. There is a woman lawyer that I can't remember her name. Q. Marilena? A. No. Sue. Q. Sue Seacrist? A. Sue Seacrist, yes. Q. How many cases have you reviewed for Ms. Seacrist? A. One.
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at the request of an attorney representing a doctor or a hospital? A. I think all of these cases. Q. So is it fair to say that your testifying experience in terms of depositions, as well as courtroom testimony, has been 100 percent at the request of an attorney representing either a doctor or a hospital? A. As far as giving depositions and court testimony, yes. Q. How many cases a year are presented to you, new cases for you to take a look at by an attorney like Mr. Warner or some other lawyer? A. Four to six cases a year. 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them. Q. How many cases have you reviewed for Jim Malone? A. One. Q. Any other lawyers that names come to mind? A. There is a woman lawyer that I can't remember her name. Q. Marilena? A. No. Sue. Q. Sue Seacrist? A. Sue Seacrist, yes. Q. How many cases have you reviewed for Ms. Seacrist? A. One. Q. Any other attorneys that you have
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at the request of an attorney representing a doctor or a hospital? A. I think all of these cases. Q. So is it fair to say that your testifying experience in terms of depositions, as well as courtroom testimony, has been 100 percent at the request of an attorney representing either a doctor or a hospital? A. As far as giving depositions and court testimony, yes. Q. How many cases a year are presented to you, new cases for you to take a look at by an attorney like Mr. Warner or some other lawyer? A. Four to six cases a year. Q. And while we are talking about 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them. Q. How many cases have you reviewed for Jim Malone? A. One. Q. Any other lawyers that names come to mind? A. There is a woman lawyer that I can't remember her name. Q. Marilena? A. No. Sue. Q. Sue Seacrist? A. Sue Seacrist, yes. Q. How many cases have you reviewed for Ms. Seacrist? A. One. Q. Any other attorneys that you have worked with at Reminger & Reminger?
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at the request of an attorney representing a doctor or a hospital? A. I think all of these cases. Q. So is it fair to say that your testifying experience in terms of depositions, as well as courtroom testimony, has been 100 percent at the request of an attorney representing either a doctor or a hospital? A. As far as giving depositions and court testimony, yes. Q. How many cases a year are presented to you, new cases for you to take a look at by an attorney like Mr. Warner or some other lawyer? A. Four to six cases a year. Q. And while we are talking about Mr. Warner, I presume you know that he is with 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them. Q. How many cases have you reviewed for Jim Malone? A. One. Q. Any other lawyers that names come to mind? A. There is a woman lawyer that I can't remember her name. Q. Marilena? A. No. Sue. Q. Sue Seacrist? A. Sue Seacrist, yes. Q. How many cases have you reviewed for Ms. Seacrist? A. One. Q. Any other attorneys that you have worked with at Reminger & Reminger? A. Not that I can remember.
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at the request of an attorney representing a doctor or a hospital? A. I think all of these cases. Q. So is it fair to say that your testifying experience in terms of depositions, as well as courtroom testimony, has been 100 percent at the request of an attorney representing either a doctor or a hospital? A. As far as giving depositions and court testimony, yes. Q. How many cases a year are presented to you, new cases for you to take a look at by an attorney like Mr. Warner or some other lawyer? A. Four to six cases a year. Q. And while we are talking about 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them. Q. How many cases have you reviewed for Jim Malone? A. One. Q. Any other lawyers that names come to mind? A. There is a woman lawyer that I can't remember her name. Q. Marilena? A. No. Sue. Q. Sue Seacrist? A. Sue Seacrist, yes. Q. How many cases have you reviewed for Ms. Seacrist? A. One. Q. Any other attorneys that you have worked with at Reminger & Reminger? A. Not that I can remember. Q. Of the five to six cases for
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at the request of an attorney representing a doctor or a hospital? A. I think all of these cases. Q. So is it fair to say that your testifying experience in terms of depositions, as well as courtroom testimony, has been 100 percent at the request of an attorney representing either a doctor or a hospital? A. As far as giving depositions and court testimony, yes. Q. How many cases a year are presented to you, new cases for you to take a look at by an attorney like Mr. Warner or some other lawyer? A. Four to six cases a year. Q. And while we are talking about Mr. Warner, I presume you know that he is with the law firm of Reminger & Reminger; correct? A. Yes. 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them. Q. How many cases have you reviewed for Jim Malone? A. One. Q. Any other lawyers that names come to mind? A. There is a woman lawyer that I can't remember her name. Q. Marilena? A. No. Sue. Q. Sue Seacrist? A. Sue Seacrist, yes. Q. How many cases have you reviewed for Ms. Seacrist? A. One. Q. Any other attorneys that you have worked with at Reminger & Reminger? A. Not that I can remember. Q. Of the five to six cases for Mr. Warner, including the Gill case, how many of
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at the request of an attorney representing a doctor or a hospital? A. I think all of these cases. Q. So is it fair to say that your testifying experience in terms of depositions, as well as courtroom testimony, has been 100 percent at the request of an attorney representing either a doctor or a hospital? A. As far as giving depositions and court testimony, yes. Q. How many cases a year are presented to you, new cases for you to take a look at by an attorney like Mr. Warner or some other lawyer? A. Four to six cases a year. Q. And while we are talking about Mr. Warner, I presume you know that he is with the law firm of Reminger & Reminger; correct? A. Yes. Q. Have you had occasion to serve as an 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them. Q. How many cases have you reviewed for Jim Malone? A. One. Q. Any other lawyers that names come to mind? A. There is a woman lawyer that I can't remember her name. Q. Marilena? A. No. Sue. Q. Sue Seacrist? A. Sue Seacrist, yes. Q. How many cases have you reviewed for Ms. Seacrist? A. One. Q. Any other attorneys that you have worked with at Reminger & Reminger? A. Not that I can remember. Q. Of the five to six cases for Mr. Warner, including the Gill case, how many of them have you given deposition testimony in?
 one time that you were a defendant, how many of those cases where you were serving as an expert, either on proximate cause of death or dealing with pathology issues, were you testifying at the request of an attorney representing a doctor or a hospital? A. I think all of these cases. Q. So is it fair to say that your testifying experience in terms of depositions, as well as courtroom testimony, has been 100 percent at the request of an attorney representing either a doctor or a hospital? A. As far as giving depositions and court testimony, yes. Q. How many cases a year are presented to you, new cases for you to take a look at by an attorney like Mr. Warner or some other lawyer? A. Four to six cases a year. Q. And while we are talking about Mr. Warner, I presume you know that he is with the law firm of Reminger & Reminger; correct? A. Yes. Q. Have you had occasion to serve as an 	 lawyers. Q. Do you remember the name of any of the attorneys? A. Mr. Malone is one of them. Q. How many cases have you reviewed for Jim Malone? A. One. Q. Any other lawyers that names come to mind? A. There is a woman lawyer that I can't remember her name. Q. Marilena? A. No. Sue. Q. Sue Seacrist? A. Sue Seacrist, yes. Q. How many cases have you reviewed for Ms. Seacrist? A. One. Q. Any other attorneys that you have worked with at Reminger & Reminger? A. Not that I can remember. Q. Of the five to six cases for Mr. Warner, including the Gill case, how many of

10 (Pages 37 to 40)

October 28, 2003

 Page 41 remember exactly because these depositions always get cancelled and I don't keep a record of which ones exactly went through. Q. Just like the cancellation of Dr. Botham that Mr. Warner's family matter caused today; right? A. Right. Q. None of those cases were nonsmall cell lung cancer cases? A. I don't think so. Q. Of the four to six cases per year that you review, how long has that been the range of cases, new cases that you look at? How many years has that been? A. I think I started about ten years ago, but I only did like maybe one or two cases a year. I was very busy when I was at UH. I already had a very hectic schedule there, so I think there were less cases per year. Overall, and I'm not talking about the depositions, but all cases that I would review, which many times do not go to depositions or testimony, there is probably 25, 	 Page 43 Q. Were any of them in the State of Ohio? A. Yes. Q. Were any of them in the Cleveland area? A. Yes. Q. Did any of those cases that you reviewed in the Cleveland area actually I just figured out my own answer but I'll ask it any way did any of those lead to deposition testimony? A. I don't remember, so, no. Q. Do you remember the names of any of the plaintiff's lawyers that you reviewed cases for? A. At least two of them were for Nurenberg, Plevin, whatever. Q. I get the gist. Do you remember which lawyer from that firm? A. There were two different ones. Tom Mester and the other guy. Q. Harley Gordon? A. Gordon. (Discussion off the record.) Q. Any other plaintiff's firms that you
 Page 42 around 25 cases. Q. That you have reviewed over the ten years? A. Yes. Q. So the amount is actually increasing as of the current year; is that correct? A. No, not really. It's been steady for the past few years. For the past three or four years it's been steady. Q. So early on in that ten year spectrum there might have been one case a year? A. Yes. Q. Of the 25 cases that you have reviewed, some of them have gone to deposition; true? A. Yes. Q. We have talked about that. A. Yes. Q. Of the total 25 that you have Yes. Q. Of the total 25 that you have f attorney representing the plaintiff as opposed to an attorney representing the defense? A. Maybe four or five plaintiff cases. 	 Page 44 recall other than Nurenberg, Plevin? A. I don't really remember the names of the firms, but as I said, there were probably three other cases that I have reviewed. Q. For plaintiff's attorneys in the Cleveland area? A. Yes. Q. Have you reviewed any cases outside of the Cleveland area? A. Yes. I think some of the cases, or at least one of the cases was in Youngstown. There were a couple of cases in the Akron-Canton area. There was some cases for a law firm in Atlanta, Georgia, but the case was actually tried in Akron-Canton. And one maybe in Columbus that never went to deposition, but just a review. Q. Do you know how your name was obtained by any of those attorneys, like, for example, the Atlanta, Georgia, attorney? A. It's either referrals from lawyers or usually the law firms call University Hospital and ask for a pathologist to review a certain case and my name is given to them. Q. Have you ever been on any type of a

11 (Pages 41 to 44)

October 28, 2003

Page 45	Page 47
1 list where your name has been made available as	1 December 9, 1999?
2 an expert to attorneys?	2 A. No. I think I mentioned I can't
3 A. No.	3 remember.
4 Q. Have you ever advertised?	4 MR. WARNER: Note my objection. Do
5 A. No.	5 you want her to look at the records? Just from
6 Q. I take it you have never had your	6 her memory?
7 privileges suspended or revoked or called into	7 Q. Doctor, based upon your review in
8 question? 9 A. That's correct.	8 this case, is there any evidence in January or 9 February that Mr. Gill had metastatic lung
9 A. That's correct. 10 Q. In your report, doctor, the last	9 February that Mr. Gill had metastatic lung 10 cancer?
11 paragraph, it says based upon the above review	11 A. What kind of evidence?
12 to a reasonable degree of medical probability, I	12 Q. Any evidence that was discovered or
13 believe that if it was possible to diagnose	13 revealed from a clinical standpoint or any
14 Mr. Gill's lung tumor in January or February of	14 diagnostic studies that were done that would
15 2000 and then the sentence goes on. I want	15 cause you to be able to say that Mr. Gill had
16 to stop at that point because that's what I want	16 metastatic lung cancer in January or February?
17 to focus in on.	17 A. You mean in retrospect now that we
18 Do you intend to testify at trial	18 know what we know about Mr. Gill or at the time
19 that it was not possible to diagnose Mr. Gill's	19 in January or February of 2000 based on his
20 lung cancer in January or February of 2000?	20 clinical presentation and his signs and symptoms
21 A. No.	21 and x-ray findings?
22 Q. Do you agree or have a basis to agree 23 that the diagnosis in December of 1999 that was	22 Q. Based upon the latter statement
 23 that the diagnosis in December of 1999 that was 24 made by Dr. Mansnerus of pneumonia was or was 	23 rather than the former statement. 24 A. So in January or February of 2000.
24 made by Dr. Mansherus of pheumonia was or was 25 not accurate?	A. So in January or February of 2000,25 basically in December, his presentation was
	2.5 basically in December, its presentation was
Page 46 1 A. I don't intend to render an opinion 2 on this issue.	Page 48 1 respiratory symptoms and numbness in the left 2 arm and neck at the time. Now, in retrospect?
 3 Q. Thank you. Was there any evidence in 4 January strike that. 5 You have enough of a time line in 6 your mind in terms of when Mr. Gill was seen by 7 Dr. Mansnerus to appreciate the temporal 8 relationship of all of what developed; true? 9 A. Yes. 10 Q. Do you know how long Mr. Gill had 11 been a patient of Dr. Mansnerus? 12 A. I can't recall that. I know that the 13 first time that he was seen in relationship to 14 this illness was in December, the beginning of 	 Q. No, no. At that time. A. If I was a physician that was seeing the patient, is that what you are asking me? If I was a physician seeing the patient in January or February of 2000 whether I would suspect that he had mets at the time? Is that what you are asking me? Q. You are kind of close, but before you answer it and you are doing exactly the right thing. I'm not asking you retrospectively. We may talk about that in a moment based upon the slides that you looked at, which are at the time
 January strike that. You have enough of a time line in your mind in terms of when Mr. Gill was seen by Dr. Mansnerus to appreciate the temporal relationship of all of what developed; true? A. Yes. Q. Do you know how long Mr. Gill had been a patient of Dr. Mansnerus? A. I can't recall that. I know that the first time that he was seen in relationship to this illness was in December, the beginning of December of 1999. 	 A. If I was a physician that was seeing the patient, is that what you are asking me? If I was a physician seeing the patient in January or February of 2000 whether I would suspect that he had mets at the time? Is that what you are asking me? Q. You are kind of close, but before you answer it and you are doing exactly the right thing. I'm not asking you retrospectively. We may talk about that in a moment based upon the slides that you looked at, which are at the time of the diagnosis, but what I'm asking you is
 January strike that. You have enough of a time line in your mind in terms of when Mr. Gill was seen by Dr. Mansnerus to appreciate the temporal relationship of all of what developed; true? A. Yes. Q. Do you know how long Mr. Gill had been a patient of Dr. Mansnerus? A. I can't recall that. I know that the first time that he was seen in relationship to this illness was in December, the beginning of December of 1999. Q. Do you remember how many times he was 	 A. If I was a physician that was seeing the patient, is that what you are asking me? If I was a physician seeing the patient in January or February of 2000 whether I would suspect that he had mets at the time? Is that what you are asking me? Q. You are kind of close, but before you answer it and you are doing exactly the right thing. I'm not asking you retrospectively. We may talk about that in a moment based upon the slides that you looked at, which are at the time of the diagnosis, but what I'm asking you is from your review of this case.
 January strike that. You have enough of a time line in your mind in terms of when Mr. Gill was seen by Dr. Mansnerus to appreciate the temporal relationship of all of what developed; true? A. Yes. Q. Do you know how long Mr. Gill had been a patient of Dr. Mansnerus? A. I can't recall that. I know that the first time that he was seen in relationship to this illness was in December, the beginning of December of 1999. Q. Do you remember how many times he was seen in December? 	 A. If I was a physician that was seeing the patient, is that what you are asking me? If I was a physician seeing the patient in January or February of 2000 whether I would suspect that he had mets at the time? Is that what you are asking me? Q. You are kind of close, but before you answer it and you are doing exactly the right thing. I'm not asking you retrospectively. We may talk about that in a moment based upon the slides that you looked at, which are at the time of the diagnosis, but what I'm asking you is from your review of this case. You have already told me that he
 January strike that. You have enough of a time line in your mind in terms of when Mr. Gill was seen by Dr. Mansnerus to appreciate the temporal relationship of all of what developed; true? A. Yes. Q. Do you know how long Mr. Gill had been a patient of Dr. Mansnerus? A. I can't recall that. I know that the first time that he was seen in relationship to this illness was in December, the beginning of December of 1999. Q. Do you remember how many times he was seen in December? 	 A. If I was a physician that was seeing the patient, is that what you are asking me? If I was a physician seeing the patient in January or February of 2000 whether I would suspect that he had mets at the time? Is that what you are asking me? Q. You are kind of close, but before you answer it and you are doing exactly the right thing. I'm not asking you retrospectively. We may talk about that in a moment based upon the slides that you looked at, which are at the time of the diagnosis, but what I'm asking you is from your review of this case.
 January strike that. You have enough of a time line in your mind in terms of when Mr. Gill was seen by Dr. Mansnerus to appreciate the temporal relationship of all of what developed; true? A. Yes. Q. Do you know how long Mr. Gill had been a patient of Dr. Mansnerus? A. I can't recall that. I know that the first time that he was seen in relationship to this illness was in December, the beginning of December of 1999. Q. Do you remember how many times he was seen in December? A. Twice. December 9th and 30th. Q. And before those two dates in December, had he been a patient for any extended 	 A. If I was a physician that was seeing the patient, is that what you are asking me? If I was a physician seeing the patient in January or February of 2000 whether I would suspect that he had mets at the time? Is that what you are asking me? Q. You are kind of close, but before you answer it and you are doing exactly the right thing. I'm not asking you retrospectively. We may talk about that in a moment based upon the slides that you looked at, which are at the time of the diagnosis, but what I'm asking you is from your review of this case. You have already told me that he appeared twice in December to see Dr. Mansnerus and then we know that there are certain events
 January strike that. You have enough of a time line in your mind in terms of when Mr. Gill was seen by Dr. Mansnerus to appreciate the temporal relationship of all of what developed; true? A. Yes. Q. Do you know how long Mr. Gill had been a patient of Dr. Mansnerus? A. I can't recall that. I know that the first time that he was seen in relationship to this illness was in December, the beginning of December of 1999. Q. Do you remember how many times he was seen in December? A. Twice. December 9th and 30th. Q. And before those two dates in December, had he been a patient for any extended period of time with Dr. Mansnerus? 	 A. If I was a physician that was seeing the patient, is that what you are asking me? If I was a physician seeing the patient in January or February of 2000 whether I would suspect that he had mets at the time? Is that what you are asking me? Q. You are kind of close, but before you answer it and you are doing exactly the right thing. I'm not asking you retrospectively. We may talk about that in a moment based upon the slides that you looked at, which are at the time of the diagnosis, but what I'm asking you is from your review of this case. You have already told me that he appeared twice in December to see Dr. Mansnerus and then we know that there are certain events that went on in the early part of 2000 leading up to his diagnosis.
 January strike that. You have enough of a time line in your mind in terms of when Mr. Gill was seen by Dr. Mansnerus to appreciate the temporal relationship of all of what developed; true? A. Yes. Q. Do you know how long Mr. Gill had been a patient of Dr. Mansnerus? A. I can't recall that. I know that the first time that he was seen in relationship to this illness was in December, the beginning of December of 1999. Q. Do you remember how many times he was seen in December? A. Twice. December 9th and 30th. Q. And before those two dates in December, had he been a patient for any extended period of time with Dr. Mansnerus? A. I can't remember. 	 A. If I was a physician that was seeing the patient, is that what you are asking me? If I was a physician seeing the patient in January or February of 2000 whether I would suspect that he had mets at the time? Is that what you are asking me? Q. You are kind of close, but before you answer it and you are doing exactly the right thing. I'm not asking you retrospectively. We may talk about that in a moment based upon the slides that you looked at, which are at the time of the diagnosis, but what I'm asking you is from your review of this case. You have already told me that he appeared twice in December to see Dr. Mansnerus and then we know that there are certain events that went on in the early part of 2000 leading up to his diagnosis.
 January strike that. You have enough of a time line in your mind in terms of when Mr. Gill was seen by Dr. Mansnerus to appreciate the temporal relationship of all of what developed; true? A. Yes. Q. Do you know how long Mr. Gill had been a patient of Dr. Mansnerus? A. I can't recall that. I know that the first time that he was seen in relationship to this illness was in December, the beginning of December of 1999. Q. Do you remember how many times he was seen in December? A. Twice. December 9th and 30th. Q. And before those two dates in December, had he been a patient for any extended period of time with Dr. Mansnerus? A. I can't remember. Can you tell me from your review how 	 A. If I was a physician that was seeing the patient, is that what you are asking me? If I was a physician seeing the patient in January or February of 2000 whether I would suspect that he had mets at the time? Is that what you are asking me? Q. You are kind of close, but before you answer it and you are doing exactly the right thing. I'm not asking you retrospectively. We may talk about that in a moment based upon the slides that you looked at, which are at the time of the diagnosis, but what I'm asking you is from your review of this case. You have already told me that he appeared twice in December to see Dr. Mansnerus and then we know that there are certain events that went on in the early part of 2000 leading up to his diagnosis. What I'm asking you is from what you have in black and white, medical records,
 January strike that. You have enough of a time line in your mind in terms of when Mr. Gill was seen by Dr. Mansnerus to appreciate the temporal relationship of all of what developed; true? A. Yes. Q. Do you know how long Mr. Gill had been a patient of Dr. Mansnerus? A. I can't recall that. I know that the first time that he was seen in relationship to this illness was in December, the beginning of December of 1999. Q. Do you remember how many times he was seen in December? A. Twice. December 9th and 30th. Q. And before those two dates in December, had he been a patient for any extended period of time with Dr. Mansnerus? A. I can't remember. Q. Can you tell me from your review how many times Mr. Gill had been seen by 	 A. If I was a physician that was seeing the patient, is that what you are asking me? If I was a physician seeing the patient in January or February of 2000 whether I would suspect that he had mets at the time? Is that what you are asking me? Q. You are kind of close, but before you answer it and you are doing exactly the right thing. I'm not asking you retrospectively. We may talk about that in a moment based upon the slides that you looked at, which are at the time of the diagnosis, but what I'm asking you is from your review of this case. You have already told me that he appeared twice in December to see Dr. Mansnerus and then we know that there are certain events that went on in the early part of 2000 leading up to his diagnosis. What I'm asking you is from what you have in black and white, medical records, diagnostic studies, examinations, is there any
 January strike that. You have enough of a time line in your mind in terms of when Mr. Gill was seen by Dr. Mansnerus to appreciate the temporal relationship of all of what developed; true? A. Yes. Q. Do you know how long Mr. Gill had been a patient of Dr. Mansnerus? A. I can't recall that. I know that the first time that he was seen in relationship to this illness was in December, the beginning of December of 1999. Q. Do you remember how many times he was seen in December? A. Twice. December 9th and 30th. Q. And before those two dates in December, had he been a patient for any extended period of time with Dr. Mansnerus? A. I can't remember. Can you tell me from your review how 	 A. If I was a physician that was seeing the patient, is that what you are asking me? If I was a physician seeing the patient in January or February of 2000 whether I would suspect that he had mets at the time? Is that what you are asking me? Q. You are kind of close, but before you answer it and you are doing exactly the right thing. I'm not asking you retrospectively. We may talk about that in a moment based upon the slides that you looked at, which are at the time of the diagnosis, but what I'm asking you is from your review of this case. You have already told me that he appeared twice in December to see Dr. Mansnerus and then we know that there are certain events that went on in the early part of 2000 leading up to his diagnosis. What I'm asking you is from what you have in black and white, medical records,

12 (Pages 45 to 48)

October 28, 2003

Page 49	
 Page 43 the case that causes you to be able to say that in January or February of 2000, that there was evidence clinically that Mr. Gill had metastatic disease or metastatic lung cancer? MR. WARNER: Objection. Asked and answered. You can answer again. A. You are asking me to answer this question based on all the records I have now? Q. Yes. A. Or based on the records that were available in January or February of 2000? Q. The records that were available in January or February of 2000, and December of '99. A. If I am reviewing a case of a patient that presented with respiratory symptoms, basically symptoms of pneumonia and numbness, would I suspect that the patient had I mean, obviously there was no definite diagnosis of cancer in Mr. Gill, so it's unlikely that someone would think of metastatic disease if there is no previous diagnosis or known history of cancer in a patient. Any of these symptoms can be related to either primary or metastatic 	 Page 51 asking me as to me reviewing records of Mr. Gill in January and February, they were not available to me at that time. Q. And additional studies were not done in January or February to rule out or confirm the existence of metastatic lung cancer; true? MR. WARNER: Objection. Go ahead. A. I don't know which ones you are referring to, but a chest x-ray can be taken or can be ordered for that purpose. Q. Is a chest x-ray usually used as diagnostic of lung cancer? MR. WARNER: Objection. A. A chest x-ray can review evidence of lung cancer. Q. Even though you are not an oncologist and you have indicated what your specialty is, do doctors typically treat a patient for lung cancer solely based upon the presentation on a chest x-ray? MR. WARNER: Objection. A. Not usually, but the chest x-ray is kind of the first test that is the least invasive test that is done, and depending on the findings, it may lead to further tests.
 Page 50 Q. So in other words, in order to be able to say definitely that there was evidence that in January or February he had metastatic disease, you wouldn't have needed to see diagnostic studies to be able to say that the patient had metastatic disease in January or February; true? MR. WARNER: Objection. Go ahead. A. Before someone concludes, before a physician concludes that a patient has metastatic disease, obviously we need more than the patient's signs and symptoms that he presents with. Or you know, even though there was a chest x-ray that was done in December 1999, that was read as an infiltrate and according to the report was not suggestive of cancer, at that time I had no reason to suspect that Mr. Gill had metastatic disease at that time. Q. Okay. A. But my opinion can change, of course, with additional diagnostic studies and data. Q. Which at that time were not done; correct? A. They were not available. You are 	 Page 52 If you are asking about the gold standard, obviously it's the pathology examination of tissue or cells to document the nature of the tumor or the mass or lesion, if found on chest x-ray. Q. There was no biopsy or pathology obtained in January or February to define the status of any tumor that Mr. Gill had at that time; true? A. That's true. Q. Any evidence from your review of the records, from clinical exam or description by any of the doctors that Mr. Gill had any nodal involvement in January or February of 2000? A. I can't remember specifically any of the doctors' comments in the records, but I think at the time of presentation in December, the beginning of December, the patient did have numbness in the arm and neck and these can be signs of lymph node involvement at the time. Q. Does Dr. Mansnerus in the description that he has in the records, does he give any indication from what you can see, either from his deposition or from his records, that the findings in early November in the neck were

13 (Pages 49 to 52)

	D		
	Page 53		Page 55
1	suggestive of nodal involvement?	1	A. I guess it was, the main cause is
2	MR. WARNER: Note my objection. Go	2	lingering cough. I am referring to the notes
3	ahead.	3	from January of 2000, January 6th.
4	A. Now, you are asking me about what	4	Q. Do you know whether this was a
5	Dr. Mansnerus, what he thought or what he	5	scheduled follow up or whether the patient
6	commented on at the time that he saw the patient	6	returned for some other reason on January 6th?
7	on December 9th; is that correct?	7	A. I don't know. It's not obvious here
8	Q. Correct.	8	whether it was scheduled or whether he just
9	A. I don't think there was mention of	9	returned, the patient returned because he wanted
10	metastatic disease in his notes of December or	10	to see the doctor again.
11	early December when he saw Mr. Gill. I don't	11	Q. On that January 6th visit, doctor, is
12	think there was mention of metastatic disease.	12	there any evidence of nodal involvement that
13	The main differential diagnosis was pneumonia	13	Dr. Mansnerus describes?
14		14	A. No, there is no mention of nodal
15	Q. And your testimony is that this was	15	involvement.
16	at the beginning of the month or the end of the	16	Q. Any evidence in January, any evidence
17	month?	17	suggestive of a metastatic disease in January
18	A. I think this was at the beginning, if	18	when Dr. Mansnerus saw the patient?
19	I recall correctly, the beginning I think	19	MR. WARNER: Objection.
20	December 9th, the first time he saw him in	20	A. I'm sorry, repeat it.
21	relationship to this illness.	21	Q. Any evidence when Dr. Mansnerus saw
22	MR. WARNER: Note my objection. You	22	him in January of any metastatic disease?
23	are allowed to look at records, but go ahead, he	23	MR. WARNER: Same objection.
24	wants you to do it from memory.	24	A. To Dr. Mansnerus or to me?
25	MR. MISHKIND: No, I don't.	25	Q. To Dr. Mansnerus.
	·		•
	Page 54		Page 56
	Page 54	_	Page 56
1	Q. You are more than welcome to look at	1	A. It's not obvious from his records
2	Q. You are more than welcome to look at any records that you want to, doctor.	2	A. It's not obvious from his records that he saw any signs of metastatic disease.
2 3	Q. You are more than welcome to look at any records that you want to, doctor.A. Well, let me verify then what I just	2 3	A. It's not obvious from his records that he saw any signs of metastatic disease.Q. As I understand it, in looking at
2 3 4	Q. You are more than welcome to look at any records that you want to, doctor.A. Well, let me verify then what I just stated.	2 3 4	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the
2 3 4 5	 Q. You are more than welcome to look at any records that you want to, doctor. A. Well, let me verify then what I just stated. Q. Sure. 	2 3 4 5	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the time of diagnosis is of some significance;
2 3 4 5 6	 Q. You are more than welcome to look at any records that you want to, doctor. A. Well, let me verify then what I just stated. Q. Sure. A. There is no mention in the December 	2 3 4 5 6	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the time of diagnosis is of some significance; correct?
2 3 4 5 6 7	 Q. You are more than welcome to look at any records that you want to, doctor. A. Well, let me verify then what I just stated. Q. Sure. A. There is no mention in the December 9th, 1999 notes of Dr. Mansnerus, there is no 	2 3 4 5 6 7	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the time of diagnosis is of some significance; correct? A. Yes.
2 3 4 5 6 7 8	 Q. You are more than welcome to look at any records that you want to, doctor. A. Well, let me verify then what I just stated. Q. Sure. A. There is no mention in the December 9th, 1999 notes of Dr. Mansnerus, there is no mention of metastatic disease or nodal disease 	2 3 4 5 6 7 8	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the time of diagnosis is of some significance; correct? A. Yes. Q. And correct me if I am wrong, but a
2 3 4 5 6 7 8 9	 Q. You are more than welcome to look at any records that you want to, doctor. A. Well, let me verify then what I just stated. Q. Sure. A. There is no mention in the December 9th, 1999 notes of Dr. Mansnerus, there is no mention of metastatic disease or nodal disease at that time. 	2 3 4 5 6 7 8 9	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the time of diagnosis is of some significance; correct? A. Yes. Q. And correct me if I am wrong, but a tumor that is less than three centimeters is
2 3 4 5 6 7 8 9	 Q. You are more than welcome to look at any records that you want to, doctor. A. Well, let me verify then what I just stated. Q. Sure. A. There is no mention in the December 9th, 1999 notes of Dr. Mansnerus, there is no mention of metastatic disease or nodal disease at that time. Q. December 9th? 	2 3 4 5 6 7 8 9 10	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the time of diagnosis is of some significance; correct? A. Yes. Q. And correct me if I am wrong, but a tumor that is less than three centimeters is considered to be a T1; is that correct?
2 3 4 5 6 7 8 9 10 11	 Q. You are more than welcome to look at any records that you want to, doctor. A. Well, let me verify then what I just stated. Q. Sure. A. There is no mention in the December 9th, 1999 notes of Dr. Mansnerus, there is no mention of metastatic disease or nodal disease at that time. Q. December 9th? A. December 9th. 	2 3 4 5 6 7 8 9 10 11	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the time of diagnosis is of some significance; correct? A. Yes. Q. And correct me if I am wrong, but a tumor that is less than three centimeters is considered to be a T1; is that correct? A. Well, that's not the only criteria
2 3 4 5 6 7 8 9 10 11 12	 Q. You are more than welcome to look at any records that you want to, doctor. A. Well, let me verify then what I just stated. Q. Sure. A. There is no mention in the December 9th, 1999 notes of Dr. Mansnerus, there is no mention of metastatic disease or nodal disease at that time. Q. December 9th? A. December 9th. Q. And would the same apply in terms of 	2 3 4 5 6 7 8 9 10 11 12	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the time of diagnosis is of some significance; correct? A. Yes. Q. And correct me if I am wrong, but a tumor that is less than three centimeters is considered to be a T1; is that correct? A. Well, that's not the only criteria for a T1 tumor.
2 3 4 5 6 7 8 9 10 11 12 13	 Q. You are more than welcome to look at any records that you want to, doctor. A. Well, let me verify then what I just stated. Q. Sure. A. There is no mention in the December 9th, 1999 notes of Dr. Mansnerus, there is no mention of metastatic disease or nodal disease at that time. Q. December 9th? A. December 9th. Q. And would the same apply in terms of any reference to or evidence of nodal 	2 3 4 5 6 7 8 9 10 11 12 13	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the time of diagnosis is of some significance; correct? A. Yes. Q. And correct me if I am wrong, but a tumor that is less than three centimeters is considered to be a T1; is that correct? A. Well, that's not the only criteria for a T1 tumor. Q. What else?
2 3 4 5 6 7 8 9 10 11 12 13 14	 Q. You are more than welcome to look at any records that you want to, doctor. A. Well, let me verify then what I just stated. Q. Sure. A. There is no mention in the December 9th, 1999 notes of Dr. Mansnerus, there is no mention of metastatic disease or nodal disease at that time. Q. December 9th? A. December 9th. Q. And would the same apply in terms of any reference to or evidence of nodal involvement at the end of December when 	2 3 4 5 6 7 8 9 10 11 12 13 14	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the time of diagnosis is of some significance; correct? A. Yes. Q. And correct me if I am wrong, but a tumor that is less than three centimeters is considered to be a T1; is that correct? A. Well, that's not the only criteria for a T1 tumor. Q. What else? A. A tumor of any size that has invaded
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 Q. You are more than welcome to look at any records that you want to, doctor. A. Well, let me verify then what I just stated. Q. Sure. A. There is no mention in the December 9th, 1999 notes of Dr. Mansnerus, there is no mention of metastatic disease or nodal disease at that time. Q. December 9th? A. December 9th? A. December 9th. Q. And would the same apply in terms of any reference to or evidence of nodal involvement at the end of December when Dr. Mansnerus saw him, as well? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the time of diagnosis is of some significance; correct? A. Yes. Q. And correct me if I am wrong, but a tumor that is less than three centimeters is considered to be a T1; is that correct? A. Well, that's not the only criteria for a T1 tumor. Q. What else? A. A tumor of any size that has invaded adjacent structures, the associated pneumonitis,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 Q. You are more than welcome to look at any records that you want to, doctor. A. Well, let me verify then what I just stated. Q. Sure. A. There is no mention in the December 9th, 1999 notes of Dr. Mansnerus, there is no mention of metastatic disease or nodal disease at that time. Q. December 9th? A. December 9th? A. December 9th. Q. And would the same apply in terms of any reference to or evidence of nodal involvement at the end of December when Dr. Mansnerus saw him, as well? A. I don't see evidence of mention of 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the time of diagnosis is of some significance; correct? A. Yes. Q. And correct me if I am wrong, but a tumor that is less than three centimeters is considered to be a T1; is that correct? A. Well, that's not the only criteria for a T1 tumor. Q. What else? A. A tumor of any size that has invaded adjacent structures, the associated pneumonitis, and there are several other features, then the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 Q. You are more than welcome to look at any records that you want to, doctor. A. Well, let me verify then what I just stated. Q. Sure. A. There is no mention in the December 9th, 1999 notes of Dr. Mansnerus, there is no mention of metastatic disease or nodal disease at that time. Q. December 9th? A. December 9th? A. December 9th. Q. And would the same apply in terms of any reference to or evidence of nodal involvement at the end of December when Dr. Mansnerus saw him, as well? A. I don't see evidence of mention of nodal disease on December 30th, 1999. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the time of diagnosis is of some significance; correct? A. Yes. Q. And correct me if I am wrong, but a tumor that is less than three centimeters is considered to be a T1; is that correct? A. Well, that's not the only criteria for a T1 tumor. Q. What else? A. A tumor of any size that has invaded adjacent structures, the associated pneumonitis, and there are several other features, then the tumor can be classified as T4.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 Q. You are more than welcome to look at any records that you want to, doctor. A. Well, let me verify then what I just stated. Q. Sure. A. There is no mention in the December 9th, 1999 notes of Dr. Mansnerus, there is no mention of metastatic disease or nodal disease at that time. Q. December 9th? A. December 9th? A. December 9th. Q. And would the same apply in terms of any reference to or evidence of nodal involvement at the end of December when Dr. Mansnerus saw him, as well? A. I don't see evidence of mention of nodal disease on December 30th, 1999. Q. In January when he returned, the 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the time of diagnosis is of some significance; correct? A. Yes. Q. And correct me if I am wrong, but a tumor that is less than three centimeters is considered to be a T1; is that correct? A. Well, that's not the only criteria for a T1 tumor. Q. What else? A. A tumor of any size that has invaded adjacent structures, the associated pneumonitis, and there are several other features, then the tumor can be classified as T4. Q. Generally speaking and you are
2 3 4 5 6 7 7 8 9 10 11 12 13 14 15 16 17 18 19	 Q. You are more than welcome to look at any records that you want to, doctor. A. Well, let me verify then what I just stated. Q. Sure. A. There is no mention in the December 9th, 1999 notes of Dr. Mansnerus, there is no mention of metastatic disease or nodal disease at that time. Q. December 9th? A. December 9th? A. December 9th. Q. And would the same apply in terms of any reference to or evidence of nodal involvement at the end of December when Dr. Mansnerus saw him, as well? A. I don't see evidence of mention of nodal disease on December 30th, 1999. Q. In January when he returned, the early part of January, do you know from your 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the time of diagnosis is of some significance; correct? A. Yes. Q. And correct me if I am wrong, but a tumor that is less than three centimeters is considered to be a T1; is that correct? A. Well, that's not the only criteria for a T1 tumor. Q. What else? A. A tumor of any size that has invaded adjacent structures, the associated pneumonitis, and there are several other features, then the tumor can be classified as T4. Q. Generally speaking and you are familiar, are you not, with the AJCC Cancer
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 Q. You are more than welcome to look at any records that you want to, doctor. A. Well, let me verify then what I just stated. Q. Sure. A. There is no mention in the December 9th, 1999 notes of Dr. Mansnerus, there is no mention of metastatic disease or nodal disease at that time. Q. December 9th? A. December 9th? A. December 9th. Q. And would the same apply in terms of any reference to or evidence of nodal involvement at the end of December when Dr. Mansnerus saw him, as well? A. I don't see evidence of mention of nodal disease on December 30th, 1999. Q. In January when he returned, the early part of January, do you know from your review in this case why it was that Mr. Gill 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the time of diagnosis is of some significance; correct? A. Yes. Q. And correct me if I am wrong, but a tumor that is less than three centimeters is considered to be a T1; is that correct? A. Well, that's not the only criteria for a T1 tumor. Q. What else? A. A tumor of any size that has invaded adjacent structures, the associated pneumonitis, and there are several other features, then the tumor can be classified as T4. Q. Generally speaking and you are familiar, are you not, with the AJCC Cancer Staging Handbook?
2 3 4 5 6 7 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 Q. You are more than welcome to look at any records that you want to, doctor. A. Well, let me verify then what I just stated. Q. Sure. A. There is no mention in the December 9th, 1999 notes of Dr. Mansnerus, there is no mention of metastatic disease or nodal disease at that time. Q. December 9th? A. December 9th? A. December 9th. Q. And would the same apply in terms of any reference to or evidence of nodal involvement at the end of December when Dr. Mansnerus saw him, as well? A. I don't see evidence of mention of nodal disease on December 30th, 1999. Q. In January when he returned, the early part of January, do you know from your review in this case why it was that Mr. Gill returned only a week after having had the 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the time of diagnosis is of some significance; correct? A. Yes. Q. And correct me if I am wrong, but a tumor that is less than three centimeters is considered to be a T1; is that correct? A. Well, that's not the only criteria for a T1 tumor. Q. What else? A. A tumor of any size that has invaded adjacent structures, the associated pneumonitis, and there are several other features, then the tumor can be classified as T4. Q. Generally speaking and you are familiar, are you not, with the AJCC Cancer Staging Handbook? A. Yes.
2 3 4 5 6 7 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 Q. You are more than welcome to look at any records that you want to, doctor. A. Well, let me verify then what I just stated. Q. Sure. A. There is no mention in the December 9th, 1999 notes of Dr. Mansnerus, there is no mention of metastatic disease or nodal disease at that time. Q. December 9th? A. December 9th? A. December 9th. Q. And would the same apply in terms of any reference to or evidence of nodal involvement at the end of December when Dr. Mansnerus saw him, as well? A. I don't see evidence of mention of nodal disease on December 30th, 1999. Q. In January when he returned, the early part of January, do you know from your review in this case why it was that Mr. Gill returned only a week after having had the diagnosis of pneumonia? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the time of diagnosis is of some significance; correct? A. Yes. Q. And correct me if I am wrong, but a tumor that is less than three centimeters is considered to be a T1; is that correct? A. Well, that's not the only criteria for a T1 tumor. Q. What else? A. A tumor of any size that has invaded adjacent structures, the associated pneumonitis, and there are several other features, then the tumor can be classified as T4. Q. Generally speaking and you are familiar, are you not, with the AJCC Cancer Staging Handbook? A. Yes. Q. And I am holding this up. Let's see,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Q. You are more than welcome to look at any records that you want to, doctor. A. Well, let me verify then what I just stated. Q. Sure. A. There is no mention in the December 9th, 1999 notes of Dr. Mansnerus, there is no mention of metastatic disease or nodal disease at that time. Q. December 9th? A. December 9th? A. December 9th. Q. And would the same apply in terms of any reference to or evidence of nodal involvement at the end of December when Dr. Mansnerus saw him, as well? A. I don't see evidence of mention of nodal disease on December 30th, 1999. Q. In January when he returned, the early part of January, do you know from your review in this case why it was that Mr. Gill returned only a week after having had the diagnosis of pneumonia? A. You are asking me why did Mr. Gill 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the time of diagnosis is of some significance; correct? A. Yes. Q. And correct me if I am wrong, but a tumor that is less than three centimeters is considered to be a T1; is that correct? A. Well, that's not the only criteria for a T1 tumor. Q. What else? A. A tumor of any size that has invaded adjacent structures, the associated pneumonitis, and there are several other features, then the tumor can be classified as T4. Q. Generally speaking and you are familiar, are you not, with the AJCC Cancer Staging Handbook? A. Yes. Q. And I am holding this up. Let's see, what edition is this one?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 Q. You are more than welcome to look at any records that you want to, doctor. A. Well, let me verify then what I just stated. Q. Sure. A. There is no mention in the December 9th, 1999 notes of Dr. Mansnerus, there is no mention of metastatic disease or nodal disease at that time. Q. December 9th? A. December 9th? A. December 9th. Q. And would the same apply in terms of any reference to or evidence of nodal involvement at the end of December when Dr. Mansnerus saw him, as well? A. I don't see evidence of mention of nodal disease on December 30th, 1999. Q. In January when he returned, the early part of January, do you know from your review in this case why it was that Mr. Gill returned only a week after having had the diagnosis of pneumonia? A. You are asking me why did Mr. Gill return to Dr. Mansnerus in January of 2000? 	2 3 4 5 6 7 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the time of diagnosis is of some significance; correct? A. Yes. Q. And correct me if I am wrong, but a tumor that is less than three centimeters is considered to be a T1; is that correct? A. Well, that's not the only criteria for a T1 tumor. Q. What else? A. A tumor of any size that has invaded adjacent structures, the associated pneumonitis, and there are several other features, then the tumor can be classified as T4. Q. Generally speaking and you are familiar, are you not, with the AJCC Cancer Staging Handbook? A. Yes. Q. And I am holding this up. Let's see, what edition is this one? The one that I have is the 5th
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Q. You are more than welcome to look at any records that you want to, doctor. A. Well, let me verify then what I just stated. Q. Sure. A. There is no mention in the December 9th, 1999 notes of Dr. Mansnerus, there is no mention of metastatic disease or nodal disease at that time. Q. December 9th? A. December 9th. Q. And would the same apply in terms of any reference to or evidence of nodal involvement at the end of December when Dr. Mansnerus saw him, as well? A. I don't see evidence of mention of nodal disease on December 30th, 1999. Q. In January when he returned, the early part of January, do you know from your review in this case why it was that Mr. Gill returned only a week after having had the diagnosis of pneumonia? A. You are asking me why did Mr. Gill return to Dr. Mansnerus in January of 2000? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 A. It's not obvious from his records that he saw any signs of metastatic disease. Q. As I understand it, in looking at lung cancer, that the size of the tumor at the time of diagnosis is of some significance; correct? A. Yes. Q. And correct me if I am wrong, but a tumor that is less than three centimeters is considered to be a T1; is that correct? A. Well, that's not the only criteria for a T1 tumor. Q. What else? A. A tumor of any size that has invaded adjacent structures, the associated pneumonitis, and there are several other features, then the tumor can be classified as T4. Q. Generally speaking and you are familiar, are you not, with the AJCC Cancer Staging Handbook? A. Yes. Q. And I am holding this up. Let's see, what edition is this one?

14 (Pages 53 to 56)

October 28, 2003

	D 57		
	Page 57		Page 59
1	generally accepted or reliable source in the	1	And I can't remember the specifics,
2	area of cancer staging, is it not?	2	because we have a list and I usually refer to it
3	MR. WARNER: Objection.	3	every time I do staging of lung cancer.
4	A. The AJCC Cancer Staging manual is a	4	Q. You have sort of a cheat sheet that
5	reliable source for clinicians to stage lung	5	you have right in front of you?
6	cancer, but I don't know about the 5th edition,	6	A. It's not a cheat sheet, but it's
7	because we have upgraded more than a year ago to	7	actually for completeness so we remember all the
8	the 6th edition and I can't really remember the	8	details.
9	exact differences in the lung.	9	Q. Is it fair to say that when the tumor
10	There are some organs where there are	10	gets to be above three centimeters, regardless
11	major differences, but I can't remember the	11	of whether or not there is atelectasis or
12	lung.	12	
13			whether or not there is any spread, just in and
14	Q. So what I would have to do is compare the 5th and the 6th edition as it relates to	13	of itself, a tumor greater than three
,		14	,
15	lung to see whether there have been any changes	15	A. Yes.
16	in the cancer staging; correct?	16	Q. And if a tumor is less than three
17	A. Right.	17	······································
18	Q. But generally speaking, subject to,	18	is no spread of the tumor, and there is no nodal
19	perhaps, some changes in the 6th edition and	19	involvement, generally speaking, that would be a
20	in fact, if we were looking at the 6th edition,	20	T1-N0; correct?
21	it's a generally reliable source of information	21	A. If all the lymph nodes are negative
22	when it comes to staging of lung cancer; true?	22	pathologically and clinically, obviously, and if
23	A. Well, let me put it this way. It is	23	
24	the protocol that we use to pathologically stage	24	none of the other criteria as stated in the AJCC
25	lung cancer.	25	manual that upstages a tumor, then it would be a
		1	
	Page 58		Page 60
	Page 58		Page 60
1	Q. You can't ask for anything more than	1	T1 tumor.
2	Q. You can't ask for anything more than that.	2	T1 tumor. Q. Are you qualified as a pathologist to
2 3	Q. You can't ask for anything more than that. In terms of cancer staging, when one		T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a
2 3 4	Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking,	2 3 4	T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer
2 3 4 5	Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three	2 3 4 5	T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a
2 3 4 5 6	Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three centimeters; correct?	2 3 4	T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer
2 3 4 5 6 7	 Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three centimeters; correct? A. As I mentioned before, not 	2 3 4 5	T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer that's diagnosed at a Stage 1, being a tumor
2 3 4 5 6 7 8	 Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three centimeters; correct? A. As I mentioned before, not necessarily. Because it depends on the other 	2 3 4 5 6	T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer that's diagnosed at a Stage 1, being a tumor less than three centimeters and no spread, no
2 3 4 5 6 7 8 9	 Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three centimeters; correct? A. As I mentioned before, not necessarily. Because it depends on the other features or criteria. If it's a tumor that is 	2 3 4 5 6 7 8 9	T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer that's diagnosed at a Stage 1, being a tumor less than three centimeters and no spread, no atelectasis, nothing outside of what you would
2 3 4 5 6 7 8 9 10	 Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three centimeters; correct? A. As I mentioned before, not necessarily. Because it depends on the other features or criteria. If it's a tumor that is less than three centimeters, but it's invading 	2 3 4 5 6 7 8	T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer that's diagnosed at a Stage 1, being a tumor less than three centimeters and no spread, no atelectasis, nothing outside of what you would expect for less than three centimeters, no nodal involvement, and no other evidence of metastasis, clearly by definition a Stage 1, are
2 3 4 5 6 7 8 9 10 11	 Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three centimeters; correct? A. As I mentioned before, not necessarily. Because it depends on the other features or criteria. If it's a tumor that is less than three centimeters, but it's invading the mediastinum or invading the pleura or chest 	2 3 4 5 6 7 8 9	T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer that's diagnosed at a Stage 1, being a tumor less than three centimeters and no spread, no atelectasis, nothing outside of what you would expect for less than three centimeters, no nodal involvement, and no other evidence of
2 3 4 5 6 7 8 9 10 11 12	 Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three centimeters; correct? A. As I mentioned before, not necessarily. Because it depends on the other features or criteria. If it's a tumor that is less than three centimeters, but it's invading the mediastinum or invading the pleura or chest wall, then it's a T4 lesion, regardless. 	2 3 4 5 6 7 8 9 10	T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer that's diagnosed at a Stage 1, being a tumor less than three centimeters and no spread, no atelectasis, nothing outside of what you would expect for less than three centimeters, no nodal involvement, and no other evidence of metastasis, clearly by definition a Stage 1, are
2 3 4 5 6 7 8 9 10 11 12 13	 Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three centimeters; correct? A. As I mentioned before, not necessarily. Because it depends on the other features or criteria. If it's a tumor that is less than three centimeters, but it's invading the mediastinum or invading the pleura or chest wall, then it's a T4 lesion, regardless. Q. You are absolutely correct. Absent 	2 3 4 5 6 7 8 9 10 11	T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer that's diagnosed at a Stage 1, being a tumor less than three centimeters and no spread, no atelectasis, nothing outside of what you would expect for less than three centimeters, no nodal involvement, and no other evidence of metastasis, clearly by definition a Stage 1, are you qualified to provide an opinion as to what
2 3 4 5 6 7 8 9 10 11 12	 Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three centimeters; correct? A. As I mentioned before, not necessarily. Because it depends on the other features or criteria. If it's a tumor that is less than three centimeters, but it's invading the mediastinum or invading the pleura or chest wall, then it's a T4 lesion, regardless. Q. You are absolutely correct. Absent any invasion or extending into the pleura or 	2 3 4 5 6 7 8 9 10 11 12	T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer that's diagnosed at a Stage 1, being a tumor less than three centimeters and no spread, no atelectasis, nothing outside of what you would expect for less than three centimeters, no nodal involvement, and no other evidence of metastasis, clearly by definition a Stage 1, are you qualified to provide an opinion as to what the prognosis is for survival of a Stage 1 nonsmall cell lung cancer?
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three centimeters; correct? A. As I mentioned before, not necessarily. Because it depends on the other features or criteria. If it's a tumor that is less than three centimeters, but it's invading the mediastinum or invading the pleura or chest wall, then it's a T4 lesion, regardless. Q. You are absolutely correct. Absent any invasion or extending into the pleura or into the chest wall, or any of the hilar regions 	2 3 4 5 6 7 8 9 10 11 12 13	T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer that's diagnosed at a Stage 1, being a tumor less than three centimeters and no spread, no atelectasis, nothing outside of what you would expect for less than three centimeters, no nodal involvement, and no other evidence of metastasis, clearly by definition a Stage 1, are you qualified to provide an opinion as to what the prognosis is for survival of a Stage 1 nonsmall cell lung cancer?
2 3 4 5 6 7 8 9 10 11 12 13 14	 Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three centimeters; correct? A. As I mentioned before, not necessarily. Because it depends on the other features or criteria. If it's a tumor that is less than three centimeters, but it's invading the mediastinum or invading the pleura or chest wall, then it's a T4 lesion, regardless. Q. You are absolutely correct. Absent any invasion or extending into the pleura or into the chest wall, or any of the hilar regions or anything of that nature, just a tumor less 	2 3 4 5 6 7 8 9 10 11 12 13 14	T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer that's diagnosed at a Stage 1, being a tumor less than three centimeters and no spread, no atelectasis, nothing outside of what you would expect for less than three centimeters, no nodal involvement, and no other evidence of metastasis, clearly by definition a Stage 1, are you qualified to provide an opinion as to what the prognosis is for survival of a Stage 1 nonsmall cell lung cancer? A. Regardless of the treatment or with
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three centimeters; correct? A. As I mentioned before, not necessarily. Because it depends on the other features or criteria. If it's a tumor that is less than three centimeters, but it's invading the mediastinum or invading the pleura or chest wall, then it's a T4 lesion, regardless. Q. You are absolutely correct. Absent any invasion or extending into the pleura or into the chest wall, or any of the hilar regions or anything of that nature, just a tumor less than three centimeters that does not go outside 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer that's diagnosed at a Stage 1, being a tumor less than three centimeters and no spread, no atelectasis, nothing outside of what you would expect for less than three centimeters, no nodal involvement, and no other evidence of metastasis, clearly by definition a Stage 1, are you qualified to provide an opinion as to what the prognosis is for survival of a Stage 1 nonsmall cell lung cancer? A. Regardless of the treatment or with the treatment?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three centimeters; correct? A. As I mentioned before, not necessarily. Because it depends on the other features or criteria. If it's a tumor that is less than three centimeters, but it's invading the mediastinum or invading the pleura or chest wall, then it's a T4 lesion, regardless. Q. You are absolutely correct. Absent any invasion or extending into the pleura or into the chest wall, or any of the hilar regions or anything of that nature, just a tumor less 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer that's diagnosed at a Stage 1, being a tumor less than three centimeters and no spread, no atelectasis, nothing outside of what you would expect for less than three centimeters, no nodal involvement, and no other evidence of metastasis, clearly by definition a Stage 1, are you qualified to provide an opinion as to what the prognosis is for survival of a Stage 1 nonsmall cell lung cancer? A. Regardless of the treatment or with the treatment? Q. Well, good question. With the treatment.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three centimeters; correct? A. As I mentioned before, not necessarily. Because it depends on the other features or criteria. If it's a tumor that is less than three centimeters, but it's invading the mediastinum or invading the pleura or chest wall, then it's a T4 lesion, regardless. Q. You are absolutely correct. Absent any invasion or extending into the pleura or into the chest wall, or any of the hilar regions or anything of that nature, just a tumor less than three centimeters that does not go outside 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer that's diagnosed at a Stage 1, being a tumor less than three centimeters and no spread, no atelectasis, nothing outside of what you would expect for less than three centimeters, no nodal involvement, and no other evidence of metastasis, clearly by definition a Stage 1, are you qualified to provide an opinion as to what the prognosis is for survival of a Stage 1 nonsmall cell lung cancer? A. Regardless of the treatment or with the treatment? Q. Well, good question. With the treatment. A. I usually refer again, this is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three centimeters; correct? A. As I mentioned before, not necessarily. Because it depends on the other features or criteria. If it's a tumor that is less than three centimeters, but it's invading the mediastinum or invading the pleura or chest wall, then it's a T4 lesion, regardless. Q. You are absolutely correct. Absent any invasion or extending into the pleura or into the chest wall, or any of the hilar regions or anything of that nature, just a tumor less than three centimeters that does not go outside of the lung, that generally is considered to be 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer that's diagnosed at a Stage 1, being a tumor less than three centimeters and no spread, no atelectasis, nothing outside of what you would expect for less than three centimeters, no nodal involvement, and no other evidence of metastasis, clearly by definition a Stage 1, are you qualified to provide an opinion as to what the prognosis is for survival of a Stage 1 nonsmall cell lung cancer? A. Regardless of the treatment or with the treatment? Q. Well, good question. With the treatment. A. I usually refer again, this is some data in the AJCC manual that refers to the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three centimeters; correct? A. As I mentioned before, not necessarily. Because it depends on the other features or criteria. If it's a tumor that is less than three centimeters, but it's invading the mediastinum or invading the pleura or chest wall, then it's a T4 lesion, regardless. Q. You are absolutely correct. Absent any invasion or extending into the pleura or into the chest wall, or any of the hilar regions or anything of that nature, just a tumor less than three centimeters that does not go outside of the lung, that generally is considered to be T1; correct? 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer that's diagnosed at a Stage 1, being a tumor less than three centimeters and no spread, no atelectasis, nothing outside of what you would expect for less than three centimeters, no nodal involvement, and no other evidence of metastasis, clearly by definition a Stage 1, are you qualified to provide an opinion as to what the prognosis is for survival of a Stage 1 nonsmall cell lung cancer? A. Regardless of the treatment or with the treatment? Q. Well, good question. With the treatment. A. I usually refer again, this is some data in the AJCC manual that refers to the prognosis of the different stages of breast
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three centimeters; correct? A. As I mentioned before, not necessarily. Because it depends on the other features or criteria. If it's a tumor that is less than three centimeters, but it's invading the mediastinum or invading the pleura or chest wall, then it's a T4 lesion, regardless. Q. You are absolutely correct. Absent any invasion or extending into the pleura or into the chest wall, or any of the hilar regions or anything of that nature, just a tumor less than three centimeters that does not go outside of the lung, that generally is considered to be T1; correct? A. I think there are other criteria, which is the presence of atelectasis, the 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer that's diagnosed at a Stage 1, being a tumor less than three centimeters and no spread, no atelectasis, nothing outside of what you would expect for less than three centimeters, no nodal involvement, and no other evidence of metastasis, clearly by definition a Stage 1, are you qualified to provide an opinion as to what the prognosis is for survival of a Stage 1 nonsmall cell lung cancer? A. Regardless of the treatment or with the treatment? Q. Well, good question. With the treatment. A. I usually refer again, this is some data in the AJCC manual that refers to the prognosis of the different stages of breast cancer I'm sorry, of lung cancer.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three centimeters; correct? A. As I mentioned before, not necessarily. Because it depends on the other features or criteria. If it's a tumor that is less than three centimeters, but it's invading the mediastinum or invading the pleura or chest wall, then it's a T4 lesion, regardless. Q. You are absolutely correct. Absent any invasion or extending into the pleura or into the chest wall, or any of the hilar regions or anything of that nature, just a tumor less than three centimeters that does not go outside of the lung, that generally is considered to be T1; correct? A. I think there are other criteria, which is the presence of atelectasis, the presence of obstructive pneumonitis, the 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer that's diagnosed at a Stage 1, being a tumor less than three centimeters and no spread, no atelectasis, nothing outside of what you would expect for less than three centimeters, no nodal involvement, and no other evidence of metastasis, clearly by definition a Stage 1, are you qualified to provide an opinion as to what the prognosis is for survival of a Stage 1 nonsmall cell lung cancer? A. Regardless of the treatment or with the treatment? Q. Well, good question. With the treatment. A. I usually refer again, this is some data in the AJCC manual that refers to the prognosis of the different stages of breast cancer I'm sorry, of lung cancer. Q. I knew what you meant.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three centimeters; correct? A. As I mentioned before, not necessarily. Because it depends on the other features or criteria. If it's a tumor that is less than three centimeters, but it's invading the mediastinum or invading the pleura or chest wall, then it's a T4 lesion, regardless. Q. You are absolutely correct. Absent any invasion or extending into the pleura or into the chest wall, or any of the hilar regions or anything of that nature, just a tumor less than three centimeters that does not go outside of the lung, that generally is considered to be T1; correct? A. I think there are other criteria, which is the presence of atelectasis, the 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer that's diagnosed at a Stage 1, being a tumor less than three centimeters and no spread, no atelectasis, nothing outside of what you would expect for less than three centimeters, no nodal involvement, and no other evidence of metastasis, clearly by definition a Stage 1, are you qualified to provide an opinion as to what the prognosis is for survival of a Stage 1 nonsmall cell lung cancer? A. Regardless of the treatment or with the treatment? Q. Well, good question. With the treatment. A. I usually refer again, this is some data in the AJCC manual that refers to the prognosis of the different stages of breast cancer I'm sorry, of lung cancer. Q. I knew what you meant. A. But, of course, the literature is
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three centimeters; correct? A. As I mentioned before, not necessarily. Because it depends on the other features or criteria. If it's a tumor that is less than three centimeters, but it's invading the mediastinum or invading the pleura or chest wall, then it's a T4 lesion, regardless. Q. You are absolutely correct. Absent any invasion or extending into the pleura or into the chest wall, or any of the hilar regions or anything of that nature, just a tumor less than three centimeters that does not go outside of the lung, that generally is considered to be T1; correct? A. I think there are other criteria, which is the presence of atelectasis, the presence of pleura effusions that can upgrade 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer that's diagnosed at a Stage 1, being a tumor less than three centimeters and no spread, no atelectasis, nothing outside of what you would expect for less than three centimeters, no nodal involvement, and no other evidence of metastasis, clearly by definition a Stage 1, are you qualified to provide an opinion as to what the prognosis is for survival of a Stage 1 nonsmall cell lung cancer? A. Regardless of the treatment or with the treatment? Q. Well, good question. With the treatment. A. I usually refer again, this is some data in the AJCC manual that refers to the prognosis of the different stages of breast cancer I'm sorry, of lung cancer. Q. I knew what you meant. A. But, of course, the literature is full of studies of different subsets and
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 9 20 21 22 23 24	 Q. You can't ask for anything more than that. In terms of cancer staging, when one refers to a T1 lung cancer, generally speaking, that's a tumor that's less than three centimeters; correct? A. As I mentioned before, not necessarily. Because it depends on the other features or criteria. If it's a tumor that is less than three centimeters, but it's invading the mediastinum or invading the pleura or chest wall, then it's a T4 lesion, regardless. Q. You are absolutely correct. Absent any invasion or extending into the pleura or into the chest wall, or any of the hilar regions or anything of that nature, just a tumor less than three centimeters that does not go outside of the lung, that generally is considered to be T1; correct? A. I think there are other criteria, which is the presence of atelectasis, the presence of pleura effusions that can upgrade the T stage of the tumor, again, regardless of 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 T1 tumor. Q. Are you qualified as a pathologist to testify as to what the prognosis is for a patient diagnosed with nonsmall cell lung cancer that's diagnosed at a Stage 1, being a tumor less than three centimeters and no spread, no atelectasis, nothing outside of what you would expect for less than three centimeters, no nodal involvement, and no other evidence of metastasis, clearly by definition a Stage 1, are you qualified to provide an opinion as to what the prognosis is for survival of a Stage 1 nonsmall cell lung cancer? A. Regardless of the treatment or with the treatment? Q. Well, good question. With the treatment. A. I usually refer again, this is some data in the AJCC manual that refers to the prognosis of the different stages of breast cancer I'm sorry, of lung cancer. Q. I knew what you meant. A. But, of course, the literature is

15 (Pages 57 to 60)

October 28, 2003

	Page 61		Page 63
1	that. So is there any one single person or	1	statistics in terms of all comers in Stage 1
2	medical expert that is qualified to comment on	2	nonsmall cell lung cancer, that statistically
3	these prognoses and the five-year survival, I	3	the five-year survival is in the 60 to 80
4	think all medical specialists that are involved	4	percent range, would you quarrel with that
5	in assessing lung cancers are qualified to some	5	statistic?
6	extent in rendering their opinion.	6	MR. WARNER: Objection.
7	Q. And you certainly consider reliable	7	A. No.
8	the cancer staging information, the AJCC Cancer	8	Q. And in fact, is that generally your
9	Staging information in terms of treatment and	9	understanding in terms of all comers in Stage 1;
10	prognosis for a Stage 1 nonsmall cell lung	10	that it's generally for five-year survival 60 to
11	cancer; true?	11	80 percent?
12	A. Well, really there is no treatment	12	A. Well, as I said, there are a lot of
13	recommendations or guidelines in the AJCC	13	other factors, so I don't really want to give an
14	manual. And the part that is nice about their	14	
15 16	survival data is it's usually their large studies. But after a couple of years, a few	15	specific group of patients and specific
17	years, they become kind of old and we have to	10	histology and specific type of treatment. Q. You have seen that statistic, though,
18	consider newer data.	18	in terms of Stage 1 nonsmall cell lung cancer,
19	Q. What is your opinion as to the likely	19	the survival rate has been reported in certain
20	five-year survival for a nonsmall cell lung	20	studies to be in the 60 to 80 percent range;
21	cancer patient diagnosed in a Stage 1 clinically	21	correct?
22	and pathologically that receives the appropriate	22	A. I think I probably have seen it. I
23	regimen of treatment?	23	don't recall specifically, but probably I have.
24	A. Well, again, it varies, depending on	24	Q. Are there any resources, doctor, that
25	if it's only surgical excision, whether the	25	you believe to be reasonably reliable or
	Page 62		Page 64
1		1	
1 2	tumor was excised entirely, and whether the	1	authoritative that support any of the opinions
1 2 3			authoritative that support any of the opinions that you hold in this case?
2 3 4	tumor was excised entirely, and whether the patient had any chemotherapy.	2	authoritative that support any of the opinions that you hold in this case?
2 3 4 5	tumor was excised entirely, and whether the patient had any chemotherapy. There are other factors, intrinsic factors to the tumor itself, which includes the exact type of the tumor and the grade of the	2 3	authoritative that support any of the opinions that you hold in this case? A. I don't consider any one source of medical information as authoritative. I look at everything critically and there are some papers
2 3 4 5 6	tumor was excised entirely, and whether the patient had any chemotherapy. There are other factors, intrinsic factors to the tumor itself, which includes the exact type of the tumor and the grade of the tumor, whether it's a low grade or a high grade	2 3 4 5 6	authoritative that support any of the opinions that you hold in this case? A. I don't consider any one source of medical information as authoritative. I look at everything critically and there are some papers and articles published by very famous physicians
2 3 4 5 6 7	tumor was excised entirely, and whether the patient had any chemotherapy. There are other factors, intrinsic factors to the tumor itself, which includes the exact type of the tumor and the grade of the tumor, whether it's a low grade or a high grade histologically, that can influence the	2 3 4 5 6 7	authoritative that support any of the opinions that you hold in this case? A. I don't consider any one source of medical information as authoritative. I look at everything critically and there are some papers and articles published by very famous physicians that have a lot of deficiencies, so I look at
2 3 4 5 6 7 8	tumor was excised entirely, and whether the patient had any chemotherapy. There are other factors, intrinsic factors to the tumor itself, which includes the exact type of the tumor and the grade of the tumor, whether it's a low grade or a high grade histologically, that can influence the prognosis. But the prognosis of Stage 1 lung	2 3 4 5 6 7 8	authoritative that support any of the opinions that you hold in this case? A. I don't consider any one source of medical information as authoritative. I look at everything critically and there are some papers and articles published by very famous physicians that have a lot of deficiencies, so I look at every article or every data critically and try
2 3 4 5 6 7 8 9	tumor was excised entirely, and whether the patient had any chemotherapy. There are other factors, intrinsic factors to the tumor itself, which includes the exact type of the tumor and the grade of the tumor, whether it's a low grade or a high grade histologically, that can influence the prognosis. But the prognosis of Stage 1 lung cancers, in general, is better than prognosis of	2 3 4 5 6 7 8 9	authoritative that support any of the opinions that you hold in this case? A. I don't consider any one source of medical information as authoritative. I look at everything critically and there are some papers and articles published by very famous physicians that have a lot of deficiencies, so I look at every article or every data critically and try to get the best out of each one of them.
2 3 4 5 6 7 8 9 10	tumor was excised entirely, and whether the patient had any chemotherapy. There are other factors, intrinsic factors to the tumor itself, which includes the exact type of the tumor and the grade of the tumor, whether it's a low grade or a high grade histologically, that can influence the prognosis. But the prognosis of Stage 1 lung cancers, in general, is better than prognosis of the higher stages.	2 3 4 5 6 7 8 9 10	 authoritative that support any of the opinions that you hold in this case? A. I don't consider any one source of medical information as authoritative. I look at everything critically and there are some papers and articles published by very famous physicians that have a lot of deficiencies, so I look at every article or every data critically and try to get the best out of each one of them. Q. Did you do any medical research at
2 3 4 5 6 7 8 9 10 11	tumor was excised entirely, and whether the patient had any chemotherapy. There are other factors, intrinsic factors to the tumor itself, which includes the exact type of the tumor and the grade of the tumor, whether it's a low grade or a high grade histologically, that can influence the prognosis. But the prognosis of Stage 1 lung cancers, in general, is better than prognosis of the higher stages. Q. Sure. And in fact, in the Stage 1,	2 3 4 5 6 7 8 9 10 11	authoritative that support any of the opinions that you hold in this case? A. I don't consider any one source of medical information as authoritative. I look at everything critically and there are some papers and articles published by very famous physicians that have a lot of deficiencies, so I look at every article or every data critically and try to get the best out of each one of them. Q. Did you do any medical research at all in preparation for this case?
2 3 4 5 6 7 8 9 10 11 12	tumor was excised entirely, and whether the patient had any chemotherapy. There are other factors, intrinsic factors to the tumor itself, which includes the exact type of the tumor and the grade of the tumor, whether it's a low grade or a high grade histologically, that can influence the prognosis. But the prognosis of Stage 1 lung cancers, in general, is better than prognosis of the higher stages. Q. Sure. And in fact, in the Stage 1, there is sort of a range in terms of prognostic	2 3 4 5 6 7 8 9 10 11 12	authoritative that support any of the opinions that you hold in this case? A. I don't consider any one source of medical information as authoritative. I look at everything critically and there are some papers and articles published by very famous physicians that have a lot of deficiencies, so I look at every article or every data critically and try to get the best out of each one of them. Q. Did you do any medical research at all in preparation for this case? A. Not specifically for this case, but I
2 3 4 5 6 7 8 9 10 11 12 13	tumor was excised entirely, and whether the patient had any chemotherapy. There are other factors, intrinsic factors to the tumor itself, which includes the exact type of the tumor and the grade of the tumor, whether it's a low grade or a high grade histologically, that can influence the prognosis. But the prognosis of Stage 1 lung cancers, in general, is better than prognosis of the higher stages. Q. Sure. And in fact, in the Stage 1, there is sort of a range in terms of prognostic factors, are there not? It's not just X percent	2 3 4 5 6 7 8 9 10 11 12 13	authoritative that support any of the opinions that you hold in this case? A. I don't consider any one source of medical information as authoritative. I look at everything critically and there are some papers and articles published by very famous physicians that have a lot of deficiencies, so I look at every article or every data critically and try to get the best out of each one of them. Q. Did you do any medical research at all in preparation for this case? A. Not specifically for this case, but I have my collection of medical literature, and
2 3 4 5 6 7 8 9 10 11 12 13 14	tumor was excised entirely, and whether the patient had any chemotherapy. There are other factors, intrinsic factors to the tumor itself, which includes the exact type of the tumor and the grade of the tumor, whether it's a low grade or a high grade histologically, that can influence the prognosis. But the prognosis of Stage 1 lung cancers, in general, is better than prognosis of the higher stages. Q. Sure. And in fact, in the Stage 1, there is sort of a range in terms of prognostic factors, are there not? It's not just X percent of patients survive five years; correct?	2 3 4 5 6 7 8 9 10 11 12 13 14	authoritative that support any of the opinions that you hold in this case? A. I don't consider any one source of medical information as authoritative. I look at everything critically and there are some papers and articles published by very famous physicians that have a lot of deficiencies, so I look at every article or every data critically and try to get the best out of each one of them. Q. Did you do any medical research at all in preparation for this case? A. Not specifically for this case, but I have my collection of medical literature, and every now and then I go back and look at certain
2 3 4 5 6 7 8 9 10 11 12 13 14 15	tumor was excised entirely, and whether the patient had any chemotherapy. There are other factors, intrinsic factors to the tumor itself, which includes the exact type of the tumor and the grade of the tumor, whether it's a low grade or a high grade histologically, that can influence the prognosis. But the prognosis of Stage 1 lung cancers, in general, is better than prognosis of the higher stages. Q. Sure. And in fact, in the Stage 1, there is sort of a range in terms of prognostic factors, are there not? It's not just X percent of patients survive five years; correct? A. Exactly. So that means that there	2 3 4 5 6 7 8 9 10 11 12 13 14 15	authoritative that support any of the opinions that you hold in this case? A. I don't consider any one source of medical information as authoritative. I look at everything critically and there are some papers and articles published by very famous physicians that have a lot of deficiencies, so I look at every article or every data critically and try to get the best out of each one of them. Q. Did you do any medical research at all in preparation for this case? A. Not specifically for this case, but I have my collection of medical literature, and every now and then I go back and look at certain issues when it comes to, when it concerns one of
2 3 4 5 6 7 8 9 10 11 12 13 14	tumor was excised entirely, and whether the patient had any chemotherapy. There are other factors, intrinsic factors to the tumor itself, which includes the exact type of the tumor and the grade of the tumor, whether it's a low grade or a high grade histologically, that can influence the prognosis. But the prognosis of Stage 1 lung cancers, in general, is better than prognosis of the higher stages. Q. Sure. And in fact, in the Stage 1, there is sort of a range in terms of prognostic factors, are there not? It's not just X percent of patients survive five years; correct? A. Exactly. So that means that there are certain patients if you take 100 patients	2 3 4 5 6 7 8 9 10 11 12 13 14	authoritative that support any of the opinions that you hold in this case? A. I don't consider any one source of medical information as authoritative. I look at everything critically and there are some papers and articles published by very famous physicians that have a lot of deficiencies, so I look at every article or every data critically and try to get the best out of each one of them. Q. Did you do any medical research at all in preparation for this case? A. Not specifically for this case, but I have my collection of medical literature, and every now and then I go back and look at certain issues when it comes to, when it concerns one of our patients.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	tumor was excised entirely, and whether the patient had any chemotherapy. There are other factors, intrinsic factors to the tumor itself, which includes the exact type of the tumor and the grade of the tumor, whether it's a low grade or a high grade histologically, that can influence the prognosis. But the prognosis of Stage 1 lung cancers, in general, is better than prognosis of the higher stages. Q. Sure. And in fact, in the Stage 1, there is sort of a range in terms of prognostic factors, are there not? It's not just X percent of patients survive five years; correct? A. Exactly. So that means that there	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 authoritative that support any of the opinions that you hold in this case? A. I don't consider any one source of medical information as authoritative. I look at everything critically and there are some papers and articles published by very famous physicians that have a lot of deficiencies, so I look at every article or every data critically and try to get the best out of each one of them. Q. Did you do any medical research at all in preparation for this case? A. Not specifically for this case, but I have my collection of medical literature, and every now and then I go back and look at certain issues when it comes to, when it concerns one of our patients. Q. What I want to understand is when you
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	tumor was excised entirely, and whether the patient had any chemotherapy. There are other factors, intrinsic factors to the tumor itself, which includes the exact type of the tumor and the grade of the tumor, whether it's a low grade or a high grade histologically, that can influence the prognosis. But the prognosis of Stage 1 lung cancers, in general, is better than prognosis of the higher stages. Q. Sure. And in fact, in the Stage 1, there is sort of a range in terms of prognostic factors, are there not? It's not just X percent of patients survive five years; correct? A. Exactly. So that means that there are certain patients if you take 100 patients with Stage 1 nonsmall cell lung cancer, out of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	authoritative that support any of the opinions that you hold in this case? A. I don't consider any one source of medical information as authoritative. I look at everything critically and there are some papers and articles published by very famous physicians that have a lot of deficiencies, so I look at every article or every data critically and try to get the best out of each one of them. Q. Did you do any medical research at all in preparation for this case? A. Not specifically for this case, but I have my collection of medical literature, and every now and then I go back and look at certain issues when it comes to, when it concerns one of our patients.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	tumor was excised entirely, and whether the patient had any chemotherapy. There are other factors, intrinsic factors to the tumor itself, which includes the exact type of the tumor and the grade of the tumor, whether it's a low grade or a high grade histologically, that can influence the prognosis. But the prognosis of Stage 1 lung cancers, in general, is better than prognosis of the higher stages. Q. Sure. And in fact, in the Stage 1, there is sort of a range in terms of prognostic factors, are there not? It's not just X percent of patients survive five years; correct? A. Exactly. So that means that there are certain patients if you take 100 patients with Stage 1 nonsmall cell lung cancer, out of these 100, some of them are going to survive five years or longer and some of them are going to die, even though they are the same pathologic	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 authoritative that support any of the opinions that you hold in this case? A. I don't consider any one source of medical information as authoritative. I look at everything critically and there are some papers and articles published by very famous physicians that have a lot of deficiencies, so I look at every article or every data critically and try to get the best out of each one of them. Q. Did you do any medical research at all in preparation for this case? A. Not specifically for this case, but I have my collection of medical literature, and every now and then I go back and look at certain issues when it comes to, when it concerns one of our patients. Q. What I want to understand is when you take the stand, not in November, but the end of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	tumor was excised entirely, and whether the patient had any chemotherapy. There are other factors, intrinsic factors to the tumor itself, which includes the exact type of the tumor and the grade of the tumor, whether it's a low grade or a high grade histologically, that can influence the prognosis. But the prognosis of Stage 1 lung cancers, in general, is better than prognosis of the higher stages. Q. Sure. And in fact, in the Stage 1, there is sort of a range in terms of prognostic factors, are there not? It's not just X percent of patients survive five years; correct? A. Exactly. So that means that there are certain patients if you take 100 patients with Stage 1 nonsmall cell lung cancer, out of these 100, some of them are going to survive five years or longer and some of them are going to die, even though they are the same pathologic and clinical stage. Some of them are going to	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 authoritative that support any of the opinions that you hold in this case? A. I don't consider any one source of medical information as authoritative. I look at everything critically and there are some papers and articles published by very famous physicians that have a lot of deficiencies, so I look at every article or every data critically and try to get the best out of each one of them. Q. Did you do any medical research at all in preparation for this case? A. Not specifically for this case, but I have my collection of medical literature, and every now and then I go back and look at certain issues when it comes to, when it concerns one of our patients. Q. What I want to understand is when you take the stand, not in November, but the end of April, in this case, do you intend to testify that a certain journal article or a section of a certain journal article as it relates to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	tumor was excised entirely, and whether the patient had any chemotherapy. There are other factors, intrinsic factors to the tumor itself, which includes the exact type of the tumor and the grade of the tumor, whether it's a low grade or a high grade histologically, that can influence the prognosis. But the prognosis of Stage 1 lung cancers, in general, is better than prognosis of the higher stages. Q. Sure. And in fact, in the Stage 1, there is sort of a range in terms of prognostic factors, are there not? It's not just X percent of patients survive five years; correct? A. Exactly. So that means that there are certain patients if you take 100 patients with Stage 1 nonsmall cell lung cancer, out of these 100, some of them are going to survive five years or longer and some of them are going to die, even though they are the same pathologic and clinical stage. Some of them are going to die for reasons that we may know, some of them	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 authoritative that support any of the opinions that you hold in this case? A. I don't consider any one source of medical information as authoritative. I look at everything critically and there are some papers and articles published by very famous physicians that have a lot of deficiencies, so I look at every article or every data critically and try to get the best out of each one of them. Q. Did you do any medical research at all in preparation for this case? A. Not specifically for this case, but I have my collection of medical literature, and every now and then I go back and look at certain issues when it comes to, when it concerns one of our patients. Q. What I want to understand is when you take the stand, not in November, but the end of April, in this case, do you intend to testify that a certain journal article or a section of a certain journal article as it relates to nonsmall cell lung cancer, staging and
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	tumor was excised entirely, and whether the patient had any chemotherapy. There are other factors, intrinsic factors to the tumor itself, which includes the exact type of the tumor and the grade of the tumor, whether it's a low grade or a high grade histologically, that can influence the prognosis. But the prognosis of Stage 1 lung cancers, in general, is better than prognosis of the higher stages. Q. Sure. And in fact, in the Stage 1, there is sort of a range in terms of prognostic factors, are there not? It's not just X percent of patients survive five years; correct? A. Exactly. So that means that there are certain patients if you take 100 patients with Stage 1 nonsmall cell lung cancer, out of these 100, some of them are going to survive five years or longer and some of them are going to die, even though they are the same pathologic and clinical stage. Some of them are going to die for reasons that we may know, some of them we may not know, or we may not know all of them.	2 3 4 5 6 7 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 authoritative that support any of the opinions that you hold in this case? A. I don't consider any one source of medical information as authoritative. I look at everything critically and there are some papers and articles published by very famous physicians that have a lot of deficiencies, so I look at every article or every data critically and try to get the best out of each one of them. Q. Did you do any medical research at all in preparation for this case? A. Not specifically for this case, but I have my collection of medical literature, and every now and then I go back and look at certain issues when it comes to, when it concerns one of our patients. Q. What I want to understand is when you take the stand, not in November, but the end of April, in this case, do you intend to testify that a certain journal article or a section of a certain journal article as it relates to nonsmall cell lung cancer, staging and prognosis, is, in your opinion, to be generally
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 tumor was excised entirely, and whether the patient had any chemotherapy. There are other factors, intrinsic factors to the tumor itself, which includes the exact type of the tumor and the grade of the tumor, whether it's a low grade or a high grade histologically, that can influence the prognosis. But the prognosis of Stage 1 lung cancers, in general, is better than prognosis of the higher stages. Q. Sure. And in fact, in the Stage 1, there is sort of a range in terms of prognostic factors, are there not? It's not just X percent of patients survive five years; correct? A. Exactly. So that means that there are certain patients if you take 100 patients with Stage 1 nonsmall cell lung cancer, out of these 100, some of them are going to survive five years or longer and some of them are going to die, even though they are the same pathologic and clinical stage. Some of them are going to die for reasons that we may not know, or we may not know all of them. Q. What I want to do is just understand 	2 3 4 5 6 7 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 authoritative that support any of the opinions that you hold in this case? A. I don't consider any one source of medical information as authoritative. I look at everything critically and there are some papers and articles published by very famous physicians that have a lot of deficiencies, so I look at every article or every data critically and try to get the best out of each one of them. Q. Did you do any medical research at all in preparation for this case? A. Not specifically for this case, but I have my collection of medical literature, and every now and then I go back and look at certain issues when it comes to, when it concerns one of our patients. Q. What I want to understand is when you take the stand, not in November, but the end of April, in this case, do you intend to testify that a certain journal article or a section of a certain journal article as it relates to nonsmall cell lung cancer, staging and prognosis, is, in your opinion, to be generally reliable or authoritative?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	tumor was excised entirely, and whether the patient had any chemotherapy. There are other factors, intrinsic factors to the tumor itself, which includes the exact type of the tumor and the grade of the tumor, whether it's a low grade or a high grade histologically, that can influence the prognosis. But the prognosis of Stage 1 lung cancers, in general, is better than prognosis of the higher stages. Q. Sure. And in fact, in the Stage 1, there is sort of a range in terms of prognostic factors, are there not? It's not just X percent of patients survive five years; correct? A. Exactly. So that means that there are certain patients if you take 100 patients with Stage 1 nonsmall cell lung cancer, out of these 100, some of them are going to survive five years or longer and some of them are going to die, even though they are the same pathologic and clinical stage. Some of them are going to die for reasons that we may know, some of them we may not know, or we may not know all of them.	2 3 4 5 6 7 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 authoritative that support any of the opinions that you hold in this case? A. I don't consider any one source of medical information as authoritative. I look at everything critically and there are some papers and articles published by very famous physicians that have a lot of deficiencies, so I look at every article or every data critically and try to get the best out of each one of them. Q. Did you do any medical research at all in preparation for this case? A. Not specifically for this case, but I have my collection of medical literature, and every now and then I go back and look at certain issues when it comes to, when it concerns one of our patients. Q. What I want to understand is when you take the stand, not in November, but the end of April, in this case, do you intend to testify that a certain journal article or a section of a certain journal article as it relates to nonsmall cell lung cancer, staging and prognosis, is, in your opinion, to be generally

16 (Pages 61 to 64)

Page 65	Page 67
1 specific journal as being authoritative.	1 less than that.
2 Q. Or a section of a particular journal?	2 Q. How about Dr. Rozman?
3 A. I don't think so.	3 A. I don't know Dr. Rozman.
4 Q. Okay.	4 Q. Dr. Botham?
5 A. I may refer to a certain article, you	5 A. I know Dr. Botham.
6 know, if something comes up or I come across it	6 Q. How do you know Dr. Botham?
7 from now until then, but I don't have anything	7 A. He is one of the cardiovascular
8 in mind now that I can tell you.	8 surgeons here at Parma Hospital.
9 Q. Well, that's a fair statement. And	9 Q. How often do you interact with
10 certainly if there is something that you deem to	10 Dr. Botham?
11 be authoritative or generally reliable that you	11 A. Very little. He works mostly at
12 plan on from an evidentiary standpoint, and more	12 Hillcrest Hospital.
13 for the lawyers to deal with than the doctors,	13 Q. How long have you known Dr. Botham?
14 but if you find something you plan on	14 A. Since I started working here at Parma
15 acknowledging as being generally reliable or	15 Hospital three years ago.
16 authoritative, the purpose of my deposition	16 Q. Have you ever talked with Dr. Botham,
17 today is to find out what knowledge you have on	17 Dr. Levitan about this case?
18 the case that we thought was going to trial in	18 A. No.
19 two weeks. If you develop some thought process	19 Q. Do you know Dr. Steele,
20 on something that's reliable, I certainly will	20 Dr. Sutherland or Dr. Bass?
21 note my objection to anything beyond today's	21 A. No.
22 deposition, but I would at the very least ask	22 Q. One of the most important questions
23 that you notify Mr. Warner so that I would have	23 that I forgot to ask you early on is how much
24 an opportunity potentially as necessary to	24 are you charging me for this deposition today?
25 reconvene the deposition or to file the	25 A. \$400 an hour.
Page 66	Page 68
1 appropriate motion with the court Okay?	1 O How much do you charge nor how for
1 appropriate motion with the court. Okay?	1 Q. How much do you charge per hour for
2 A. Okay. I will.	2 reviewing of records and slides?
 A. Okay. I will. Q. Thank you. By the way, do you know 	2 reviewing of records and slides?3 A. \$300 an hour for reviews.
 2 A. Okay. I will. 3 Q. Thank you. By the way, do you know 4 Dr. Mansnerus? 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at
 2 A. Okay. I will. 3 Q. Thank you. By the way, do you know 4 Dr. Mansnerus? 5 A. No. 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at 5 trial?
 2 A. Okay. I will. 3 Q. Thank you. By the way, do you know 4 Dr. Mansnerus? 5 A. No. 6 Q. There are several other experts in 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at 5 trial? 6 A. \$400 an hour.
 2 A. Okay. I will. 3 Q. Thank you. By the way, do you know 4 Dr. Mansnerus? 5 A. No. 6 Q. There are several other experts in 7 this case. Dr. Levitan. Do you know Dr. 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at 5 trial? 6 A. \$400 an hour. 7 Q. Do you know how many hours you have
 A. Okay. I will. Q. Thank you. By the way, do you know Dr. Mansnerus? A. No. Q. There are several other experts in 7 this case. Dr. Levitan. Do you know Dr. 8 Levitan? 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at 5 trial? 6 A. \$400 an hour. 7 Q. Do you know how many hours you have 8 put in on this case thus far?
 A. Okay. I will. Q. Thank you. By the way, do you know Dr. Mansnerus? A. No. Q. There are several other experts in This case. Dr. Levitan. Do you know Dr. 8 Levitan? A. Yes. 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at 5 trial? 6 A. \$400 an hour. 7 Q. Do you know how many hours you have 8 put in on this case thus far? 9 A. I can't remember. I have not
 A. Okay. I will. Q. Thank you. By the way, do you know Dr. Mansnerus? A. No. Q. There are several other experts in this case. Dr. Levitan. Do you know Dr. Levitan? A. Yes. Q. How do you know him? 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at 5 trial? 6 A. \$400 an hour. 7 Q. Do you know how many hours you have 8 put in on this case thus far? 9 A. I can't remember. I have not 10 reviewed the bills or the statements, but it's
 A. Okay. I will. Q. Thank you. By the way, do you know Dr. Mansnerus? A. No. Q. There are several other experts in T this case. Dr. Levitan. Do you know Dr. Levitan? A. Yes. Q. How do you know him? A. I knew him from when I was working at 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at 5 trial? 6 A. \$400 an hour. 7 Q. Do you know how many hours you have 8 put in on this case thus far? 9 A. I can't remember. I have not 10 reviewed the bills or the statements, but it's 11 probably not more than four or five hours.
 A. Okay. I will. Q. Thank you. By the way, do you know Dr. Mansnerus? A. No. Q. There are several other experts in This case. Dr. Levitan. Do you know Dr. Levitan? A. Yes. Q. How do you know him? A. I knew him from when I was working at University Hospitals. 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at 5 trial? 6 A. \$400 an hour. 7 Q. Do you know how many hours you have 8 put in on this case thus far? 9 A. I can't remember. I have not 10 reviewed the bills or the statements, but it's 11 probably not more than four or five hours. 12 That's a guesstimate.
 A. Okay. I will. Q. Thank you. By the way, do you know Dr. Mansnerus? A. No. Q. There are several other experts in T this case. Dr. Levitan. Do you know Dr. Levitan? A. Yes. Q. How do you know him? A. I knew him from when I was working at University Hospitals. Q. Was it just sort of a passing 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at 5 trial? 6 A. \$400 an hour. 7 Q. Do you know how many hours you have 8 put in on this case thus far? 9 A. I can't remember. I have not 10 reviewed the bills or the statements, but it's 11 probably not more than four or five hours. 12 That's a guesstimate. 13 Q. You have your report in front of you.
 A. Okay. I will. Q. Thank you. By the way, do you know Dr. Mansnerus? A. No. Q. There are several other experts in This case. Dr. Levitan. Do you know Dr. Levitan? A. Yes. Q. How do you know him? A. I knew him from when I was working at University Hospitals. Q. Was it just sort of a passing familiarity with him or did you have occasion 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at 5 trial? 6 A. \$400 an hour. 7 Q. Do you know how many hours you have 8 put in on this case thus far? 9 A. I can't remember. I have not 10 reviewed the bills or the statements, but it's 11 probably not more than four or five hours. 12 That's a guesstimate. 13 Q. You have your report in front of you. 14 Other than there being the omission of the date
 A. Okay. I will. Q. Thank you. By the way, do you know Dr. Mansnerus? A. No. Q. There are several other experts in This case. Dr. Levitan. Do you know Dr. Levitan? A. Yes. Q. How do you know him? A. I knew him from when I was working at University Hospitals. Q. Was it just sort of a passing familiarity with him or did you have occasion A. It was a professional relationship. 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at 5 trial? 6 A. \$400 an hour. 7 Q. Do you know how many hours you have 8 put in on this case thus far? 9 A. I can't remember. I have not 10 reviewed the bills or the statements, but it's 11 probably not more than four or five hours. 12 That's a guesstimate. 13 Q. You have your report in front of you. 14 Other than there being the omission of the date 15 on the report, are there any other corrections
 A. Okay. I will. Q. Thank you. By the way, do you know Dr. Mansnerus? A. No. Q. There are several other experts in this case. Dr. Levitan. Do you know Dr. Levitan? A. Yes. Q. How do you know him? A. I knew him from when I was working at University Hospitals. Q. Was it just sort of a passing familiarity with him or did you have occasion A. It was a professional relationship. We talked about cases, cancer patients that he 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at 5 trial? 6 A. \$400 an hour. 7 Q. Do you know how many hours you have 8 put in on this case thus far? 9 A. I can't remember. I have not 10 reviewed the bills or the statements, but it's 11 probably not more than four or five hours. 12 That's a guesstimate. 13 Q. You have your report in front of you. 14 Other than there being the omission of the date 15 on the report, are there any other corrections 16 or modifications that you feel need to be made
 A. Okay. I will. Q. Thank you. By the way, do you know Dr. Mansnerus? A. No. Q. There are several other experts in this case. Dr. Levitan. Do you know Dr. Levitan? A. Yes. Q. How do you know him? A. I knew him from when I was working at University Hospitals. Q. Was it just sort of a passing familiarity with him or did you have occasion A. It was a professional relationship. We talked about cases, cancer patients that he is involved with that I have been involved with. 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at 5 trial? 6 A. \$400 an hour. 7 Q. Do you know how many hours you have 8 put in on this case thus far? 9 A. I can't remember. I have not 10 reviewed the bills or the statements, but it's 11 probably not more than four or five hours. 12 That's a guesstimate. 13 Q. You have your report in front of you. 14 Other than there being the omission of the date 15 on the report, are there any other corrections 16 or modifications that you feel need to be made 17 to that report to make it entirely accurate?
 A. Okay. I will. Q. Thank you. By the way, do you know Dr. Mansnerus? A. No. Q. There are several other experts in this case. Dr. Levitan. Do you know Dr. Levitan? A. Yes. Q. How do you know him? A. I knew him from when I was working at University Hospitals. Q. Was it just sort of a passing familiarity with him or did you have occasion A. It was a professional relationship. We talked about cases, cancer patients that he Is involved with that I have been involved with. Q. Is it fair to say that you had fairly 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at 5 trial? 6 A. \$400 an hour. 7 Q. Do you know how many hours you have 8 put in on this case thus far? 9 A. I can't remember. I have not 10 reviewed the bills or the statements, but it's 11 probably not more than four or five hours. 12 That's a guesstimate. 13 Q. You have your report in front of you. 14 Other than there being the omission of the date 15 on the report, are there any other corrections 16 or modifications that you feel need to be made 17 to that report to make it entirely accurate? 18 A. I don't think so.
 A. Okay. I will. Q. Thank you. By the way, do you know Dr. Mansnerus? A. No. Q. There are several other experts in this case. Dr. Levitan. Do you know Dr. Levitan? A. Yes. Q. How do you know him? A. I knew him from when I was working at University Hospitals. Q. Was it just sort of a passing familiarity with him or did you have occasion A. It was a professional relationship. We talked about cases, cancer patients that he is involved with that I have been involved with. Q. Is it fair to say that you had fairly regular contact with Dr. Levitan when you were 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at 5 trial? 6 A. \$400 an hour. 7 Q. Do you know how many hours you have 8 put in on this case thus far? 9 A. I can't remember. I have not 10 reviewed the bills or the statements, but it's 11 probably not more than four or five hours. 12 That's a guesstimate. 13 Q. You have your report in front of you. 14 Other than there being the omission of the date 15 on the report, are there any other corrections 16 or modifications that you feel need to be made 17 to that report to make it entirely accurate? 18 A. I don't think so. 19 Q. And does that report contain all of
 A. Okay. I will. Q. Thank you. By the way, do you know Dr. Mansnerus? A. No. Q. There are several other experts in this case. Dr. Levitan. Do you know Dr. Levitan? A. Yes. Q. How do you know him? A. I knew him from when I was working at University Hospitals. Q. Was it just sort of a passing familiarity with him or did you have occasion A. It was a professional relationship. We talked about cases, cancer patients that he is involved with that I have been involved with. Q. Is it fair to say that you had fairly regular contact with Dr. Levitan when you were at UH? 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at 5 trial? 6 A. \$400 an hour. 7 Q. Do you know how many hours you have 8 put in on this case thus far? 9 A. I can't remember. I have not 10 reviewed the bills or the statements, but it's 11 probably not more than four or five hours. 12 That's a guesstimate. 13 Q. You have your report in front of you. 14 Other than there being the omission of the date 15 on the report, are there any other corrections 16 or modifications that you feel need to be made 17 to that report to make it entirely accurate? 18 A. I don't think so. 19 Q. And does that report contain all of 20 the opinions that you hold in this case?
 A. Okay. I will. Q. Thank you. By the way, do you know Dr. Mansnerus? A. No. Q. There are several other experts in this case. Dr. Levitan. Do you know Dr. Levitan? A. Yes. Q. How do you know him? A. I knew him from when I was working at University Hospitals. Q. Was it just sort of a passing familiarity with him or did you have occasion A. It was a professional relationship. We talked about cases, cancer patients that he is involved with that I have been involved with. Q. Is it fair to say that you had fairly regular contact with Dr. Levitan when you were at UH? A. I don't know what regular means. 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at 5 trial? 6 A. \$400 an hour. 7 Q. Do you know how many hours you have 8 put in on this case thus far? 9 A. I can't remember. I have not 10 reviewed the bills or the statements, but it's 11 probably not more than four or five hours. 12 That's a guesstimate. 13 Q. You have your report in front of you. 14 Other than there being the omission of the date 15 on the report, are there any other corrections 16 or modifications that you feel need to be made 17 to that report to make it entirely accurate? 18 A. I don't think so. 19 Q. And does that report contain all of 20 the opinions that you hold in this case? 21 A. Yes.
 A. Okay. I will. Q. Thank you. By the way, do you know Dr. Mansnerus? A. No. Q. There are several other experts in this case. Dr. Levitan. Do you know Dr. Levitan? A. Yes. Q. How do you know him? A. I knew him from when I was working at University Hospitals. Q. Was it just sort of a passing familiarity with him or did you have occasion A. It was a professional relationship. We talked about cases, cancer patients that he is involved with that I have been involved with. Q. Is it fair to say that you had fairly regular contact with Dr. Levitan when you were at UH? A. I don't know what regular means. Q. Either do I. Was it more than once a 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at 5 trial? 6 A. \$400 an hour. 7 Q. Do you know how many hours you have 8 put in on this case thus far? 9 A. I can't remember. I have not 10 reviewed the bills or the statements, but it's 11 probably not more than four or five hours. 12 That's a guesstimate. 13 Q. You have your report in front of you. 14 Other than there being the omission of the date 15 on the report, are there any other corrections 16 or modifications that you feel need to be made 17 to that report to make it entirely accurate? 18 A. I don't think so. 19 Q. And does that report contain all of 20 the opinions that you hold in this case? 21 A. Yes. 22 Q. Doctor, can we agree that it's always
 A. Okay. I will. Q. Thank you. By the way, do you know Dr. Mansnerus? A. No. Q. There are several other experts in this case. Dr. Levitan. Do you know Dr. Levitan? A. Yes. Q. How do you know him? A. I knew him from when I was working at University Hospitals. Q. Was it just sort of a passing familiarity with him or did you have occasion A. It was a professional relationship. We talked about cases, cancer patients that he is involved with that I have been involved with. Q. Is it fair to say that you had fairly regular contact with Dr. Levitan when you were at UH? A. I don't know what regular means. Week that you had contact with him? 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at 5 trial? 6 A. \$400 an hour. 7 Q. Do you know how many hours you have 8 put in on this case thus far? 9 A. I can't remember. I have not 10 reviewed the bills or the statements, but it's 11 probably not more than four or five hours. 12 That's a guesstimate. 13 Q. You have your report in front of you. 14 Other than there being the omission of the date 15 on the report, are there any other corrections 16 or modifications that you feel need to be made 17 to that report to make it entirely accurate? 18 A. I don't think so. 19 Q. And does that report contain all of 20 the opinions that you hold in this case? 21 A. Yes. 22 Q. Doctor, can we agree that it's always 23 best to diagnose lung cancer as early as
 A. Okay. I will. Q. Thank you. By the way, do you know Dr. Mansnerus? A. No. Q. There are several other experts in this case. Dr. Levitan. Do you know Dr. Levitan? A. Yes. Q. How do you know him? A. I knew him from when I was working at University Hospitals. Q. Was it just sort of a passing familiarity with him or did you have occasion A. It was a professional relationship. We talked about cases, cancer patients that he is involved with that I have been involved with. Q. Is it fair to say that you had fairly regular contact with Dr. Levitan when you were at UH? A. I don't know what regular means. Q. Either do I. Was it more than once a week that you had contact with him? A. No. It was less than that. Probably 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at 5 trial? 6 A. \$400 an hour. 7 Q. Do you know how many hours you have 8 put in on this case thus far? 9 A. I can't remember. I have not 10 reviewed the bills or the statements, but it's 11 probably not more than four or five hours. 12 That's a guesstimate. 13 Q. You have your report in front of you. 14 Other than there being the omission of the date 15 on the report, are there any other corrections 16 or modifications that you feel need to be made 17 to that report to make it entirely accurate? 18 A. I don't think so. 19 Q. And does that report contain all of 20 the opinions that you hold in this case? 21 A. Yes. 22 Q. Doctor, can we agree that it's always 23 best to diagnose lung cancer as early as 24 possible?
 A. Okay. I will. Q. Thank you. By the way, do you know Dr. Mansnerus? A. No. Q. There are several other experts in this case. Dr. Levitan. Do you know Dr. Levitan? A. Yes. Q. How do you know him? A. I knew him from when I was working at University Hospitals. Q. Was it just sort of a passing familiarity with him or did you have occasion A. It was a professional relationship. We talked about cases, cancer patients that he is involved with that I have been involved with. Q. Is it fair to say that you had fairly regular contact with Dr. Levitan when you were at UH? A. I don't know what regular means. Week that you had contact with him? 	 2 reviewing of records and slides? 3 A. \$300 an hour for reviews. 4 Q. How much do you charge to testify at 5 trial? 6 A. \$400 an hour. 7 Q. Do you know how many hours you have 8 put in on this case thus far? 9 A. I can't remember. I have not 10 reviewed the bills or the statements, but it's 11 probably not more than four or five hours. 12 That's a guesstimate. 13 Q. You have your report in front of you. 14 Other than there being the omission of the date 15 on the report, are there any other corrections 16 or modifications that you feel need to be made 17 to that report to make it entirely accurate? 18 A. I don't think so. 19 Q. And does that report contain all of 20 the opinions that you hold in this case? 21 A. Yes. 22 Q. Doctor, can we agree that it's always 23 best to diagnose lung cancer as early as

17 (Pages 65 to 68)

October 28, 2003

Page 69	Page 71
 A. As a general statement, it's good to identify any cancer at an early stage, preferably at the noninvasive stage, if possible. Q. And noninvasive would be where there isn't any evidence of clinically significant metastasis? A. No. Invasion refers to, in a field of tumors, usually they start at the stage that we call in situ. For squamous cell carcinomas they start within the epithelium linings, the airways or skin or other parts of the body. The in situ stage they are limited to that epithelium. When they invade beyond the epithelium into the surrounding tissue and stoma, then that's the stage when they become potentially, when they potentially have the ability to spread and metastasize. Before that So before that, it's basically curable if you can diagnose a tumor at that stage. Q. So at the point where it hasn't invaded the epithelium 	 there are some factors that we don't know yet. Q. How many cells does it take once the tumor gets beyond the epithelium to create a metastatic phenomenon? A. Well, I don't think anyone knows how many cells it takes. And it's really not a function of the number of cells, it's rather a function of the type of cells and their biologic behavior and their biologic differences that contributes more to their ability to metastasize, rather than the actual number of cells or the size of the mass of the cells or the mass of the tumor. Q. Are most patients that are diagnosed with nonsmall cell lung cancer at a Stage 1 surgical candidates? MR. WARNER: Objection. A. I don't know the exact percentages of these patients that are surgical candidates. Q. Do you know whether there is a greater than 50 percent phenomenon where patients that are diagnosed at Stage 1 are surgical candidates, assuming there aren't any other comorbidities, that affect the ability to
 Page 70 A. Beyond the epithelium. The epithelium is the lining, so that's where the tumor usually starts. Q. Originates? A. Yes, either in the squamous epithelium or the glandular epithelium. But once it invades beyond the epithelium. But once it invades beyond the epithelium to the stoma surrounding the tumor where usually the lymphatics and the blood vessels are located, that's when the tumor has the potential to spread beyond that location and metastasize. Q. Do all nonsmall cell cancers that invade beyond the epithelium metastasize? A. Not necessarily, but they do have the potential to metastasize. Q. How do we know which ones will from an epidemiological standpoint metastasize and which ones will not metastasize, or don't we know? A. Well, that's the million dollar question. Q. Okay. A. There are some factors that we do know contribute to faster and eartier spread of the tumor of the nonsmall cell lung cancers and 	 Page 72 A. Well, in general, the earlier the stage of the tumor, the more likely that it would be clinically resectable. Q. Assuming Mr. Gill's cancer had been diagnosed at a stage where it was Stage 1 and he was clinically resectable, hypothetically, because of what you see by way of the molecular structure and what you see on the slides, would he have required chemotherapy and radiation as an adjunctive therapy to surgery? A. I think I would leave that question to the medical oncologists. Q. Fair enough. A. That's what they do for a living. Q. Fair enough. I just want to find out what the limitations are of your knowledge. When Mr. Gill was diagnosed, what stage was he? A. Stage 4. Q. And what is it that we see in this case that constitutes sufficient clinical or pathological evidence to say that he was Stage 4 when he was diagnosed? A. He had metastatic disease into the

18 (Pages 69 to 72)

October 28, 2003

Page 73	Page 75
 contralateral, I think contralateral mediastinum or hilar nodes and multiple nodules on the same side. Q. I was trying to mark down. He had metastatic disease of the bone, the mediastinum, the hilar nodes and A. The neck and contralateral hilar nodes and multiple nodules on the same side of the tumor. Q. And at the time that he was diagnosed, what was the size of the tumor, the primary tumor? A. According to CT report? Q. Are you able to tell me to a reasonable degree of medical probability what the size of the tumor was back in January or February? A. I think so. Q. On what basis? A. Based on the knowledge that we know about the tumor growth and the tumor doubling time that is usually done in a more experimental 	 treatment, it's very important to identify the cell type so that the best treatment can be given? A. Yes. Not only for treatment purposes, but for prognostic purposes, as well. Q. In terms of nonsmall cell lung cancer, what percentage does that make up of all lung cancer cases? A. I think it's more than the nonsmall cell lung cancer, in general. I would say one-third is nonsmall cell and then if you lump all the non-small cells together, it's two-thirds or more, maybe. Q. Where does squamous cell, the squamous cell strike that. I can just refer to nonsmall cell rather than elongating my sentence. A. Okay. Q. In terms of the origination of squamous cell when you are dealing with lung cancer, where is the most common site where it originates? A. Usually it's central or closer to the larger bronchi, and the cell of origin is thought to be metaplastic squamous epithelium
 Page 74 1 in vitro type of environment, as well as some of 2 the clinical studies that have been performed 3 following patients with lung tumors over several 4 month intervals. Q. I think you told me earlier that he 6 had different types of, different cell types in 7 his nonsmall cell; correct? A. Different types of differentiation 9 within the same tumor. Q. The squamous cell, the 11 adenocarcinoma, and then they were poorly 12 differentiated. Is that an accurate statement? I. A. Yes. I. Q. The progression rate for squamous 15 cell carcinoma, can you tell me about that? First, when I use the term 17 progression rate, is that a medical term? I. A. No. I. Mo. Well, it's a vague term. I 21 don't know what you really are referring to by 22 using that term. Q. Would you agree with this statement? 24 Because of the different types of lung cancers 25 and different ways that they may respond to 	 Page 76 from the lining epithelium of the bronchi, which are the airways that bring the air into the lungs. Q. When you are dealing with squamous cell carcinoma, does it stay within the large bronchi or in that area frequently for extended periods of time without spreading? A. You mean at the in situ stage, the noninvasive stage? Q. Yes. A. We don't really know much about the in situ stage, how long it stays there because it's frequently not diagnosed because it's asymptomatic. We frequently see the in situ stage in connection with the invasive tumor of the periphery or some of the other bronchi adjacent to the tumor. So the answer to your question is that we do not know how long it stays as a noninvasive stage, but probably for years. Q. Would you agree that with squamous cell cancers that usually start in the large bronchi, that without spreading outside of that area, that typically they stay for longer periods than other types of lung cancers?

19 (Pages 73 to 76)

October 28, 2003

11			
	Page 77		Page 79
	ARNER: Objection.	1	alveolar spaces.
	do you mean they stay for a long	2	Q. Can you say in this case, given the
3 period?		3	cell structure that we have and the combination
4 Q. With	out spreading.	4	of the squamous cell, as well as the
	out spreading, without	5	adenocarcinoma, where the cancer originated in
6 metastasizing c		6	Dan Gill's case?
7 Q. Yes.		7	A. As I said, it most likely originated
	first of all, even though most	8	from the lining of either the tracheobronchial
	ung, or most squamous cell	9	tree or the more distal airways. But exactly to
	ot all nonsmall cell cancers, but	10	pinpoint where it started, the exact point, I
	s cell carcinomas arise proximal in	11	don't think I can do that.
	heobronchial tree branches. There	12	Q. Can you tell me to a probability when
	ategory of peripheral squamous	13	his adenosquamous cell carcinoma metastasized?
	that arises peripheral in the	14	A. His tumor was a high grade tumor,
	Il documented entity.	15	which means that it's biologically a more
	d of all is that it depends on	16	aggressive tumor. These tumors usually
	differentiation of the squamous	17	metastasize earlier in the course of the disease
	. The well differentiated ones	18	than the lower grade tumors, which are the well
	ower, invade mostly into the	19	differentiated nonsmall cell carcinomas.
20 lumen of the t	racheobronchial tree and causes	20	When did this tumor exactly
	d obstructive pneumonia and	21	metastasize, I can't tell you an exact date that
	by the time they are	22	this tumor metastasized.
	ey are usually large tumors.	23	MR. WARNER: Doctor, are you done
	ver, the poorly differentiated	24	
	carcinomas, when they are	25	A. Well, I have an opinion as to the
• • • • • • • • • • • • • • • • • • • •			, a weily that's an opinion as to the
11			
	Page 78		Page 80
1 discovered, the	-	1	-
	y can also be large tumors, but	1	approximate time period as to when, you know, a
2 they may be po	ey can also be large tumors, but eripheral, as well, the poorly	2	approximate time period as to when, you know, a general range of time where the tumor probably
2 they may be po 3 differentiated s	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas.		approximate time period as to when, you know, a general range of time where the tumor probably metastasized.
2 they may be po 3 differentiated s 4 They c	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas. an, depending on their biologic	2 3 4	approximate time period as to when, you know, a general range of time where the tumor probably metastasized. Q. Before you give me that answer, tell
2 they may be po 3 differentiated s 4 They c 5 potential, they	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas. an, depending on their biologic may be associated at the time of	2 3 4 5	approximate time period as to when, you know, a general range of time where the tumor probably metastasized.Q. Before you give me that answer, tell me what you're basing that statement on as to
2 they may be po 3 differentiated s 4 They c 5 potential, they 6 diagnosis, they	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas. an, depending on their biologic	2 3 4	approximate time period as to when, you know, a general range of time where the tumor probably metastasized. Q. Before you give me that answer, tell
2 they may be po 3 differentiated s 4 They c 5 potential, they 6 diagnosis, they 7 either the local 8 sites.	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas. an, depending on their biologic may be associated at the time of may already have metastasized to	2 3 4 5 6	approximate time period as to when, you know, a general range of time where the tumor probably metastasized.Q. Before you give me that answer, tell me what you're basing that statement on as to the general range as to when it metastasized in Mr. Gill?
 2 they may be point of the second s	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas. an, depending on their biologic may be associated at the time of may already have metastasized to lymph nodes or to distant s case, do you have an opinion	2 3 4 5 6 7	 approximate time period as to when, you know, a general range of time where the tumor probably metastasized. Q. Before you give me that answer, tell me what you're basing that statement on as to the general range as to when it metastasized in Mr. Gill? A. On two factors, mostly, which is
 2 they may be point of the second s	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas. an, depending on their biologic may be associated at the time of may already have metastasized to lymph nodes or to distant	2 3 4 5 6 7 8	approximate time period as to when, you know, a general range of time where the tumor probably metastasized.Q. Before you give me that answer, tell me what you're basing that statement on as to the general range as to when it metastasized in Mr. Gill?
 2 they may be point of the second s	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas. an, depending on their biologic may be associated at the time of may already have metastasized to lymph nodes or to distant s case, do you have an opinion s squamous cell carcinoma	2 3 4 5 6 7 8 9 10 11	 approximate time period as to when, you know, a general range of time where the tumor probably metastasized. Q. Before you give me that answer, tell me what you're basing that statement on as to the general range as to when it metastasized in Mr. Gill? A. On two factors, mostly, which is well, make it three factors: The size of the tumor at the time of diagnosis in August 2000. The histologic grade, which is a high grade.
 2 they may be point of the second s	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas. an, depending on their biologic may be associated at the time of may already have metastasized to lymph nodes or to distant s case, do you have an opinion	2 3 4 5 6 7 8 9 10	 approximate time period as to when, you know, a general range of time where the tumor probably metastasized. Q. Before you give me that answer, tell me what you're basing that statement on as to the general range as to when it metastasized in Mr. Gill? A. On two factors, mostly, which is well, make it three factors: The size of the tumor at the time of diagnosis in August 2000.
 2 they may be point of the second s	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas. an, depending on their biologic may be associated at the time of may already have metastasized to lymph nodes or to distant s case, do you have an opinion s squamous cell carcinoma mean which of the bronchial tree?	2 3 4 5 6 7 8 9 10 11	 approximate time period as to when, you know, a general range of time where the tumor probably metastasized. Q. Before you give me that answer, tell me what you're basing that statement on as to the general range as to when it metastasized in Mr. Gill? A. On two factors, mostly, which is well, make it three factors: The size of the tumor at the time of diagnosis in August 2000. The histologic grade, which is a high grade. These tumors usually metastasize earlier. And the clinical information at the time of
 2 they may be point of the second s	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas. an, depending on their biologic may be associated at the time of may already have metastasized to lymph nodes or to distant s case, do you have an opinion s squamous cell carcinoma nean which of the bronchial tree? without referring to the CT scan.	2 3 4 5 6 7 8 9 10 11 12 13 14	 approximate time period as to when, you know, a general range of time where the tumor probably metastasized. Q. Before you give me that answer, tell me what you're basing that statement on as to the general range as to when it metastasized in Mr. Gill? A. On two factors, mostly, which is well, make it three factors: The size of the tumor at the time of diagnosis in August 2000. The histologic grade, which is a high grade. These tumors usually metastasize earlier. And the clinical information at the time of presentation in December where the patient,
 2 they may be point of the second s	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas. an, depending on their biologic may be associated at the time of may already have metastasized to lymph nodes or to distant s case, do you have an opinion s squamous cell carcinoma mean which of the bronchial tree? without referring to the CT scan. ink even the CT scan does not	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 approximate time period as to when, you know, a general range of time where the tumor probably metastasized. Q. Before you give me that answer, tell me what you're basing that statement on as to the general range as to when it metastasized in Mr. Gill? A. On two factors, mostly, which iswell, make it three factors: The size of the tumor at the time of diagnosis in August 2000. The histologic grade, which is a high grade. These tumors usually metastasize earlier. And the clinical information at the time of presentation in December where the patient, Mr. Gill, presented with numbness in the left
 2 they may be point of the second s	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas. an, depending on their biologic may be associated at the time of may already have metastasized to lymph nodes or to distant s case, do you have an opinion s squamous cell carcinoma nean which of the bronchial tree? without referring to the CT scan. ink even the CT scan does not he time cannot tell exactly where	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 approximate time period as to when, you know, a general range of time where the tumor probably metastasized. Q. Before you give me that answer, tell me what you're basing that statement on as to the general range as to when it metastasized in Mr. Gill? A. On two factors, mostly, which iswell, make it three factors: The size of the tumor at the time of diagnosis in August 2000. The histologic grade, which is a high grade. These tumors usually metastasize earlier. And the clinical information at the time of presentation in December where the patient, Mr. Gill, presented with numbness in the left arm and the neck, and these are in retrospect.
 2 they may be point of the second s	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas. an, depending on their biologic may be associated at the time of may already have metastasized to lymph nodes or to distant s case, do you have an opinion s squamous cell carcinoma nean which of the bronchial tree? without referring to the CT scan. ink even the CT scan does not he time cannot tell exactly where ed.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 approximate time period as to when, you know, a general range of time where the tumor probably metastasized. Q. Before you give me that answer, tell me what you're basing that statement on as to the general range as to when it metastasized in Mr. Gill? A. On two factors, mostly, which iswell, make it three factors: The size of the tumor at the time of diagnosis in August 2000. The histologic grade, which is a high grade. These tumors usually metastasize earlier. And the clinical information at the time of presentation in December where the patient, Mr. Gill, presented with numbness in the left arm and the neck, and these are in retrospect. Now, you asked me before if I had
2they may be point3differentiated s4They c5potential, they6diagnosis, they7either the local8sites.9Q.10as to where thi11originated?12A.13Q.14A.15And I don't thi16have, most of the17the tumor start18In this	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas. an, depending on their biologic may be associated at the time of may already have metastasized to lymph nodes or to distant s case, do you have an opinion s squamous cell carcinoma nean which of the bronchial tree? without referring to the CT scan. ink even the CT scan does not he time cannot tell exactly where ed. case, the tumor is not a pure	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 approximate time period as to when, you know, a general range of time where the tumor probably metastasized. Q. Before you give me that answer, tell me what you're basing that statement on as to the general range as to when it metastasized in Mr. Gill? A. On two factors, mostly, which iswell, make it three factors: The size of the tumor at the time of diagnosis in August 2000. The histologic grade, which is a high grade. These tumors usually metastasize earlier. And the clinical information at the time of presentation in December where the patient, Mr. Gill, presented with numbness in the left arm and the neck, and these are in retrospect. Now, you asked me before if I had seen the patient or assessed or reviewed the
2they may be performed and the second and	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas. an, depending on their biologic may be associated at the time of may already have metastasized to lymph nodes or to distant s case, do you have an opinion s squamous cell carcinoma nean which of the bronchial tree? without referring to the CT scan. ink even the CT scan does not he time cannot tell exactly where ed. case, the tumor is not a pure carcinoma; in fact, an	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 approximate time period as to when, you know, a general range of time where the tumor probably metastasized. Q. Before you give me that answer, tell me what you're basing that statement on as to the general range as to when it metastasized in Mr. Gill? A. On two factors, mostly, which iswell, make it three factors: The size of the tumor at the time of diagnosis in August 2000. The histologic grade, which is a high grade. These tumors usually metastasize earlier. And the clinical information at the time of presentation in December where the patient, Mr. Gill, presented with numbness in the left arm and the neck, and these are in retrospect. Now, you asked me before if I had seen the patient or assessed or reviewed the case in January of 2000, whether I would think
2they may be performed and the second and	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas. an, depending on their biologic may be associated at the time of may already have metastasized to lymph nodes or to distant s case, do you have an opinion s squamous cell carcinoma nean which of the bronchial tree? without referring to the CT scan. ink even the CT scan does not he time cannot tell exactly where ed. case, the tumor is not a pure carcinoma; in fact, an s or a tumor with both squamous and	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 approximate time period as to when, you know, a general range of time where the tumor probably metastasized. Q. Before you give me that answer, tell me what you're basing that statement on as to the general range as to when it metastasized in Mr. Gill? A. On two factors, mostly, which iswell, make it three factors: The size of the tumor at the time of diagnosis in August 2000. The histologic grade, which is a high grade. These tumors usually metastasize earlier. And the clinical information at the time of presentation in December where the patient, Mr. Gill, presented with numbness in the left arm and the neck, and these are in retrospect. Now, you asked me before if I had seen the patient or assessed or reviewed the case in January of 2000, whether I would think that the patient had mets, and I said no,
2they may be performed and the second and	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas. an, depending on their biologic may be associated at the time of may already have metastasized to lymph nodes or to distant s case, do you have an opinion s squamous cell carcinoma nean which of the bronchial tree? without referring to the CT scan. ink even the CT scan does not he time cannot tell exactly where ed. case, the tumor is not a pure carcinoma; in fact, an s or a tumor with both squamous and entiation, and many times these	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 approximate time period as to when, you know, a general range of time where the tumor probably metastasized. Q. Before you give me that answer, tell me what you're basing that statement on as to the general range as to when it metastasized in Mr. Gill? A. On two factors, mostly, which iswell, make it three factors: The size of the tumor at the time of diagnosis in August 2000. The histologic grade, which is a high grade. These tumors usually metastasize earlier. And the clinical information at the time of presentation in December where the patient, Mr. Gill, presented with numbness in the left arm and the neck, and these are in retrospect. Now, you asked me before if I had seen the patient or assessed or reviewed the case in January of 2000, whether I would think that the patient had mets, and I said no, because the patient did not have cancer. Now
2they may be performed and the second and	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas. an, depending on their biologic may be associated at the time of may already have metastasized to lymph nodes or to distant s case, do you have an opinion s squamous cell carcinoma nean which of the bronchial tree? without referring to the CT scan. ink even the CT scan does not he time cannot tell exactly where ed. case, the tumor is not a pure carcinoma; in fact, an s or a tumor with both squamous and entiation, and many times these ore peripheral than the pure	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 approximate time period as to when, you know, a general range of time where the tumor probably metastasized. Q. Before you give me that answer, tell me what you're basing that statement on as to the general range as to when it metastasized in Mr. Gill? A. On two factors, mostly, which iswell, make it three factors: The size of the tumor at the time of diagnosis in August 2000. The histologic grade, which is a high grade. These tumors usually metastasize earlier. And the clinical information at the time of presentation in December where the patient, Mr. Gill, presented with numbness in the left arm and the neck, and these are in retrospect. Now, you asked me before if I had seen the patient or assessed or reviewed the case in January of 2000, whether I would think that the patient had mets, and I said no, because the patient did not have cancer. Now that I know that Mr. Gill has had cancer and J
2they may be performed and the second and	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas. an, depending on their biologic may be associated at the time of may already have metastasized to lymph nodes or to distant s case, do you have an opinion s squamous cell carcinoma nean which of the bronchial tree? without referring to the CT scan. ink even the CT scan does not he time cannot tell exactly where ed. case, the tumor is not a pure carcinoma; in fact, an s or a tumor with both squamous and entiation, and many times these ore peripheral than the pure carcinomas. But they do usually	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	approximate time period as to when, you know, a general range of time where the tumor probably metastasized. Q. Before you give me that answer, tell me what you're basing that statement on as to the general range as to when it metastasized in Mr. Gill? A. On two factors, mostly, which iswell, make it three factors: The size of the tumor at the time of diagnosis in August 2000. The histologic grade, which is a high grade. These tumors usually metastasize earlier. And the clinical information at the time of presentation in December where the patient, Mr. Gill, presented with numbness in the left arm and the neck, and these are in retrospect. Now, you asked me before if I had seen the patient or assessed or reviewed the case in January of 2000, whether I would think that the patient had mets, and I said no, because the patient did not have cancer. Now that I know that Mr. Gill has had cancer and I know the features of his lung cancer, now I can
2they may be performed a differentiated s3differentiated s4They of5potential, they6diagnosis, they7either the local8sites.9Q.10as to where thi11originated?12A.13Q.14A.15And I don't thi16have, most of the17the tumor start18In this19squamous cell of20adenosquamou21glandular differ22tumors arise m23squamous cell of24arise from the	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas. an, depending on their biologic may be associated at the time of may already have metastasized to lymph nodes or to distant s case, do you have an opinion s squamous cell carcinoma nean which of the bronchial tree? without referring to the CT scan. ink even the CT scan does not he time cannot tell exactly where ed. case, the tumor is not a pure carcinoma; in fact, an s or a tumor with both squamous and entiation, and many times these ore peripheral than the pure carcinomas. But they do usually ining of either the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	approximate time period as to when, you know, a general range of time where the tumor probably metastasized. Q. Before you give me that answer, tell me what you're basing that statement on as to the general range as to when it metastasized in Mr. Gill? A. On two factors, mostly, which iswell, make it three factors: The size of the tumor at the time of diagnosis in August 2000. The histologic grade, which is a high grade. These tumors usually metastasize earlier. And the clinical information at the time of presentation in December where the patient, Mr. Gill, presented with numbness in the left arm and the neck, and these are in retrospect. Now, you asked me before if I had seen the patient or assessed or reviewed the case in January of 2000, whether I would think that the patient had mets, and I said no, because the patient did not have cancer. Now that I know that Mr. Gill has had cancer and J know the features of his lung cancer, now I can say that he probably did have mets at the time
2they may be performed and the second and	ey can also be large tumors, but eripheral, as well, the poorly quamous cell carcinomas. an, depending on their biologic may be associated at the time of may already have metastasized to lymph nodes or to distant s case, do you have an opinion s squamous cell carcinoma nean which of the bronchial tree? without referring to the CT scan. ink even the CT scan does not he time cannot tell exactly where ed. case, the tumor is not a pure carcinoma; in fact, an s or a tumor with both squamous and entiation, and many times these ore peripheral than the pure carcinomas. But they do usually	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	approximate time period as to when, you know, a general range of time where the tumor probably metastasized. Q. Before you give me that answer, tell me what you're basing that statement on as to the general range as to when it metastasized in Mr. Gill? A. On two factors, mostly, which iswell, make it three factors: The size of the tumor at the time of diagnosis in August 2000. The histologic grade, which is a high grade. These tumors usually metastasize earlier. And the clinical information at the time of presentation in December where the patient, Mr. Gill, presented with numbness in the left arm and the neck, and these are in retrospect. Now, you asked me before if I had seen the patient or assessed or reviewed the case in January of 2000, whether I would think that the patient had mets, and I said no, because the patient did not have cancer. Now that I know that Mr. Gill has had cancer and I know the features of his lung cancer, now I can

20 (Pages 77 to 80)

October 28, 2003

3 about that. First, as of December, it's your 3 MR. WARNER	Page 83 I fall in that spectrum? I: Objection. Go ahead. a lot of controversy,
1that.1A. Yes.2Q. Let me ask you a couple questions2Q. Where do you3about that. First, as of December, it's your3MR. WARNER4opinion that on December 9th and December 30th4A. Well, there is a5that when he was seen by Dr. Mansnerus, knowing5because doubling time -6everything that you know and I think you used6like to refer to it as dou7the term retrospectively what you are saying7it's really the time that	a fall in that spectrum? :: Objection. Go ahead. a lot of controversy,
2Q. Let me ask you a couple questions2Q. Where do you3about that. First, as of December, it's your3MR. WARNER4opinion that on December 9th and December 30th4A. Well, there is a5that when he was seen by Dr. Mansnerus, knowing5because doubling time -6everything that you know and I think you used6like to refer to it as dou7the term retrospectively what you are saying7it's really the time that	: Objection. Go ahead. a lot of controversy,
3 about that. First, as of December, it's your3MR. WARNER4 opinion that on December 9th and December 30th4A. Well, there is a5 that when he was seen by Dr. Mansnerus, knowing5because doubling time -6 everything that you know and I think you used6like to refer to it as dou7 the term retrospectively what you are saying7it's really the time that	: Objection. Go ahead. a lot of controversy,
3 about that. First, as of December, it's your3MR. WARNER4 opinion that on December 9th and December 30th4A. Well, there is a5 that when he was seen by Dr. Mansnerus, knowing5because doubling time -6 everything that you know and I think you used6like to refer to it as dou7 the term retrospectively what you are saying7it's really the time that	: Objection. Go ahead. a lot of controversy,
5that when he was seen by Dr. Mansnerus, knowing everything that you know and I think you used 75because doubling time -6everything that you know and I think you used 76like to refer to it as dou 77the term retrospectively what you are saying7it's really the time that	
5that when he was seen by Dr. Mansnerus, knowing5because doubling time -6everything that you know and I think you used6like to refer to it as dou7the term retrospectively what you are saying7it's really the time that	
6everything that you know and I think you used6like to refer to it as dou7the term retrospectively what you are saying7it's really the time that	well, first of all, l
8 to me is that Mr. Gill had cancer when he was 8 double the volume of the	
	he tumor.
9 seen by the doctor on those two occasions; 9 But these usual	ly refer to the tumors
10 correct? 10 In the ideal situations w	here the tumor has
11 A. I'm sorry, say it again. 11 grown in vitro in a cultu	ure type of environment,
12 Q. Sure. Based upon everything that you 12 provided all the nutrien	its of all the ideal
	ng into account the tumor
14 retrospectively going back to the symptoms that 14 necrosis that sometimes	
15 he had in December, it's your opinion that most 15 tumor growth, not taking	ng into account the
16 likely Mr. Gill had metastatic lung cancer in 16 intrinsic factors such as	
17 December of 1999; true? 17 other factors that we do	
18 A. That's correct. 18 contributes to the tumo	or growth, not taking into
	nse or immunologic system
20 the metastasis existed in December of 1999? 20 that sometimes can arre	
21 A. You mean where exactly it was, the 21 taking into account cha	
22 metastasis? 22 of the tumor, we are as	
23 Q. Yes. 23 Q. Exponential?	-
24 A. It was probably in the neck and 24 A exponential,	, but it's not
25 probably in the mediastinum, from the symptoms. 25 necessarily that.	
Page 82	Page 84
1 Q. No bone involvement from the 1 So therefore, ye	ou know, with all of
2 symptoms; correct? 2 these pitfalls and the tur	
	time, it is only a general
4 records. That doesn't exclude that he did not 4 guideline. And what it	
5 have bone mets at the time, but according to the 5 really takes a very, very	
6 medical records, I can't say that he had bone 6 to divide in the ideal sit	
	ecome actually visible on
8 Q. Can you tell me based upon your 8 x-ray or clinically on sou	
9 expertise in this area what size the tumor was 9 palpation and so forth.	
	relate, however, with
11 A. It was probably a few millimeters 11 our observations, our cl	· · ·
12 smaller than it was at the time of diagnosis in 12 many patients that for c	
13 August. 13 have an abnormal x-ray	
14 Q. And what do you base that on? 14 result, a mass in the case	
15 A. Based on my experience and the 15 lung or nodes and thing	
16 knowledge that we know about lung cancers and 16 very, very long time to	change and grow in size
	diologic examinations and
18 Q. You have seen a lot of articles on 18 serial radiologic examination	
	ed that this was a high
20 A. Yes. 20 grade tumor?	
21 Q. And you have also seen that there is 21 A. Yes.	
	mors of this type, in
23 pathologists in terms of the efficacy or the 23 your experience, and ba	
24 appropriateness of using doubling times; 24 and training, metastasize	e early in the disease
24 appropriateness of using doubling times; 24 and training, metastasize	e early in the disease

21 (Pages 81 to 84)

October 28, 2003

	Page 85		Page 87
1	A. Usually, yes.	1	cancer, lung cancer that was the primary
2	Q. Can you state in this case, based	2	tumor; correct?
3	upon your review of the pathology slides, that	3	A. Yes.
4	Mr. Gill's tumor did metastasize early in the	4	Q. That he had lung cancer going back to
5	disease?	5	either 1995 or 1997, roughly speaking?
6	A. I cannot only based on the histologic	6	A. Yes.
7	rate of the tumor that it's a high grade, but as	7	Q. And when along that spectrum, if we
8	I mentioned based on the size as well as the	8	take 1995 to 1997, given the tumor type that he
9	grade as well as the clinical signs and symptoms	9	had, when in your opinion did this high grade
10	that he presented with, I have an opinion that	10	tumor first metastasize? At what interval from
11	it's very likely and it's probable that the	11	'95 up to 2000?
12	patient, that Mr. Gill had metastasis at the	12	A. I don't really know exactly when. I
13 14	time of presentation, and as I said, probably a long time before that.	13 14	can't tell, but again, from the clinical signs
15	Q. Okay.	15	and symptoms, when he presented with the neck, the symptoms in the neck and the left arm, he
16	A. Whether you are asking me early in	16	probably had the met at that time. How long
17	the disease, I don't know what early in the	17	· · ·
18	disease means.	18	Q. You would just be speculating to give
19	Q. I pretty much understand that you are	19	me an opinion as to how long before December he
20	saying that as of December your opinion in this	20	had had metastatic disease; is that a fair
21	case and what you intend to testify to at trial	21	statement?
22	is that he had metastatic lung cancer in	22	A. Yes.
23	December when he was seen by Dr. Mansnerus;	23	Q. Don't squamous cell carcinomas
24	true?	24	normally spread late as opposed to early?
25	A. Yes, most likely.	25	A. It depends on a lot of factors.
			
1			
	Page 86		Page 88
1		1	· · · · ·
1	Q. And do you intend to testify that	1	Q. What is it about
	Q. And do you intend to testify that most likely it was Stage 4 metastatic lung	1 2 3	Q. What is it about A. If you are asking
2	Q. And do you intend to testify that	2	 Q. What is it about A. If you are asking Q. Go ahead.
2 3	Q. And do you intend to testify that most likely it was Stage 4 metastatic lung cancer or are you not of that opinion as of	2 3	 Q. What is it about A. If you are asking Q. Go ahead.
2 3 4	Q. And do you intend to testify that most likely it was Stage 4 metastatic lung cancer or are you not of that opinion as of December?	2 3 4	 Q. What is it about A. If you are asking Q. Go ahead. A if squamous cell carcinomas
2 3 4 5 6 7	 Q. And do you intend to testify that most likely it was Stage 4 metastatic lung cancer or are you not of that opinion as of December? A. Yes, I think it was Stage 4 at that time. Q. When did he first develop the lung 	2 3 4 5	 Q. What is it about A. If you are asking Q. Go ahead. A if squamous cell carcinomas metastasize later in the stage of the disease than small cell cancers, the answer is yes. If you are asking whether there is a difference
2 3 4 5 6 7 8	 Q. And do you intend to testify that most likely it was Stage 4 metastatic lung cancer or are you not of that opinion as of December? A. Yes, I think it was Stage 4 at that time. Q. When did he first develop the lung cancer? How many years before, given everything 	2 3 4 5 6 7 8	 Q. What is it about A. If you are asking Q. Go ahead. A if squamous cell carcinomas metastasize later in the stage of the disease than small cell cancers, the answer is yes. If you are asking whether there is a difference between the spread rate of squamous cell
2 3 4 5 6 7 8 9	 Q. And do you intend to testify that most likely it was Stage 4 metastatic lung cancer or are you not of that opinion as of December? A. Yes, I think it was Stage 4 at that time. Q. When did he first develop the lung cancer? How many years before, given everything that you know, looking at the slides, knowing 	2 3 4 5 6 7 8 9	 Q. What is it about A. If you are asking Q. Go ahead. A if squamous cell carcinomas metastasize later in the stage of the disease than small cell cancers, the answer is yes. If you are asking whether there is a difference between the spread rate of squamous cell carcinomas versus adenocarcinomas, not that
2 3 4 5 6 7 8 9 10	 Q. And do you intend to testify that most likely it was Stage 4 metastatic lung cancer or are you not of that opinion as of December? A. Yes, I think it was Stage 4 at that time. Q. When did he first develop the lung cancer? How many years before, given everything that you know, looking at the slides, knowing what stage he was at when he was diagnosed? 	2 3 4 5 6 7 8 9 10	 Q. What is it about A. If you are asking Q. Go ahead. A if squamous cell carcinomas metastasize later in the stage of the disease than small cell cancers, the answer is yes. If you are asking whether there is a difference between the spread rate of squamous cell carcinomas versus adenocarcinomas, not that significant a difference.
2 3 4 5 6 7 8 9 10 11	 Q. And do you intend to testify that most likely it was Stage 4 metastatic lung cancer or are you not of that opinion as of December? A. Yes, I think it was Stage 4 at that time. Q. When did he first develop the lung cancer? How many years before, given everything that you know, looking at the slides, knowing what stage he was at when he was diagnosed? A. Probably a few years, but I can't 	2 3 4 5 6 7 8 9 10 11	 Q. What is it about A. If you are asking Q. Go ahead. A if squamous cell carcinomas metastasize later in the stage of the disease than small cell cancers, the answer is yes. If you are asking whether there is a difference between the spread rate of squamous cell carcinomas versus adenocarcinomas, not that significant a difference. If you are asking in general,
2 3 4 5 6 7 8 9 10 11 12	 Q. And do you intend to testify that most likely it was Stage 4 metastatic lung cancer or are you not of that opinion as of December? A. Yes, I think it was Stage 4 at that time. Q. When did he first develop the lung cancer? How many years before, given everything that you know, looking at the slides, knowing what stage he was at when he was diagnosed? A. Probably a few years, but I can't really specify it any further than that. 	2 3 4 5 6 7 8 9 10 11 12	 Q. What is it about A. If you are asking Q. Go ahead. A if squamous cell carcinomas metastasize later in the stage of the disease than small cell cancers, the answer is yes. If you are asking whether there is a difference between the spread rate of squamous cell carcinomas versus adenocarcinomas, not that significant a difference. If you are asking in general, squamous cell carcinomas anywhere in the body
2 3 4 5 6 7 8 9 10 11 12 13	 Q. And do you intend to testify that most likely it was Stage 4 metastatic lung cancer or are you not of that opinion as of December? A. Yes, I think it was Stage 4 at that time. Q. When did he first develop the lung cancer? How many years before, given everything that you know, looking at the slides, knowing what stage he was at when he was diagnosed? A. Probably a few years, but I can't really specify it any further than that. Q. All right. One person's few may be 	2 3 4 5 6 7 8 9 10 11 12 13	 Q. What is it about A. If you are asking Q. Go ahead. A if squamous cell carcinomas metastasize later in the stage of the disease than small cell cancers, the answer is yes. If you are asking whether there is a difference between the spread rate of squamous cell carcinomas versus adenocarcinomas, not that significant a difference. If you are asking in general, squamous cell carcinomas anywhere in the body versus lungs, then actually that depends on
2 3 4 5 6 7 8 9 10 11 12 13 14	 Q. And do you intend to testify that most likely it was Stage 4 metastatic lung cancer or are you not of that opinion as of December? A. Yes, I think it was Stage 4 at that time. Q. When did he first develop the lung cancer? How many years before, given everything that you know, looking at the slides, knowing what stage he was at when he was diagnosed? A. Probably a few years, but I can't really specify it any further than that. Q. All right. One person's few may be another person's not so few, so I am going to 	2 3 4 5 6 7 8 9 10 11 12 13 14	 Q. What is it about A. If you are asking Q. Go ahead. A if squamous cell carcinomas metastasize later in the stage of the disease than small cell cancers, the answer is yes. If you are asking whether there is a difference between the spread rate of squamous cell carcinomas versus adenocarcinomas, not that significant a difference. If you are asking in general, squamous cell carcinomas anywhere in the body versus lungs, then actually that depends on their differentiation, the degree of
2 3 4 5 6 7 8 9 10 11 12 13 14 15	 Q. And do you intend to testify that most likely it was Stage 4 metastatic lung cancer or are you not of that opinion as of December? A. Yes, I think it was Stage 4 at that time. Q. When did he first develop the lung cancer? How many years before, given everything that you know, looking at the slides, knowing what stage he was at when he was diagnosed? A. Probably a few years, but I can't really specify it any further than that. Q. All right. One person's few may be another person's not so few, so I am going to press you just a little bit as best I can. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15	 Q. What is it about A. If you are asking Q. Go ahead. A if squamous cell carcinomas metastasize later in the stage of the disease than small cell cancers, the answer is yes. If you are asking whether there is a difference between the spread rate of squamous cell carcinomas versus adenocarcinomas, not that significant a difference. If you are asking in general, squamous cell carcinomas anywhere in the body versus lungs, then actually that depends on their differentiation, the degree of differentiation.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 Q. And do you intend to testify that most likely it was Stage 4 metastatic lung cancer or are you not of that opinion as of December? A. Yes, I think it was Stage 4 at that time. Q. When did he first develop the lung cancer? How many years before, given everything that you know, looking at the slides, knowing what stage he was at when he was diagnosed? A. Probably a few years, but I can't really specify it any further than that. Q. All right. One person's few may be another person's not so few, so I am going to press you just a little bit as best I can. When you say few, are you talking two 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	 Q. What is it about A. If you are asking Q. Go ahead. A if squamous cell carcinomas metastasize later in the stage of the disease than small cell cancers, the answer is yes. If you are asking whether there is a difference between the spread rate of squamous cell carcinomas versus adenocarcinomas, not that significant a difference. If you are asking in general, squamous cell carcinomas anywhere in the body versus lungs, then actually that depends on their differentiation, the degree of differentiation. Q. What I'm talking about is in lung
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 Q. And do you intend to testify that most likely it was Stage 4 metastatic lung cancer or are you not of that opinion as of December? A. Yes, I think it was Stage 4 at that time. Q. When did he first develop the lung cancer? How many years before, given everything that you know, looking at the slides, knowing what stage he was at when he was diagnosed? A. Probably a few years, but I can't really specify it any further than that. Q. All right. One person's few may be another person's not so few, so I am going to press you just a little bit as best I can. When you say few, are you talking two or three or are you talking five or six? Give 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 Q. What is it about A. If you are asking Q. Go ahead. A if squamous cell carcinomas metastasize later in the stage of the disease than small cell cancers, the answer is yes. If you are asking whether there is a difference between the spread rate of squamous cell carcinomas versus adenocarcinomas, not that significant a difference. If you are asking in general, squamous cell carcinomas anywhere in the body versus lungs, then actually that depends on their differentiation, the degree of differentiation. Q. What I'm talking about is in lung cancer cases, squamous cell lung cancer patients
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 Q. And do you intend to testify that most likely it was Stage 4 metastatic lung cancer or are you not of that opinion as of December? A. Yes, I think it was Stage 4 at that time. Q. When did he first develop the lung cancer? How many years before, given everything that you know, looking at the slides, knowing what stage he was at when he was diagnosed? A. Probably a few years, but I can't really specify it any further than that. Q. All right. One person's few may be another person's not so few, so I am going to press you just a little bit as best I can. When you say few, are you talking two or three or are you talking five or six? Give me your best estimate. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	 Q. What is it about A. If you are asking Q. Go ahead. A if squamous cell carcinomas metastasize later in the stage of the disease than small cell cancers, the answer is yes. If you are asking whether there is a difference between the spread rate of squamous cell carcinomas versus adenocarcinomas, not that significant a difference. If you are asking in general, squamous cell carcinomas anywhere in the body versus lungs, then actually that depends on their differentiation, the degree of differentiation. Q. What I'm talking about is in lung cancer cases, squamous cell lung cancer patients that also have adenocarcinoma components and are
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 Q. And do you intend to testify that most likely it was Stage 4 metastatic lung cancer or are you not of that opinion as of December? A. Yes, I think it was Stage 4 at that time. Q. When did he first develop the lung cancer? How many years before, given everything that you know, looking at the slides, knowing what stage he was at when he was diagnosed? A. Probably a few years, but I can't really specify it any further than that. Q. All right. One person's few may be another person's not so few, so I am going to press you just a little bit as best I can. When you say few, are you talking two or three or are you talking five or six? Give me your best estimate. A. The way I use few is three to five. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	 Q. What is it about A. If you are asking Q. Go ahead. A if squamous cell carcinomas metastasize later in the stage of the disease than small cell cancers, the answer is yes. If you are asking whether there is a difference between the spread rate of squamous cell carcinomas versus adenocarcinomas, not that significant a difference. If you are asking in general, squamous cell carcinomas anywhere in the body versus lungs, then actually that depends on their differentiation, the degree of differentiation. Q. What I'm talking about is in lung cancer cases, squamous cell lung cancer patients that also have adenocarcinoma components and are poorly differentiated because I don't want to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 Q. And do you intend to testify that most likely it was Stage 4 metastatic lung cancer or are you not of that opinion as of December? A. Yes, I think it was Stage 4 at that time. Q. When did he first develop the lung cancer? How many years before, given everything that you know, looking at the slides, knowing what stage he was at when he was diagnosed? A. Probably a few years, but I can't really specify it any further than that. Q. All right. One person's few may be another person's not so few, so I am going to press you just a little bit as best I can. When you say few, are you talking two or three or are you talking five or six? Give me your best estimate. A. The way I use few is three to five. Q. And in the spectrum of the three to 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	 Q. What is it about A. If you are asking Q. Go ahead. A if squamous cell carcinomas metastasize later in the stage of the disease than small cell cancers, the answer is yes. If you are asking whether there is a difference between the spread rate of squamous cell carcinomas versus adenocarcinomas, not that significant a difference. If you are asking in general, squamous cell carcinomas anywhere in the body versus lungs, then actually that depends on their differentiation, the degree of differentiation. Q. What I'm talking about is in lung cancer cases, squamous cell lung cancer patients that also have adenocarcinoma components and are poorly differentiated because I don't want to exclude any of the variables that we have in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 Q. And do you intend to testify that most likely it was Stage 4 metastatic lung cancer or are you not of that opinion as of December? A. Yes, I think it was Stage 4 at that time. Q. When did he first develop the lung cancer? How many years before, given everything that you know, looking at the slides, knowing what stage he was at when he was diagnosed? A. Probably a few years, but I can't really specify it any further than that. Q. All right. One person's few may be another person's not so few, so I am going to press you just a little bit as best I can. When you say few, are you talking two or three or are you talking five or six? Give me your best estimate. A. The way I use few is three to five. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	 Q. What is it about A. If you are asking Q. Go ahead. A if squamous cell carcinomas metastasize later in the stage of the disease than small cell cancers, the answer is yes. If you are asking whether there is a difference between the spread rate of squamous cell carcinomas versus adenocarcinomas, not that significant a difference. If you are asking in general, squamous cell carcinomas anywhere in the body versus lungs, then actually that depends on their differentiation, the degree of differentiation. Q. What I'm talking about is in lung cancer cases, squamous cell lung cancer patients that also have adenocarcinoma components and are poorly differentiated because I don't want to exclude any of the variables that we have in this case are you aware of medical literature
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 Q. And do you intend to testify that most likely it was Stage 4 metastatic lung cancer or are you not of that opinion as of December? A. Yes, I think it was Stage 4 at that time. Q. When did he first develop the lung cancer? How many years before, given everything that you know, looking at the slides, knowing what stage he was at when he was diagnosed? A. Probably a few years, but I can't really specify it any further than that. Q. All right. One person's few may be another person's not so few, so I am going to press you just a little bit as best I can. When you say few, are you talking two or three or are you talking five or six? Give me your best estimate. A. The way I use few is three to five. Q. And in the spectrum of the three to five years 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	 Q. What is it about A. If you are asking Q. Go ahead. A if squamous cell carcinomas metastasize later in the stage of the disease than small cell cancers, the answer is yes. If you are asking whether there is a difference between the spread rate of squamous cell carcinomas versus adenocarcinomas, not that significant a difference. If you are asking in general, squamous cell carcinomas anywhere in the body versus lungs, then actually that depends on their differentiation, the degree of differentiation. Q. What I'm talking about is in lung cancer cases, squamous cell lung cancer patients that also have adenocarcinoma components and are poorly differentiated because I don't want to exclude any of the variables that we have in
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 9 20 21 22 23 24	 Q. And do you intend to testify that most likely it was Stage 4 metastatic lung cancer or are you not of that opinion as of December? A. Yes, I think it was Stage 4 at that time. Q. When did he first develop the lung cancer? How many years before, given everything that you know, looking at the slides, knowing what stage he was at when he was diagnosed? A. Probably a few years, but I can't really specify it any further than that. Q. All right. One person's few may be another person's not so few, so I am going to press you just a little bit as best I can. When you say few, are you talking two or three or are you talking five or six? Give me your best estimate. A. The way I use few is three to five. Q. And in the spectrum of the three to five years before, is it three to five years before, is it three to five years before 1999 that he developed the cancer? A. Before the diagnosis of the cancer in August of 2000. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	 Q. What is it about A. If you are asking Q. Go ahead. A if squamous cell carcinomas metastasize later in the stage of the disease than small cell cancers, the answer is yes. If you are asking whether there is a difference between the spread rate of squamous cell carcinomas versus adenocarcinomas, not that significant a difference. If you are asking in general, squamous cell carcinomas anywhere in the body versus lungs, then actually that depends on their differentiation, the degree of differentiation. Q. What I'm talking about is in lung cancer cases, squamous cell lung cancer patients that also have adenocarcinoma components and are poorly differentiated because I don't want to exclude any of the variables that we have in this case are you aware of medical literature that indicates that the spread of that type of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Q. And do you intend to testify that most likely it was Stage 4 metastatic lung cancer or are you not of that opinion as of December? A. Yes, I think it was Stage 4 at that time. Q. When did he first develop the lung cancer? How many years before, given everything that you know, looking at the slides, knowing what stage he was at when he was diagnosed? A. Probably a few years, but I can't really specify it any further than that. Q. All right. One person's few may be another person's not so few, so I am going to press you just a little bit as best I can. When you say few, are you talking two or three or are you talking five or six? Give me your best estimate. A. The way I use few is three to five. Q. And in the spectrum of the three to five years before, is it three to five years before, is it three to five years before 1999 that he developed the cancer? A. Before the diagnosis of the cancer in 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	 Q. What is it about A. If you are asking Q. Go ahead. A if squamous cell carcinomas metastasize later in the stage of the disease than small cell cancers, the answer is yes. If you are asking whether there is a difference between the spread rate of squamous cell carcinomas versus adenocarcinomas, not that significant a difference. If you are asking in general, squamous cell carcinomas anywhere in the body versus lungs, then actually that depends on their differentiation, the degree of differentiation. Q. What I'm talking about is in lung cancer cases, squamous cell lung cancer patients that also have adenocarcinoma components and are poorly differentiated because I don't want to exclude any of the variables that we have in this case are you aware of medical literature that indicates that the spread of that type of lung cancer is usually late as opposed to early
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 Q. And do you intend to testify that most likely it was Stage 4 metastatic lung cancer or are you not of that opinion as of December? A. Yes, I think it was Stage 4 at that time. Q. When did he first develop the lung cancer? How many years before, given everything that you know, looking at the slides, knowing what stage he was at when he was diagnosed? A. Probably a few years, but I can't really specify it any further than that. Q. All right. One person's few may be another person's not so few, so I am going to press you just a little bit as best I can. When you say few, are you talking two or three or are you talking five or six? Give me your best estimate. A. The way I use few is three to five. Q. And in the spectrum of the three to five years before, is it three to five years before, is it three to five years before 1999 that he developed the cancer? A. Before the diagnosis of the cancer in August of 2000. 	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	 Q. What is it about A. If you are asking Q. Go ahead. A if squamous cell carcinomas metastasize later in the stage of the disease than small cell cancers, the answer is yes. If you are asking whether there is a difference between the spread rate of squamous cell carcinomas versus adenocarcinomas, not that significant a difference. If you are asking in general, squamous cell carcinomas anywhere in the body versus lungs, then actually that depends on their differentiation, the degree of differentiation. Q. What I'm talking about is in lung cancer cases, squamous cell lung cancer patients that also have adenocarcinoma components and are poorly differentiated because I don't want to exclude any of the variables that we have in this case are you aware of medical literature that indicates that the spread of that type of lung cancer is usually late as opposed to early in the life span of the cancer?

22 (Pages 85 to 88)

October 28, 2003

Page 89	Page 91
1 we comparing the squamous cell carcinoma, the	1 biologic behavior and the biologic features of
2 high grade with what type of tumor?	2 the tumor. So high grade tumors are those
3 Q. With small cell.	3 tumors that have very bizarre nuclei.
4 A. Yes, I answered that. Small cell	4 Usually they have and employ DNA
5 cancers spread earlier in the course of the	5 contents and these are the tumors that behave
6 disease than squamous cell carcinomas. Usually,	6 bad and spread fast and more lethal than the
7 many times they actually present with metastatic 8 disease in other organs.	7 tumors that are low grade. And these are the
	8 tumors, the high grade tumors are those tumors 9 that can metastasize and metastasize earlier
9 Q. So that if you had to develop a lung 10 cancer, statistically, all things being equal,	
11 you have a better chance of survival if you have	 10 than the low grade tumors. 11 Q. Do you use the term, when you are
12 a nonsmall cell as opposed to a small cell	12 talking about a high grade or a low grade and
13 carcinoma; true?	13 we will put aside the use of the term poorly
14 MR. WARNER: Objection.	14 differentiated and try to get a little more
15 A. Well, there are a lot of other	15 scientific.
16 variables. The most important is really the	16 But when you use the term high
17 stage of the disease and the responsiveness to	17 grade with a lung cancer, do you ever use the
18 whether there is available chemotherapy for	18 term that a high grade lung cancer has from its
19 small cell cancer. Sometimes they disappear	19 inception a bad personality? Have you ever
20 with chemotherapy, so there are lots of	20 heard that term used?
21 variables.	21 A. Yes. And that's exactly what the
22 Q. Does adenocarcinoma, nonsmall cell	22 biologic behavior of the tumor refers to is that
23 adenocarcinoma spread quicker and earlier than	23 this tumor is determined to be bad, regardless
24 squamous cell, nonsmall cell or are they	24 of its size, regardless of the treatment.
25 pretty	25 Q. But still can you cite me to any
Bogo 00	Dere 00
Page 90	Page 92
1 A. It depends really mostly on the	1 statistics that even in a high grade nonsmall
1 A. It depends really mostly on the 2 degree of differentiation.	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate
 A. It depends really mostly on the degree of differentiation. Q. In poorly differentiated. Do they 	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage
 A. It depends really mostly on the degree of differentiation. Q. In poorly differentiated. Do they both spread at about the same juncture or do you 	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage 1, and all of the criteria are met from the
 A. It depends really mostly on the degree of differentiation. Q. In poorly differentiated. Do they both spread at about the same juncture or do you normally see adeno spread earlier than squamous 	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage 1, and all of the criteria are met from the standpoint of it being high grade but yet you
 A. It depends really mostly on the degree of differentiation. Q. In poorly differentiated. Do they both spread at about the same juncture or do you normally see adeno spread earlier than squamous cell? 	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage 1, and all of the criteria are met from the standpoint of it being high grade but yet you were in the right place at the right time, can
 A. It depends really mostly on the degree of differentiation. Q. In poorly differentiated. Do they both spread at about the same juncture or do you normally see adeno spread earlier than squamous cell? A. Well, I want to say that the poorly 	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage 1, and all of the criteria are met from the standpoint of it being high grade but yet you were in the right place at the right time, can you cite me to any literature that would suggest
 A. It depends really mostly on the degree of differentiation. Q. In poorly differentiated. Do they both spread at about the same juncture or do you normally see adeno spread earlier than squamous cell? A. Well, I want to say that the poorly differentiated, even though I use that term also 	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage 1, and all of the criteria are met from the standpoint of it being high grade but yet you were in the right place at the right time, can you cite me to any literature that would suggest that those patients still more often than not
 A. It depends really mostly on the degree of differentiation. Q. In poorly differentiated. Do they both spread at about the same juncture or do you normally see adeno spread earlier than squamous cell? A. Well, I want to say that the poorly differentiated, even though I use that term also 	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage 1, and all of the criteria are met from the standpoint of it being high grade but yet you were in the right place at the right time, can you cite me to any literature that would suggest that those patients still more often than not die and don't make it to a five-year survival?
 A. It depends really mostly on the degree of differentiation. Q. In poorly differentiated. Do they both spread at about the same juncture or do you normally see adeno spread earlier than squamous cell? A. Well, I want to say that the poorly differentiated, even though I use that term also and I am a pathologist, is really a vague term and it's very misleading because it's based on a 	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage 1, and all of the criteria are met from the standpoint of it being high grade but yet you were in the right place at the right time, can you cite me to any literature that would suggest that those patients still more often than not die and don't make it to a five-year survival? A. I can't cite the literature now, but
 A. It depends really mostly on the degree of differentiation. Q. In poorly differentiated. Do they both spread at about the same juncture or do you normally see adeno spread earlier than squamous cell? A. Well, I want to say that the poorly differentiated, even though I use that term also and I am a pathologist, is really a vague term and it's very misleading because it's based on a very old concept of the resemblance of the tumor to the tissue of origin. 	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage 1, and all of the criteria are met from the standpoint of it being high grade but yet you were in the right place at the right time, can you cite me to any literature that would suggest that those patients still more often than not die and don't make it to a five-year survival? A. I can't cite the literature now, but I know that it is present. There is literature
 A. It depends really mostly on the degree of differentiation. Q. In poorly differentiated. Do they both spread at about the same juncture or do you normally see adeno spread earlier than squamous cell? A. Well, I want to say that the poorly differentiated, even though I use that term also and I am a pathologist, is really a vague term and It's very misleading because it's based on a very old concept of the resemblance of the tumor to the tissue of origin. So in the case of squamous cell 	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage 1, and all of the criteria are met from the standpoint of it being high grade but yet you were in the right place at the right time, can you cite me to any literature that would suggest that those patients still more often than not die and don't make it to a five-year survival? A. I can't cite the literature now, but I know that it is present. There is literature that correlates the survival, the survival of patients with high grade tumors versus survival
 A. It depends really mostly on the degree of differentiation. Q. In poorly differentiated. Do they both spread at about the same juncture or do you normally see adeno spread earlier than squamous cell? A. Well, I want to say that the poorly differentiated, even though I use that term also and I am a pathologist, is really a vague term and it's very misleading because it's based on a very old concept of the resemblance of the tumor to the tissue of origin. So in the case of squamous cell carcinoma, based on the well differentiated 	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage 1, and all of the criteria are met from the standpoint of it being high grade but yet you were in the right place at the right time, can you cite me to any literature that would suggest that those patients still more often than not die and don't make it to a five-year survival? A. I can't cite the literature now, but I know that it is present. There is literature that correlates the survival, the survival of patients with high grade tumors, versus survival of patients with low grade tumors, if we compare
 A. It depends really mostly on the degree of differentiation. Q. In poorly differentiated. Do they both spread at about the same juncture or do you normally see adeno spread earlier than squamous cell? A. Well, I want to say that the poorly differentiated, even though I use that term also and I am a pathologist, is really a vague term and I t's very misleading because it's based on a very old concept of the resemblance of the tumor to the tissue of origin. So in the case of squamous cell carcinoma, based on the well differentiated tumor, is that the tumors that they resemble, 	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage 1, and all of the criteria are met from the standpoint of it being high grade but yet you were in the right place at the right time, can you cite me to any literature that would suggest that those patients still more often than not die and don't make it to a five-year survival? A. I can't cite the literature now, but I know that it is present. There is literature that correlates the survival, the survival of patients with high grade tumors versus survival of patients with low grade tumors, if we compare apples to apples, same stage, same size,
 A. It depends really mostly on the degree of differentiation. Q. In poorly differentiated. Do they both spread at about the same juncture or do you normally see adeno spread earlier than squamous cell? A. Well, I want to say that the poorly differentiated, even though I use that term also and I am a pathologist, is really a vague term and it's very misleading because it's based on a very old concept of the resemblance of the tumor to the tissue of origin. So in the case of squamous cell carcinoma, based on the well differentiated tumor, is that the tumors that they resemble, benign squamous epithelium, the poorly 	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage 1, and all of the criteria are met from the standpoint of it being high grade but yet you were in the right place at the right time, can you cite me to any literature that would suggest that those patients still more often than not die and don't make it to a five-year survival? A. I can't cite the literature now, but I know that it is present. There is literature that correlates the survival, the survival of patients with high grade tumors, versus survival of patients with low grade tumors, if we compare apples to apples, same stage, same size, basically same time, same stage at the time of
 A. It depends really mostly on the degree of differentiation. Q. In poorly differentiated. Do they both spread at about the same juncture or do you normally see adeno spread earlier than squamous cell? A. Well, I want to say that the poorly differentiated, even though I use that term also and I am a pathologist, is really a vague term and it's very misleading because it's based on a very old concept of the resemblance of the tumor to the tissue of origin. So in the case of squamous cell carcinoma, based on the well differentiated tumor, is that the tumors that they resemble, benign squamous epithelium, the poorly 	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage 1, and all of the criteria are met from the standpoint of it being high grade but yet you were in the right place at the right time, can you cite me to any literature that would suggest that those patients still more often than not die and don't make it to a five-year survival? A. I can't cite the literature now, but I know that it is present. There is literature that correlates the survival, the survival of patients with high grade tumors, if we compare apples to apples, same stage, same size, basically same time, same stage at the time of diagnosis and same treatment versus those that
 A. It depends really mostly on the degree of differentiation. Q. In poorly differentiated. Do they both spread at about the same juncture or do you normally see adeno spread earlier than squamous cell? A. Well, I want to say that the poorly differentiated, even though I use that term also and I am a pathologist, is really a vague term and it's very misleading because it's based on a very old concept of the resemblance of the tumor to the tissue of origin. So in the case of squamous cell carcinoma, based on the well differentiated tumor, is that the tumors that they resemble, benign squamous epithelium, the poorly differentiated are those that do not resemble the normal squamous epithelium. But it's really 	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage 1, and all of the criteria are met from the standpoint of it being high grade but yet you were in the right place at the right time, can you cite me to any literature that would suggest that those patients still more often than not die and don't make it to a five-year survival? A. I can't cite the literature now, but I know that it is present. There is literature that correlates the survival, the survival of patients with high grade tumors, if we compare apples to apples, same stage, same size, basically same time, same stage at the time of diagnosis and same treatment versus those that are low grade.
 A. It depends really mostly on the degree of differentiation. Q. In poorly differentiated. Do they both spread at about the same juncture or do you normally see adeno spread earlier than squamous cell? A. Well, I want to say that the poorly differentiated, even though I use that term also and I am a pathologist, is really a vague term and I at yet of the resemblance of the tumor to the tissue of origin. So in the case of squamous cell carcinoma, based on the well differentiated tumor, is that the tumors that they resemble, benign squamous epithelium, the poorly differentiated are those that do not resemble the normal squamous epithelium. But it's really vague and inconsistently used by pathologists, 	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage 1, and all of the criteria are met from the standpoint of it being high grade but yet you were in the right place at the right time, can you cite me to any literature that would suggest that those patients still more often than not die and don't make it to a five-year survival? A. I can't cite the literature now, but I know that it is present. There is literature that correlates the survival, the survival of patients with high grade tumors versus survival of patients with low grade tumors, if we compare apples to apples, same stage, same size, basically same time, same stage at the time of diagnosis and same treatment versus those that are low grade. Q. So I want to make sure I understand.
 A. It depends really mostly on the degree of differentiation. Q. In poorly differentiated. Do they both spread at about the same juncture or do you normally see adeno spread earlier than squamous cell? A. Well, I want to say that the poorly differentiated, even though I use that term also and I am a pathologist, is really a vague term and it's very misleading because it's based on a very old concept of the resemblance of the tumor to the tissue of origin. So in the case of squamous cell carcinoma, based on the well differentiated tumor, is that the tumors that they resemble, benign squamous epithelium, the poorly differentiated are those that do not resemble the normal squamous epithelium. But it's really vague and inconsistently used by pathologists, let alone other medical specialists. 	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage 1, and all of the criteria are met from the standpoint of it being high grade but yet you were in the right place at the right time, can you cite me to any literature that would suggest that those patients still more often than not die and don't make it to a five-year survival? A. I can't cite the literature now, but I know that it is present. There is literature that correlates the survival, the survival of patients with high grade tumors versus survival of patients with low grade tumors, if we compare apples to apples, same stage, same size, basically same time, same stage at the time of diagnosis and same treatment versus those that are low grade. Q. So I want to make sure I understand. In Mr. Gill's case, hypothetically, if he had
 A. It depends really mostly on the degree of differentiation. Q. In poorly differentiated. Do they both spread at about the same juncture or do you normally see adeno spread earlier than squamous cell? A. Well, I want to say that the poorly differentiated, even though I use that term also and I am a pathologist, is really a vague term and it's very misleading because it's based on a very old concept of the resemblance of the tumor to the tissue of origin. So in the case of squamous cell carcinoma, based on the well differentiated tumor, is that the tumors that they resemble, benign squamous epithelium, the poorly differentiated are those that do not resemble the normal squamous epithelium. But it's really vague and inconsistently used by pathologists, let alone other medical specialists. Let alone lawyers, as well? 	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage 1, and all of the criteria are met from the standpoint of it being high grade but yet you were in the right place at the right time, can you cite me to any literature that would suggest that those patients still more often than not die and don't make it to a five-year survival? A. I can't cite the literature now, but I know that it is present. There is literature that correlates the survival, the survival of patients with high grade tumors versus survival of patients with low grade tumors, if we compare apples to apples, same stage, same size, basically same time, same stage at the time of diagnosis and same treatment versus those that are low grade. Q. So I want to make sure I understand. In Mr. Gill's case, hypothetically, if he had been diagnosed at Stage 1 with the high grade
 A. It depends really mostly on the degree of differentiation. Q. In poorly differentiated. Do they both spread at about the same juncture or do you normally see adeno spread earlier than squamous cell? A. Well, I want to say that the poorly differentiated, even though I use that term also and I am a pathologist, is really a vague term and it's very misleading because it's based on a very old concept of the resemblance of the tumor to the tissue of origin. So in the case of squamous cell carcinoma, based on the well differentiated tumor, is that the tumors that they resemble, benign squamous epithelium, the poorly differentiated are those that do not resemble the normal squamous epithelium. But it's really vague and inconsistently used by pathologists, let alone lawyers, as well? A. Let alone lawyers, yes. 	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage 1, and all of the criteria are met from the standpoint of it being high grade but yet you were in the right place at the right time, can you cite me to any literature that would suggest that those patients still more often than not die and don't make it to a five-year survival? A. I can't cite the literature now, but I know that it is present. There is literature that correlates the survival, the survival of patients with high grade tumors versus survival of patients with low grade tumors, if we compare apples to apples, same stage, same size, basically same time, same stage at the time of diagnosis and same treatment versus those that are low grade. Q. So I want to make sure I understand. In Mr. Gill's case, hypothetically, if he had been diagnosed at Stage 1 with the high grade
 A. It depends really mostly on the degree of differentiation. Q. In poorly differentiated. Do they both spread at about the same juncture or do you normally see adeno spread earlier than squamous cell? A. Well, I want to say that the poorly differentiated, even though I use that term also and I am a pathologist, is really a vague term and it's very misleading because it's based on a very old concept of the resemblance of the tumor to the tissue of origin. So in the case of squamous cell carcinoma, based on the well differentiated tumor, is that the tumors that they resemble, benign squamous epithelium, the poorly differentiated are those that do not resemble the normal squamous epithelium. But it's really vague and inconsistently used by pathologists, let alone other medical specialists. Q. Let alone lawyers, as well? A. Let alone lawyers, yes. The better term and the better 	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage 1, and all of the criteria are met from the standpoint of it being high grade but yet you were in the right place at the right time, can you cite me to any literature that would suggest that those patients still more often than not die and don't make it to a five-year survival? A. I can't cite the literature now, but I know that it is present. There is literature that correlates the survival, the survival of patients with high grade tumors versus survival of patients with low grade tumors, if we compare apples to apples, same stage, same size, basically same time, same stage at the time of diagnosis and same treatment versus those that are low grade. Q. So I want to make sure I understand. In Mr. Gill's case, hypothetically, if he had been diagnosed at Stage 1 with the high grade nonsmall cell components that we know that he had, regardless of when that time period was
 A. It depends really mostly on the degree of differentiation. Q. In poorly differentiated. Do they both spread at about the same juncture or do you normally see adeno spread earlier than squamous cell? A. Well, I want to say that the poorly differentiated, even though I use that term also and I am a pathologist, is really a vague term and it's very misleading because it's based on a very old concept of the resemblance of the tumor to the tissue of origin. So in the case of squamous cell carcinoma, based on the well differentiated tumor, is that the tumors that they resemble, benign squamous epithelium, the poorly differentiated are those that do not resemble the normal squamous epithelium. But it's really vague and inconsistently used by pathologists, let alone other medical specialists. Q. Let alone lawyers, as well? A. Let alone lawyers, yes. 	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage 1, and all of the criteria are met from the standpoint of it being high grade but yet you were in the right place at the right time, can you cite me to any literature that would suggest that those patients still more often than not die and don't make it to a five-year survival? A. I can't cite the literature now, but I know that it is present. There is literature that correlates the survival, the survival of patients with high grade tumors versus survival of patients with low grade tumors, if we compare apples to apples, same stage, same size, basically same time, same stage at the time of diagnosis and same treatment versus those that are low grade. Q. So I want to make sure I understand. In Mr. Gill's case, hypothetically, if he had been diagnosed at Stage 1 with the high grade nonsmall cell components that we know that he had, regardless of when that time period was
1A.It depends really mostly on the2degree of differentiation.3Q.In poorly differentiated. Do they4both spread at about the same juncture or do you5normally see adeno spread earlier than squamous6cell?7A.Well, I want to say that the poorly8differentiated, even though I use that term also9and I am a pathologist, is really a vague term10and it's very misleading because it's based on a11very old concept of the resemblance of the tumor12to the tissue of origin.13So in the case of squamous cell14carcinoma, based on the well differentiated15tumor, is that the tumors that they resemble,16benign squamous epithelium, the poorly17differentiated are those that do not resemble18the normal squamous epithelium. But it's really19vague and inconsistently used by pathologists,20let alone lawyers, as well?21A.22A.23The better term and the better24criteria to use is the high grade versus the low	 statistics that even in a high grade nonsmall cell lung cancer case, if one is fortunate enough to be diagnosed early in the stage, Stage 1, and all of the criteria are met from the standpoint of it being high grade but yet you were in the right place at the right time, can you cite me to any literature that would suggest that those patients still more often than not die and don't make it to a five-year survival? A. I can't cite the literature now, but I know that it is present. There is literature that correlates the survival, the survival of patients with high grade tumors versus survival of patients with low grade tumors, if we compare apples to apples, same stage, same size, basically same time, same stage at the time of diagnosis and same treatment versus those that are low grade. Q. So I want to make sure I understand. In Mr. Gill's case, hypothetically, if he had been diagnosed at Stage 1 with the high grade nonsmall cell components that we know that he had, regardless of when that time period was that he was at Stage 1, do you have an opinion

23 (Pages 89 to 92)

Œ

October 28, 2003

Page 93	Page 95
 been, his five-year survival, if he was fortunate enough to have been diagnosed at Stage 1? MR. WARNER: Objection. Go ahead. A. I can't tell you exactly what his prognosis specifically would be. It would be better than his prognosis at the stage that he was diagnosed in, which was Stage 4. However, many of these that's the reason why we don't have a lot of these tumors that are high grades that are diagnosed at an early stage, because most of them are diagnosed at a later stage. Q. But you are aware, are you not, from the literature and from your training of studies that have talked about high grade nonsmall cell carcinomas that are diagnosed at a Stage 1 in terms of the prognosis for that patient? A. As I said, yes, there are definitely some patients that are diagnosed with an earlier stage high grade nonsmall cell cancers and the survival and the prognosis of these patients is in general better than similar tumors that are diagnosed at Stage 4. Q. Can you tell me what the statistics 	 reasons that I already mentioned, which is the size of the tumor at the time of diagnosis in August of 2000, the histologic type and the high grade of the biologic type of the tumor, as well as the clinical information about the presence of the symptoms related to the metastatic sites in December of 1999. Q. You acknowledge nonetheless that while you don't believe that the size of the tumor would have been significantly smaller, you do acknowledge that the tumor would have likely been back in January smaller than it was in July; true? MR. WARNER: Objection. Asked and answered. Go ahead. A. It probably was a few millimeters smaller, but not to the extent of changing the stage. Q. And I understand your opinion. But I just want to get a general agreement, that even though in your opinion it would have only been millimeters, you would agree at least that in January, comparing the size of the tumor, not the stage, but the size of the tumor, versus the size of the tumor in July, that we would have
 Page 94 show for a high grade Stage 1 survivor? A. I can't really remember the number. I can look it up for you, but I can't just throw a number at you today. Q. As you sit here right now, you are not able to tell me whether or not it's greater than 50 percent survival or less than 50 percent survival, high grade Stage 1? A. That's correct. Q. Now, we have been talking around a lot of the pathology in an indirect manner, but what I would like to do is I would like you to tell me what it is that you saw on the microscopic sildes other than what you have already told me that causes you to say that if it was possible to diagnose Mr. Gill in January or February of 2000 that the outcome would not have been any different than it was when it was diagnosed in July. And you don't have to repeat that which you have told me, but I would like you to tell me everything else that perhaps you haven't told me that is pathologically significant. A. I don't think there is - I can't think of any other reason in addition to those 	 Page 96 been looking at a smaller tumor in January than the tumor in July; true? A. As I said, probably it would have been a few millimeters smaller, but not clinically significant Q. Okay. A in terms of altering the staging, whether it's the clinical group staging or the pathologic staging of the tumor. Q. And again, I understand and I qualified my question by saying we are not dealing with staging or the clinical factors. But as a general principle, if you look back, if you had diagnosed the cancer back in January, we can agree that even though it may not have been clinically significant and even though it may not have changed the staging, in your opinion, the tumor would have probably been smaller even if only by millimeters than what we saw in July; true? A. Probably. Q. When you put those slides under your microscope, which I presume is what you did A. Yes. Q you didn't hold it up to a light.

24 (Pages 93 to 96)

	_
Page 97	Page 99
1 When you looked at the cell structure, did you	1 would treat the patient based on our assessment
2 see cubes or column shaped cells?	2 of the pathologic material. So if we say it's
3 A. Well, the cells and again I have	3 small cell carcinoma, the patient usually gets
4 not reviewed the slides since I reviewed them	4 referred to an oncologist for further studies
	· ····································
6 basically agreed with the outside report. And	6 squamous cell carcinoma or nonsmall cell
7 again, I am talking about these tumors in	7 carcinoma, then the patient either gets more
8 general. I cannot recall specifics.	8 diagnostic tests to assess a stage or goes to
9 If you want me to give you more	9 surgery and so forth.
10 specific information, I have to review the	10 So what we say, yeah, we do provide,
11 slides and tell you exactly what I see.	11 the pathologists do provide essential
12 Q. You don't have a microscope in your	12 information for the clinician to manage the
13 purse with you today?	13 patient, but I'm not going to tell the surgeon
14 A. No. Sorry.	14 to go ahead and resect the tumor. That's a
15 Q. So when I refer to cubes or column	15 decision that he or she has to make for
16 shaped, is that something that typically is used	16 themselves.
17 to describe the molecular structure in	17 Q. Do you know whether this tumor back
18 adenocarcinoma?	18 in January would have been less bulky in size
19 A. Well, I think what you are trying to	19 than it was at the time of diagnosis in July?
20 say is cuboidal or columnar cells.	20 A. Do you mean bulky by bulky you
21 Q. You said it better than I did.	
	······································
	22 the size?
23 we use to describe the shape of the cell, not	23 Q. Is the term bulky a medical term?
24 the molecular structure of the cell. It's just	A. Well, it's a term that is really,
25 really the shape, how they look to our eyes.	25 it's more descriptive and it's not used in lung
Page 98	Page 100
	Page 100
1 And again, in general, they refer to	1 cancer, let's say. It's usually used in, for
1 And again, in general, they refer to 2 tumor types. Columnar cells usually are seen in	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there
1 And again, in general, they refer to 2 tumor types. Columnar cells usually are seen in 3 adenocarcinomas, while polygonal cells are seen	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor.
1 And again, in general, they refer to 2 tumor types. Columnar cells usually are seen in 3 adenocarcinomas, while polygonal cells are seen 4 in squamous cell carcinoma. But there is a lot	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung
1 And again, in general, they refer to 2 tumor types. Columnar cells usually are seen in 3 adenocarcinomas, while polygonal cells are seen 4 in squamous cell carcinoma. But there is a lot 5 of overlapping and a lot of subjectivity in	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the
1 And again, in general, they refer to 2 tumor types. Columnar cells usually are seen in 3 adenocarcinomas, while polygonal cells are seen 4 in squamous cell carcinoma. But there is a lot 5 of overlapping and a lot of subjectivity in 6 characterizing these cells as such.	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the term bulky when describing the mass; correct?
1 And again, in general, they refer to 2 tumor types. Columnar cells usually are seen in 3 adenocarcinomas, while polygonal cells are seen 4 in squamous cell carcinoma. But there is a lot 5 of overlapping and a lot of subjectivity in	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the
1 And again, in general, they refer to 2 tumor types. Columnar cells usually are seen in 3 adenocarcinomas, while polygonal cells are seen 4 in squamous cell carcinoma. But there is a lot 5 of overlapping and a lot of subjectivity in 6 characterizing these cells as such.	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the term bulky when describing the mass; correct?
 And again, in general, they refer to tumor types. Columnar cells usually are seen in adenocarcinomas, while polygonal cells are seen in squamous cell carcinoma. But there is a lot of overlapping and a lot of subjectivity in characterizing these cells as such. Q. So one pathologist looking at the cells and describing them, another pathologist looking at the same cells may describe them in a 	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the term bulky when describing the mass; correct? A. Well, as I said, you know, people use different terms and some of them more accurately
 And again, in general, they refer to tumor types. Columnar cells usually are seen in adenocarcinomas, while polygonal cells are seen in squamous cell carcinoma. But there is a lot of overlapping and a lot of subjectivity in characterizing these cells as such. Q. So one pathologist looking at the cells and describing them, another pathologist 	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the term bulky when describing the mass; correct? A. Well, as I said, you know, people use different terms and some of them more accurately describe the tumor, some do not. I won't be
 And again, in general, they refer to tumor types. Columnar cells usually are seen in adenocarcinomas, while polygonal cells are seen in squamous cell carcinoma. But there is a lot of overlapping and a lot of subjectivity in characterizing these cells as such. Q. So one pathologist looking at the cells and describing them, another pathologist looking at the same cells may describe them in a different way? 	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the term bulky when describing the mass; correct? A. Well, as I said, you know, people use different terms and some of them more accurately describe the tumor, some do not. I won't be surprised if I see that description in some of
 And again, in general, they refer to tumor types. Columnar cells usually are seen in adenocarcinomas, while polygonal cells are seen in squamous cell carcinoma. But there is a lot of overlapping and a lot of subjectivity in characterizing these cells as such. Q. So one pathologist looking at the cells and describing them, another pathologist looking at the same cells may describe them in a different way? A. Yes. In general. 	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the term bulky when describing the mass; correct? A. Well, as I said, you know, people use different terms and some of them more accurately describe the tumor, some do not. I won't be surprised if I see that description in some of the medical or op reports.
 And again, in general, they refer to tumor types. Columnar cells usually are seen in adenocarcinomas, while polygonal cells are seen in squamous cell carcinoma. But there is a lot of overlapping and a lot of subjectivity in characterizing these cells as such. Q. So one pathologist looking at the cells and describing them, another pathologist looking at the same cells may describe them in a different way? A. Yes. In general. Q. As a pathologist here at the hospital 	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the term bulky when describing the mass; correct? A. Well, as I said, you know, people use different terms and some of them more accurately describe the tumor, some do not. I won't be surprised if I see that description in some of the medical or op reports. Q. Is it your opinion that Mr. Gill in
 And again, in general, they refer to tumor types. Columnar cells usually are seen in adenocarcinomas, while polygonal cells are seen in squamous cell carcinoma. But there is a lot of overlapping and a lot of subjectivity in characterizing these cells as such. Q. So one pathologist looking at the cells and describing them, another pathologist looking at the same cells may describe them in a different way? A. Yes. In general. Q. As a pathologist here at the hospital or back over at UH, when you would look at 	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the term bulky when describing the mass; correct? A. Well, as I said, you know, people use different terms and some of them more accurately describe the tumor, some do not. I won't be surprised if I see that description in some of the medical or op reports. Q. Is it your opinion that Mr. Gill in December of '99 had bronchogenic carcinoma?
 And again, in general, they refer to tumor types. Columnar cells usually are seen in adenocarcinomas, while polygonal cells are seen in squamous cell carcinoma. But there is a lot of overlapping and a lot of subjectivity in characterizing these cells as such. Q. So one pathologist looking at the cells and describing them, another pathologist looking at the same cells may describe them in a different way? A. Yes. In general. Q. As a pathologist here at the hospital or back over at UH, when you would look at slides, would they typically be after surgical 	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the term bulky when describing the mass; correct? A. Well, as I said, you know, people use different terms and some of them more accurately describe the tumor, some do not. I won't be surprised if I see that description in some of the medical or op reports. Q. Is it your opinion that Mr. Gill in December of '99 had bronchogenic carcinoma? A. Yes.
 And again, in general, they refer to tumor types. Columnar cells usually are seen in adenocarcinomas, while polygonal cells are seen in squamous cell carcinoma. But there is a lot of overlapping and a lot of subjectivity in characterizing these cells as such. Q. So one pathologist looking at the cells and describing them, another pathologist looking at the same cells may describe them in a different way? A. Yes. In general. Q. As a pathologist here at the hospital or back over at UH, when you would look at slides, would they typically be after surgical resection or would it be after an initial 	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the term bulky when describing the mass; correct? A. Well, as I said, you know, people use different terms and some of them more accurately describe the tumor, some do not. I won't be surprised if I see that description in some of the medical or op reports. Q. Is it your opinion that Mr. Gill in December of '99 had bronchogenic carcinoma? A. Yes. Q. Again, do you have an opinion as to
 And again, in general, they refer to tumor types. Columnar cells usually are seen in adenocarcinomas, while polygonal cells are seen in squamous cell carcinoma. But there is a lot of overlapping and a lot of subjectivity in characterizing these cells as such. Q. So one pathologist looking at the cells and describing them, another pathologist looking at the same cells may describe them in a different way? A. Yes. In general. Q. As a pathologist here at the hospital or back over at UH, when you would look at slides, would they typically be after surgical resection or would it be after an initial biopsy, perhaps at the time of a bronchoscopy? 	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the term bulky when describing the mass; correct? A. Well, as I said, you know, people use different terms and some of them more accurately describe the tumor, some do not. I won't be surprised if I see that description in some of the medical or op reports. Q. Is it your opinion that Mr. Gill in December of '99 had bronchogenic carcinoma? A. Yes. Q. Again, do you have an opinion as to when Mr. Gill developed the bony metastasis in
 And again, in general, they refer to tumor types. Columnar cells usually are seen in adenocarcinomas, while polygonal cells are seen in squamous cell carcinoma. But there is a lot of overlapping and a lot of subjectivity in characterizing these cells as such. Q. So one pathologist looking at the cells and describing them, another pathologist looking at the same cells may describe them in a different way? A. Yes. In general. Q. As a pathologist here at the hospital or back over at UH, when you would look at slides, would they typically be after surgical resection or would it be after an initial biopsy, perhaps at the time of a bronchoscopy? A. Usually, in most cases it is either 	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the term bulky when describing the mass; correct? A. Well, as I said, you know, people use different terms and some of them more accurately describe the tumor, some do not. I won't be surprised if I see that description in some of the medical or op reports. Q. Is it your opinion that Mr. Gill in December of '99 had bronchogenic carcinoma? A. Yes. Q. Again, do you have an opinion as to when Mr. Gill developed the bony metastasis in this case?
 And again, in general, they refer to tumor types. Columnar cells usually are seen in adenocarcinomas, while polygonal cells are seen in squamous cell carcinoma. But there is a lot of overlapping and a lot of subjectivity in characterizing these cells as such. Q. So one pathologist looking at the cells and describing them, another pathologist looking at the same cells may describe them in a different way? A. Yes. In general. Q. As a pathologist here at the hospital or back over at UH, when you would look at slides, would they typically be after surgical resection or would it be after an initial biopsy, perhaps at the time of a bronchoscopy? A. Usually, in most cases it is either 	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the term bulky when describing the mass; correct? A. Well, as I said, you know, people use different terms and some of them more accurately describe the tumor, some do not. I won't be surprised if I see that description in some of the medical or op reports. Q. Is it your opinion that Mr. Gill in December of '99 had bronchogenic carcinoma? A. Yes. Q. Again, do you have an opinion as to when Mr. Gill developed the bony metastasis in this case? A. Not specific to the time point, but
 And again, in general, they refer to tumor types. Columnar cells usually are seen in adenocarcinomas, while polygonal cells are seen in squamous cell carcinoma. But there is a lot of overlapping and a lot of subjectivity in characterizing these cells as such. Q. So one pathologist looking at the cells and describing them, another pathologist looking at the same cells may describe them in a different way? A. Yes. In general. Q. As a pathologist here at the hospital or back over at UH, when you would look at slides, would they typically be after surgical resection or would it be after an initial biopsy, perhaps at the time of a bronchoscopy? A. Usually, in most cases it is either bronchoscopic biopsy or needle guided or fine needle aspiration and then the resection comes 	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the term bulky when describing the mass; correct? A. Well, as I said, you know, people use different terms and some of them more accurately describe the tumor, some do not. I won't be surprised if I see that description in some of the medical or op reports. Q. Is it your opinion that Mr. Gill in December of '99 had bronchogenic carcinoma? A. Yes. Q. Again, do you have an opinion as to when Mr. Gill developed the bony metastasis in this case? A. Not specific to the time point, but
 And again, in general, they refer to tumor types. Columnar cells usually are seen in adenocarcinomas, while polygonal cells are seen in squamous cell carcinoma. But there is a lot of overlapping and a lot of subjectivity in characterizing these cells as such. Q. So one pathologist looking at the cells and describing them, another pathologist looking at the same cells may describe them in a different way? A. Yes. In general. Q. As a pathologist here at the hospital or back over at UH, when you would look at slides, would they typically be after surgical resection or would it be after an initial biopsy, perhaps at the time of a bronchoscopy? A. Usually, in most cases it is either bronchoscopic biopsy or needle guided or fine needle aspiration and then the resection comes 	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the term bulky when describing the mass; correct? A. Well, as I said, you know, people use different terms and some of them more accurately describe the tumor, some do not. I won't be surprised if I see that description in some of the medical or op reports. Q. Is it your opinion that Mr. Gill in December of '99 had bronchogenic carcinoma? A. Yes. Q. Again, do you have an opinion as to when Mr. Gill developed the bony metastasis in this case? A. Not specific to the time point, but probably the same time frame as when he developed the neck metastasis.
 And again, in general, they refer to tumor types. Columnar cells usually are seen in adenocarcinomas, while polygonal cells are seen in squamous cell carcinoma. But there is a lot of overlapping and a lot of subjectivity in characterizing these cells as such. Q. So one pathologist looking at the cells and describing them, another pathologist looking at the same cells may describe them in a different way? A. Yes. In general. Q. As a pathologist here at the hospital or back over at UH, when you would look at slides, would they typically be after surgical resection or would it be after an initial biopsy, perhaps at the time of a bronchoscopy? A. Usually, in most cases it is either bronchoscopic biopsy or needle guided or fine needle aspiration and then the resection comes and that's when we look at the entire tumor. 	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the term bulky when describing the mass; correct? A. Well, as I said, you know, people use different terms and some of them more accurately describe the tumor, some do not. I won't be surprised if I see that description in some of the medical or op reports. Q. Is it your opinion that Mr. Gill in December of '99 had bronchogenic carcinoma? A. Yes. Q. Again, do you have an opinion as to when Mr. Gill developed the bony metastasis in this case? A. Not specific to the time point, but probably the same time frame as when he developed the neck metastasis. Q. So we are talking so you are
 And again, in general, they refer to tumor types. Columnar cells usually are seen in adenocarcinomas, while polygonal cells are seen in squamous cell carcinoma. But there is a lot of overlapping and a lot of subjectivity in characterizing these cells as such. Q. So one pathologist looking at the cells and describing them, another pathologist looking at the same cells may describe them in a different way? A. Yes. In general. Q. As a pathologist here at the hospital or back over at UH, when you would look at slides, would they typically be after surgical resection or would it be after an initial biopsy, perhaps at the time of a bronchoscopy? A. Usually, in most cases it is either bronchoscopic biopsy or needle guided or fine needle aspiration and then the resection comes and that's when we look at the entire tumor. Q. Do you provide any input to the surgeon at the time of either needle guided or 	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the term bulky when describing the mass; correct? A. Well, as I said, you know, people use different terms and some of them more accurately describe the tumor, some do not. I won't be surprised if I see that description in some of the medical or op reports. Q. Is it your opinion that Mr. Gill in December of '99 had bronchogenic carcinoma? A. Yes. Q. Again, do you have an opinion as to when Mr. Gill developed the bony metastasis in this case? A. Not specific to the time point, but probably the same time frame as when he developed the neck metastasis. Q. So we are talking so you are
 And again, in general, they refer to tumor types. Columnar cells usually are seen in adenocarcinomas, while polygonal cells are seen in squamous cell carcinoma. But there is a lot of overlapping and a lot of subjectivity in characterizing these cells as such. Q. So one pathologist looking at the cells and describing them, another pathologist looking at the same cells may describe them in a different way? A. Yes. In general. Q. As a pathologist here at the hospital or back over at UH, when you would look at slides, would they typically be after surgical resection or would it be after an initial biopsy, perhaps at the time of a bronchoscopy? A. Usually, in most cases it is either bronchoscopic biopsy or needle guided or fine needle aspiration and then the resection comes and that's when we look at the entire tumor. Q. Do you provide any input to the surgeon at the time of either needle guided or 	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the term bulky when describing the mass; correct? A. Well, as I said, you know, people use different terms and some of them more accurately describe the tumor, some do not. I won't be surprised if I see that description in some of the medical or op reports. Q. Is it your opinion that Mr. Gill in December of '99 had bronchogenic carcinoma? A. Yes. Q. Again, do you have an opinion as to when Mr. Gill developed the bony metastasis in this case? A. Not specific to the time point, but probably the same time frame as when he developed the neck metastasis. Q. So we are talking so you are thinking that he had bony metastasis in
 And again, in general, they refer to tumor types. Columnar cells usually are seen in adenocarcinomas, while polygonal cells are seen in squamous cell carcinoma. But there is a lot of overlapping and a lot of subjectivity in characterizing these cells as such. Q. So one pathologist looking at the cells and describing them, another pathologist looking at the same cells may describe them in a different way? A. Yes. In general. Q. As a pathologist here at the hospital or back over at UH, when you would look at slides, would they typically be after surgical resection or would it be after an initial biopsy, perhaps at the time of a bronchoscopy? A. Usually, in most cases it is either bronchoscopic biopsy or needle guided or fine needle aspiration and then the resection comes and that's when we look at the entire tumor. Q. Do you provide any input to the surgeon at the time of either needle guided or bronchoscopy biopsy or any of the other modalities as to how to proceed with treatment? 	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the term bulky when describing the mass; correct? A. Well, as I said, you know, people use different terms and some of them more accurately describe the tumor, some do not. I won't be surprised if I see that description in some of the medical or op reports. Q. Is it your opinion that Mr. Gill in December of '99 had bronchogenic carcinoma? A. Yes. Q. Again, do you have an opinion as to when Mr. Gill developed the bony metastasis in this case? A. Not specific to the time point, but probably the same time frame as when he developed the neck metastasis. Q. So we are talking so you are thinking that he had bony metastasis in December? A. Or before that, yes.
 And again, in general, they refer to tumor types. Columnar cells usually are seen in adenocarcinomas, while polygonal cells are seen in squamous cell carcinoma. But there is a lot of overlapping and a lot of subjectivity in characterizing these cells as such. Q. So one pathologist looking at the cells and describing them, another pathologist looking at the same cells may describe them in a different way? A. Yes. In general. Q. As a pathologist here at the hospital or back over at UH, when you would look at slides, would they typically be after surgical resection or would it be after an initial biopsy, perhaps at the time of a bronchoscopy? A. Usually, in most cases it is either bronchoscopic biopsy or needle guided or fine needle aspiration and then the resection comes and that's when we look at the entire tumor. Q. Do you provide any input to the surgeon at the time of either needle guided or 	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the term bulky when describing the mass; correct? A. Well, as I said, you know, people use different terms and some of them more accurately describe the tumor, some do not. I won't be surprised if I see that description in some of the medical or op reports. Q. Is it your opinion that Mr. Gill in December of '99 had bronchogenic carcinoma? A. Yes. Q. Again, do you have an opinion as to when Mr. Gill developed the bony metastasis in this case? A. Not specific to the time point, but probably the same time frame as when he developed the neck metastasis. Q. So we are talking so you are thinking that he had bony metastasis in
 And again, in general, they refer to tumor types. Columnar cells usually are seen in adenocarcinomas, while polygonal cells are seen in squamous cell carcinoma. But there is a lot of overlapping and a lot of subjectivity in characterizing these cells as such. Q. So one pathologist looking at the cells and describing them, another pathologist looking at the same cells may describe them in a different way? A. Yes. In general. Q. As a pathologist here at the hospital or back over at UH, when you would look at slides, would they typically be after surgical resection or would it be after an initial biopsy, perhaps at the time of a bronchoscopy? A. Usually, in most cases it is either bronchoscopic biopsy or needle guided or fine needle aspiration and then the resection comes and that's when we look at the entire tumor. Q. Do you provide any input to the surgeon at the time of either needle guided or bronchoscopy biopsy or any of the other modalities as to how to proceed with treatment? 	 cancer, let's say. It's usually used in, for example, tumors in the peritoneum, where there is a lot of tumor. Q. So really from the standpoint of lung cancer, you wouldn't expect one to be using the term bulky when describing the mass; correct? A. Well, as I said, you know, people use different terms and some of them more accurately describe the tumor, some do not. I won't be surprised if I see that description in some of the medical or op reports. Q. Is it your opinion that Mr. Gill in December of '99 had bronchogenic carcinoma? A. Yes. Q. Again, do you have an opinion as to when Mr. Gill developed the bony metastasis in this case? A. Not specific to the time point, but probably the same time frame as when he developed the neck metastasis. Q. So we are talking so you are thinking that he had bony metastasis in December? A. Or before that, yes.

25 (Pages 97 to 100)

 Page 101 so when he had pain in the femur? A. Well, the patient had other symptoms that may or may not have been related to his bone mets; fatigue and malaise. And we all have I have back pain, if you don't any way. Q. Lawyers never have back pain. A. Lawyers are perfect. Q. Doctor, I think I am done. I just want to make sure that we have covered the opinions that you hold in this case and also that you have told me the areas within which you do not feel qualified to render opinions. Have I given you an opportunity during the course of this deposition to explain the bases for your opinions? A. I think so. Q. I haven't cut you off or limited you in any way, have I? A. I don't think so. MR. MISHKIND: I thank you very much. I have nothing further. Do you want the doctor to read the transcript? MR. WARNER: I will leave it up to you. Do you want to read? 	1 CERTIFICATE 2 State of Ohio, 3 SS: 5 County of Cuyahoga. 7 I, Vivian L. Gordon, a Notary Public within and for the State of Ohio, duly commissioned and 9 qualified, do hereby certify that the within named NADIA KAISI, M.D. was by me first duly 10 sworn to testify to the truth, the whole truth and nothing but the truth in the cause 11 aforesald; that the testimony as above set forth was by me reduced to stenotypy, afterwards 12 transcribed, and that the foregoing is a true and correct transcription of the testimony. 13 I do further certify that this deposition 14 was taken at the time and place specified and was completed without adjournment; that I am not 15 a relative or attorney for either party or otherwise interested in the event of this 16 action. I am not, nor is the court reporting firm with which I am affliated, under a 17 contract as defined in Civil Rule 28(D). 18 IN WITNESS WHEREOF, I have hereunto set my hand and affixed my seal of office at Cleveland, 10 Ohio, on this 3rd day of November, 2003. 21 MAMAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
Page 102 1 THE WITNESS: I'll defer to you. 2 MR. WARNER: I will trust her 3 abilities. You can waive. 4	Page 104 1 INDEX 2 EXAMINATION OF NADIA KAISI, M.D. 3 BY MR. MISHKIND:

26 (Pages 101 to 104)

Page 1

·				1
A	additional 11:2,4	airways 69:12 76:2	appreciate 46:7	77:22
abilities 102:3	13:2,5 39:13	79:9	appropriate 28:23	Atlanta 44:14,20
ability 69:19 71:10	50:22 51:4	AJCC 56:19 57:4	61:22 66:1	attention 30:7
71:24	adeno 20:15 90:5	59:24 60:19 61:8	appropriateness	attorney 32:18
able 9:7 37:4,7	adenocarcinoma	61:13	82:24	33:16 35:2 38:5
47:15 49:1 50:2,5	19:11,23 20:7	Akron-Canton	approximate 80:1	38:11,17 42:23,24
73:17 81:19 94:6	74:11 79:5 88:18	44:12,15	Approximately	44:20 103:15
abnormal 84:13,13	89:22,23 97:18	al 1:9	30:15	attorneys 38:25
about 4:13,13 13:25	adenocarcinomas	alive 34:7	April 22:3 64:19	40:3,19 44:5,19
14:5 18:2 20:22	88:9 98:3	allegations 31:3,17	area 15:21 16:17	45:2
20:24 23:24 30:5	adenosquamous	alleged 36:16	18:17 24:1 26:24	audience 23:9
30:9 32:22 33:22	20:6,18 29:20	allowed 53:23	27:10 43:5,8 44:6	August 80:10 82:13
35:8 37:13 38:20	78:20 79:13	alone 90:20,21,22	44:9,13 57:2 76:6	86:24 95:3
39:22 41:17,22	adjacent 56:15	along 4:23 87:7	76:24 82:9	authored 5:22 6:1
42:17 47:18 48:13	76:17	already 35:4 41:20	areas 27:4,5 101:11	authoritative 64:1
52:1 53:4 57:6	adjournment	48:17 78:6 94:15	arise 77:11 78:22	64:4,24 65:1,11
61:14 63:14 66:16	103:14	95:1	78:24	65:16
67:2,17 73:24	adjunctive 28:23	alteration 13:21	arises 77:14	available 45:1
74:15 76:11 81:3	72:10	altering 96:7	arm 48:2 52:19	49:11,12 50:25
82:16 83:17 88:1	administrative	alveolar 79:1	80:16 87:15	51:2 89:18
88:16 90:4 91:12	17:17	always 41:2 68:22	around 42:1 94:10	Avenue 1:22
93:16 95:5 97:7	advertised 45:4	Al-Kaisi 3:17,19	arrest 83:20	avoid 37:4,8
above 1:24 45:11	affect 71:24	American 21:16	article 64:8,20,21	Avoiding 37:9
59:10 103:11	affiliated 103:16	22:1 23:20	65:5	aware 88:21 93:14
Absent 58:13	affiliation 17:6	amongst 82:22	articles 25:6 26:7	away 30:1
absolutely 58:13	affixed 103:18	amount 42:5	64:6 82:18	A-L-K-A-I-S-I 3:17
abstract 22:10	aforesaid 103:11	anatomic 27:3	aside 35:22 37:2	199.1
abstracts 23:1 25:5	after 10:14,14,25	Angelina 15:4	91:13	<u></u>
accepted 57:1	11:12 54:21 61:16	another 20:17	asked 26:19 28:2	back 5:15 23:11
accompanied 10:5	98:14,15	84:12 86:14 98:8	29:7 32:21 39:7	25:4 64:14 73:19
10:12	afterwards 103:11	answer 4:25 5:8,11	49:5 80:17 95:14	81:14 82:10 87:4
according 50:16	again 8:7 25:22	6:23 18:11 27:20	asking 4:12 18:9	95:12 96:13,14
73:13 82:5	32:11 35:14 49:6	33:4 43:9 48:11	48:5,9,12,15,22	98:13 99:17 101:5
account 83:13,15	55:10 58:24 60:18	49:6,7 76:18	49:7 51:1 52:1	101:6
83:19,21	61:24 81:11 87:13	79:24 80:4 88:6	53:4 54:23,25	background 4:13
accurate 6:10 39:14	96:10 97:3,7 98:1	answered 49:6 89:4	85:16 88:2,7,11	14:4
45:25 68:17 74:12	100:15	95:15	aspect 20:17 25:23	bad 91:6,19,23
accurately 100:8	aggressive 79:16	answering 5:2	aspiration 98:19	Bagdad 16:25,25
acknowledge 95:8	ago 16:14 26:13	anticipate 12:22	assess 99:8	base 82:14 84:17
95:11	33:22 34:4 36:8	anyone 71:5	assessed 80:18	based 28:15 45:11
acknowledging	41:18 57:7 67:15	anything 21:11	assessing 61:5	47:7,19,22 48:13
65:15	.agree 9:22 18:9	22:8 26:16 30:2	assessment 99:1	49:8,10 51:19
acquire 22:20	45:22,22 68:22	58:1,16 65:7,21	assigned 27:16	73:23 81:12 82:8
across 65:6	74:23 76:21 95:22	anywhere 33:20	assist 28:19	82:15 84:23 85:2
action 103:16	96:15	88:12	assisting 16:2	85:6,8 90:10,14
actual 36:18 71:11	agreed 39:7 97:6	appearance 32:1	associate 14:8	99:1
actually 16:3,10	agreement 1:20	APPEARANCES	associated 56:15	bases 101:15
24:14 27:22 36:21	95:20	2:1	78:5	basic 23:17
42:5 43:8 44:14	ahead 5:10 50:8	appeared 48:18	assuming 71:23	basically 29:5
59:7 84:7 88:13	51:7 53:3,23 83:3	appears 11:1,16,19	72:4 83:22	47:25 49:17 69:21
89:7	88:3 93:4 95:15	13:8	asymptomatic	92:16 97:6
added 39:17	99:14	apples 92:15,15	76:14	basing 80:5
addition 94:25	air 76:2	apply 54:12	atelectasis 58:21	basis 29:17 45:22
			59:11,17 60:7	

Page 2

	r			
73:22	board 15:14,17	49:23 50:17 51:6	22:12 23:25 30:23	79:13,19 87:23
Bass 67:20	27:3	51:12,15,19 56:4	30:24 31:2,11	88:4,6,8,12,17
Bautista 15:4	body 69:12 88:12	56:19 57:2,4,6,16	32:24 33:4 34:4	89:1,3,4,6,12,12
became 14:19	bone 73:5 82:1,5,6	57:22,25 58:3,4	35:3,15,16,22	89:19,22,24,24
17:16	101:4	59:3 60:4,13,21	36:11,12,13,23	90:6,13 92:2,22
Becker 2:3	bones 72:25	60:21 61:8,8,11	37:23 39:12 40:23	93:16,21 97:1,23
become 61:17	bony 100:16,22	61:21 62:17 63:2	42:11 44:14,24	97:24 98:4 99:3,6
69:17 84:7	book 26:13,19,23	63:18 64:22 66:16	47:8 48:16 49:1	99:6
before 1:18 4:7,18	30:3	68:23 69:2 71:15	49:15 54:20 64:2	cells 17:23 18:22
4:25 5:2 8:8 9:13	born 17:2	72:4 75:7,8,10,21	64:11,12,19 65:18	19:19 52:3 71:2,6
9:17,23 10:8 17:6	both 78:20 90:4	79:5 80:21,22,23	66:7 67:17 68:8	71:7,8,12,12
27:22 30:1 46:19	Botham 41:5 67:4,5	81:8,16 82:19	68:20 72:21 78:9	75:12 83:20 97:2
48:10 50:9,9 58:7	67:6,10,13,16	85:22 86:3,8,22	78:18 79:2,6	97:3,20 98:2,3,6,8
69:19,21 80:4,17	bottom 7:24 8:10	86:23 87:1,1,4	80:19 81:13 84:14	98:9
80:25 85:14 86:8	branches 77:12	88:17,17,23,24	85:2,21 88:21	center 24:25 27:14
86:21,22,23 87:19	breast 27:6,10,14	89:10,19 91:17,18	90:13 92:2,20	centimeters 56:9
100:24	27:23 28:10 34:5	92:2 96:14 100:1	100:17 101:10	58:6,10,17 59:10
beginning 46:14	34:6 60:20	100:5	cases 31:1 32:5,6,7	59:14,17,23 60:6
52:18 53:16,18,19	bring 76:2	cancers 20:19	32:9,10 33:5,9,12	60:8 73:16
behalf 1:16 2:2,10	bronchi 75:24 76:1	25:15 61:5 62:9	33:13,15 34:17,23	central 75:23
4:2 39:8 42:22	76:6,17,23	70:12,25 74:24	36:1 38:2,7,15,16	certain 6:22 8:9
behave 91:5	bronchial 26:8	76:22,25 77:10	38:19 39:2,25	44:23 48:19 62:16
behavior 71:9 91:1	78:12	82:16 88:6 89:5	40:5,16,22 41:8,9	63:19 64:14,20,21
91:22	bronchitis 53:14	93:21	41:11,13,15,15,18	65:5
being 3:9 6:11 37:5	bronchogenic	candidates 71:16	41:21,23 42:1,13	certainly 61:7
60:5 65:1,15	100:13	71:19,23	42:25 43:7,14	65:10,20 77:13
68:14 89:10 92:5	bronchoscopic	capacity 31:22,25	44:4,8,10,11,12	CERTIFICATE
believe 6:20,21	98:18	carcinoid 25:14	44:13 66:16 75:8	103:1
12:23 45:13 63:25	bronchoscopy	26:9	88:17 98:17	certification 27:2
95:9	98:16,23	carcinoma 18:8	categories 18:13	certified 3:10 15:14
benign 90:16	Building 2:13	19:5,11,12,15	category 18:7,18	15:17
besides 25:3	bulky 99:18,20,20	20:3,6,8,11 21:4	21:25 25:15 77:13	certify 103:9,13
best 39:15,17 64:9	99:23 100:6	25:13 29:20 74:15	cause 37:21 38:3	chance 89:11
68:23 75:2 86:15	busy 41:19	76:5 77:14,18	47:15 55:1 103:10	change 23:14 50:21
86:18	B-A-U-T-I-S-T-A	78:10,19 79:13	caused 41:6	84:16
better 62:9 89:11	15:4	89:1,13 90:14	causes 49:1 77:20	changed 96:17
90:23,23 93:7,23	Wolf	98:4 99:3,6,7	94:15	changes 57:15,19
97:21	<u> </u>	100:13	cell 18:2,8,11,17,20	83:21
between 88:8	calendar 35:20	carcinomas 19:6,13	18:23,24 19:4,5,6	
beyond 65:21 69:15	call 44:22 69:10	20:14,18 69:10	19:10,11,14,19	chapter 26:14
70:1,7,11,13 71:3	called 1:16 3:7 45:7	77:10,11,25 78:3	20:2,8,11,14,19	chapters 30:3
bibliography 25:7	came 9:18	78:23 79:19 87:23	21:4 25:9 28:16	characterization
bills 68:10	Cancel 35:19	88:4,9,12 89:6	29:19,20 37:23	20:17
biologic 71:8,9 78:4	cancellation 41:4	93:17	41:9 60:4,13	characterizing 98:6
91:1,1,22 95:4 biologically 79:15	cancelled 41:2 cancer 13:19 16:4,5	cardiovascular	61:10,20 62:17	charge 27:18 68:1,4
biopsy 52:6 98:16	16:9 18:2,11,14	67:7	63:2,18 64:22	charging 67:24
98:18,23	19:10 21:13 24:2	care 13:10,16 31:4 31:9	69:10 70:12,25	cheat 59:4,6
bit 20:23 86:15	25:9,11,19,22	career 37:6	71:15 74:6,7,10	chemotherapy 62:2
bizarre 91:3	26:17 28:20,21	Caroline 15:7	74:15 75:2,6,10	72:9 89:18,20
black 48:23	30:5 34:5,6 37:23	case 1:7 4:14 5:23	75:11,14,15,16,20 75:24 76:5,22	chest 50:14 51:9,11
blastoma 26:4	41:9,11 45:20	6:1,19 7:8,11,13	77:9,9,10,11,14	51:14,20,22 52:5
blood 17:24 70:9	47:10,16 49:4,20	10:22 11:6 12:19	77:18,25 78:3,10	58:11,15 Chuck 36:24
83:16	· · · · · · · · · · · · · · · · · · ·	12:25 13:21 18:2	78:19,23 79:3,4	CHUCK 30:24
		12.20 10.21 10.2	10.17,23 19.3,4	

October 28, 2003

Page 3

	······································			
cite 91:25 92:7,10	comparing 89:1	28:17 29:3 31:9	24:11 26:18,19	definitely 50:2
civil 3:9 32:6,7	95:23	31:10 38:22 42:6	cytopathology	93:19
103:17	completed 103:14	45:9 50:24 53:7,8	17:16 27:5	definition 60:10
classified 56:17	completeness 59:7	56:6,8,10 57:16	C-O-T-T-L-E 15:3	degree 45:12 73:18
classify 19:9,9	complied 13:15	58:6,13,19 59:20		77:17 88:14 90:2
clearly 60:10	comply 31:4	62:14 63:21 74:7	D	demanding 27:24
Cleveland 2:7,14	component 19:18	81:10,18 82:2,19	D 2:4,12	depending 23:8
17:9 25:21 26:2	components 88:18	82:25 87:2 94:9	daily 29:11	51:24 61:24 78:4
33:20,23 43:4,8	92:22	100:6 103:12	Dan 79:6	depends 58:8 77:16
44:6,9 103:18	computer 7:1 34:20	corrections 68:15	DANIEL 1:5	87:25 88:13 90:1
clinical 21:16 22:1	concept 90:11	correctly 53:19	data 50:22 60:19	deposed 3:10
23:20 27:3 28:22	concern 29:21	correlate 84:10	61:15,18 64:8	deposition 1:12,15
47:13,20 52:12	concerns 64:15	correlates 16:21	date 1:24 7:21,24	3:2 4:6,18,23
62:21 72:21 74:2	concluded 102:5	90:25 92:12	8:18 9:3,6 10:19	11:17,22,23,24
80:13 84:11,13	concludes 50:9,10	Cottle 14:10 15:3	10:23 35:18 68:14	36:25 37:13,22
85:9 87:13 95:5	conditions 83:13	cough 55:2	79:21	40:24 42:14 43:10
96:8,12	conferences 27:20	counsel 1:16,21	dated 9:20 10:11	44:16 52:24 65:16
clinically 49:3	29:16	County 1:2 103:5	dates 46:19	65:22,25 67:24
59:22 61:21 69:6	confidential 35:9	couple 4:21 39:24	day 1:23 8:5 103:19	101:14 102:5
72:3,6 84:8 96:5	configuration 19:3	44:12 61:16 81:2	day-to-day 29:17	103:13
96:16	29:21	course 16:19 50:21	deal 65:13	depositions 11:14
clinician 28:14	confirm 51:5	60:23 79:17 89:5	dealing 38:3 75:20	11:20 12:1,6,14
29:22 99:12	connection 5:22	101:14	76:4 96:12	12:15 30:13,14
clinicians 57:5	12:19 76:16	court 1:1 5:6 31:22	death 37:21 38:3	35:7 36:1 38:9,13
close 48:10	consider 26:25 61:7	32:5,9 35:7 38:14	debate 82:22	41:1,23,25
closer 75:23 CME 21:25	61:18 64:3	66:1 103:16	deceased 1:5	describe 97:17,23
collection 23:5	consideration 19:8 considered 56:10	courtroom 30:17	December 9:21,23	98:9 100:9
64:13	56:25 58:18	30:22 31:17,25 32:16,17 33:20	10:4,11 45:23	described 25:12 73:15
Columbus 44:16	constitutes 72:21	35:12 38:10	46:14,15,17,18,20 47:1,25 48:18	describes 55:13
column 97:2,15	consultant 35:9	cover 9:18,20 10:10	49:13 50:14 52:17	describing 98:8
columnar 97:20	contact 66:19,23	12:1,1,2,3	52:18 53:7,10,11	100:6
98:2	contain 68:19	covered 101:9	53:20 54:6,10,11	description 52:12
combination 20:7	contents 91:5	create 71:3	54:14,17 80:14	52:21 100:10
79:3	context 31:16	criminal 32:5	81:3,4,4,15,17,20	descriptive 20:2
come 32:14 33:16	continued 23:12	criteria 19:7 56:11	82:10 85:20,23	97:22 99:25
40:8 65:6	35:16	58:9,20 59:24	86:4 87:19 95:7	DeShriver 28:4,5
comers 63:1,9	contract 103:17	90:24 92:4	100:13,23	details 33:2 59:8
comes 57:22 64:15	contralateral 73:1	critically 64:5,8	decision 28:22	determined 91:23
65:6 98:19	73:1,7	CT 73:13 78:14,15	99:15	determining 29:23
commencing 1:23	contribute 70:24	cubes 97:2,15	declined 26:20	32:2
comment 61:2	contributes 71:10	cuboidal 97:20	deem 65:10	develop 27:9 65:19
commented 53:6	83:18	culture 83:11	defendant 2:10	86:7 89:9
comments 52:16	controversy 83:4	curable 69:22	31:13,15 36:4,5	developed 27:15
commission 103:24	copies 24:4,20	current 42:6	37:5 38:1	46:8 86:22 100:16
commissioned	copy 8:4 22:20 24:7	cut 101:17	Defendants 1:10	100:20
103:8	- 24:25	Cuyahoga 1:2	defense 31:7 33:16	devote 26:23
common 1:1 27:11	corner 8:11,25	103:5	42:24	diagnose 45:13,19
75:21	correct 3:24 4:19	CV 14:1,5 17:19	defer 102:1	68:23 69:22 94:16
Community 1:21	6:12,15,17 8:19	20:25 21:5,18	deficiencies 64:7	diagnosed 18:6
comorbidities	8:20 9:14 10:17	24:14,22 25:4	define 19:4 52:7	60:4,5 61:21
71:24	10:18 13:12 15:18	26:12 30:2,2	defined 103:17	71:14,22 72:5,17
compare 57:13	15:19,21 18:3,14	cytology 17:19,20	definite 49:19	72:23 73:11 76:13
92:14	18:24 19:6 20:4,9	17:22,23 21:21,24		86:10 92:3,21

Page 4

[£	
93:2,8,11,12,17	53:10,12 54:8,8	E	69:14,16,25 70:1	exceeds 83:14
93:20,24 94:19	54:17 55:17,22	each 5:3 11:25 64:9	70:2,6,6,7,13 71:3	excised 62:1
96:14	56:2 72:24 73:5	earlier 34:10 70:24	75:25 76:1 90:16	excision 61:25
diagnosis 18:6	79:17 84:24,25	72:1 74:5 79:17	90:18	exclude 82:4 88:20
20:24 21:4,13	85:5,17,18 87:20	80:12 84:25 89:5	equal 89:10	excluding 37:25
24:1 25:11,23	88:5 89:6,8,17	89:23 90:5 91:9	ESQ 2:4,12	exclusively 15:9,10
34:10 45:23 48:15	99:5	93:20	essential 99:11	Executor 1:4
48:21 49:19,22	disseminated 22:21	early 42:10 48:20	essentially 34:9	exhibit 5:18,19 7:5
53:13 54:22 56:5	distal 78:25 79:9	52:25 53:11 54:19	Estate 1:4	10:2 12:17 14:1
78:6 80:10 82:12	distant 78:7	67:23 68:23 69:2	estimate 39:18	25:2
86:23 92:17 95:2	divide 84:6	84:24 85:4,16,17	86:18	Exhibits 3:3 104:4
99:19	DNA 91:4	87:24 88:23 92:3	estimates 39:15	104:5
diagnostic 47:14	doctor 24:10 25:3	93:12	et 1:9	existed 81:20
48:24 50:5,22	32:19 38:5,12	easier 11:21 32:12	evaluating 16:1	existence 51:6
51:12 99:8	45:10 47:7 54:2	easy 21:7	even 4:17 19:17	expect 60:8 100:5
die 34:6 62:20,22	55:10,11 63:24	edition 56:23,25	25:11 33:10 50:13	experience 30:8
92:9	68:22 79:23 81:9	57:6,8,14,19,20	51:16 62:20 66:25	37:2,3,5 38:9
difference 88:7,10	101:8,22	education 16:23	77:8 78:15 82:22	82:15 84:23
differences 57:9,11	doctors 12:5 39:8	educational 25:6	90:8 92:1 95:20	experimental 73:25
71:9	51:18 52:13,16	26:3	96:15,16,18	expert 4:1 10:13
different 18:13	65:13	Edward 15:3	event 103:15	15:21 16:17,22
19:10 20:1,10	document 52:3	efficacy 82:23	events 48:19	27:17 30:22 36:2
21:22,22 26:5	documented 77:15	effusions 58:23	ever 30:16,21 37:22	37:15 38:2,25
32:14 34:11 43:20	documents 7:15	eight 26:10	44:25 45:4 67:16	39:8,19 45:2
60:20,24,25 74:6	doing 48:11	either 20:15 31:23	91:17,19	48:25 61:2
74:6,8,24,25	dollar 70:20	33:20 38:3,12	every 59:3 64:8,8	expertise 27:6 82:9
94:18 98:10 100:8	done 4:24 5:1 47:14	44:21 49:24 52:23	64:14 66:25	experts 66:6
differential 53:13	50:14,23 51:4,24	66:22 70:5 78:7	everything 64:5	expires 103:24
differentiated	73:25 79:23 101:8	78:24 79:8 87:5	81:6,12 86:8	explain 32:21
19:18 20:11,14,16	double 83:8 84:7	98:17,22 99:7	94:22	101:14
20:19,20,21 29:19	doubling 73:24	103:15	evidence 46:3 47:8	exponential 83:23
74:12 77:18,24	82:19,24 83:5,6	elongating 75:17	47:11,12 48:25	83:24
78:3 79:19 88:19	84:2,3	employ 91:4	49:3 50:2 51:14	express 19:20
90:3,8,14,17	down 5:7 24:25	employed 14:9,11	52:11 54:13,16	expressed 11:8
91:14	73:4	encompassing	55:12,16,16,21	extended 46:20
differentiation	Dr 3:19,19,21 4:2	39:12	60:9 69:6 72:22	76:6
19:17,20,22,24	11:17,22,23,23	end 53:16 54:14	evidentiary 65:12	extending 58:14
20:16 74:8 77:17	13:10,15 15:11	64:18	exact 57:9 62:5	extent 61:6 95:17
78:21 88:14,15	28:4,5 31:3,8,15	ended 24:15,22	63:14 71:18 79:10	99:5
90:2	41:5 45:24 46:7	enough 12:4 46:5	79:21	eyes 97:25
Diplomate 1:19	46:11,21,25 48:18	72:13,15 92:3	exactly 10:17 17:20	
direction 32:14	52:21 53:5 54:7	93:2	41:1,3 48:11	F
director 17:18,19	54:15,24 55:13,18	enter 25:14	62:15 78:16 79:9	fact 5:21 8:19 9:2
directors 27:18	55:21,24,25 66:4	entire 7:13 32:25	79:20 81:21 87:12	57:20 62:11 63:8
disappear 89:19	66:7,7,19 67:2,3,4	98:20	91:21 93:5 97:11	78:19
disclosing 35:5	67:5,6,10,13,16	entirely 30:1 62:1	exam 52:12	factors 62:3,4,13
discovered 47:12	67:17,19,20,20	68:17	examination 1:17	63:13 70:23 71:1
77:23 78:1	81:5 85:23	entity 77:15	3:8,12 52:3 104:2	80:8,9 83:16,17
discussing 26:6 Discussion 17:5	dropped 36:23	environment 74:1	examinations 48:24	87:25 96:12
	duly 3:9 103:8,9	83:11	84:17,18	fair 5:16 10:22
35:21 43:24 discussions 29:15	during 22:14 46:25	epidemiological	examining 16:11	11:11 13:22 38:8
disease 49:4,21,25	101:14	70:17	example 44:20	59:9 65:9 66:18
50:4,6,11,18		epithelium 69:11	100:2	72:13,15 87:20
50.4,0,11,10				

Page 5

				
fairly 66:18	39:9 40:22 42:25	103:13	going 4:12 5:20 7:3	hereinafter 3:10
fairness 6:22	62:14,19 68:11		13:24 14:18 30:7	hereunto 103:18
fall 18:16,19 83:2	86:17,19,21,21	G	34:22 62:18,19,21	high 62:6 79:14
falling 18:7	five-year 61:3,20	gave 23:11 25:21	64:25 65:18 81:14	80:11 84:19,22
familiar 12:5 56:19	63:3,10 92:9 93:1	general 1:22 20:23	86:14 87:4 99:13	85:7 87:9 89:2
familiarity 66:14	focus 13:18 20:25	25:11 27:8 62:9	gold 52:1	90:24 91:2,8,12
family 41:5	30:7 45:17	69:1 72:1 75:10	gone 42:14,19	91:16,18 92:1,5
famous 36:12 64:6	focusing 21:23	80:2,6 84:3 88:11	good 60:16 69:1	92:13,21 93:11,16
far 38:13 68:8	follow 8:4 55:5	93:23 95:20 96:13	Gordon 1:18 43:22	93:21 94:1,8 95:3
fast 91:6	following 74:3	97:8 98:1,11	43:23 103:8,22	higher 62:10
faster 70:24	follows 3:11	generally 4:11	grade 62:5,6,6	hilar 58:15 73:2,6,7
fatigue 101:4	foregoing 103:12	56:18 57:1,18,21	79:14,18 80:11,11	Hillcrest 67:12
fault 24:17	forgot 67:23	58:4,18 59:19	84:20,22,25 85:7	him 16:11 53:20
fax 8:3,3,21,22,24	former 47:23	63:8,10 64:23	85:9 87:9 89:2	54:15 55:22 66:10
faxed 8:5,18,19,21	forth 1:24 84:9 99:9	65:11,15	90:24,25 91:2,7,8	66:11,14,23
24:14	103:11	Georgia 44:14,20	91:10,12,12,17,18	histologic 18:25
features 56:16 58:9	fortunate 92:2 93:2	gets 59:10 71:3 99:3	92:1,5,13,14,18	29:6 80:11 85:6
80:23 91:1	found 36:20 52:5	99:7	92:21 93:16,21	95:3
February 45:14,20	founded 27:14	getting 12:11	94:1,8 95:4	histologically 62:7
47:9,16,19,24	four 14:23 19:21,22	Gill 1:4,5 13:10	grades 93:11	histology 17:18,21
48:7 49:2,11,13	26:4 30:20 31:20	18:5,10 19:14	gradually 27:25	17:24 63:16
50:3,7 51:2,5	32:15,22,25 33:9	20:25 35:15,22	greater 59:13 71:21	histories 22:13
52:7,14 73:20	33:9 38:19 39:9	39:12,17 40:23	94:6	history 49:22
94:17	40:25 41:13 42:8	46:6,10,24 47:9	group 14:12,15	hold 4:14 15:20
feel 68:16 101:12	42:25 68:11 73:15	47:15,18 49:3,20	17:7 63:15 96:8	16:17 64:2 68:20
fellow 36:9	fourth 14:18 21:20	50:18 51:1 52:8	grouped 18:17	96:25 101:10
fellowship 17:15	frame 100:19	52:13 53:11 54:20	grow 77:19 84:16	holding 56:22
femur 101:1	frequently 76:6,13	54:23 72:17 80:7	grown 83:11	hospital 1:22 14:6,7
few 14:3,5 27:22	76:15	80:15,22 81:8,16	growth 73:24 82:17	29:14 32:19 36:16
42:8 61:16 82:11	from 7:18 9:9,13,17	85:12 94:16	83:15,18,21	38:6,12 44:22
86:11,13,14,16,19	10:4,11 11:5 12:1	100:12,16	guess 55:1	67:8,12,15 98:12
95:16 96:4	12:2 16:1 17:12	Gill's 45:14,19 72:4	guessing 8:24	hospitals 15:12
field 69:8	17:14 18:10 20:10	79:6 85:4 92:20	guesstimate 68:12	17:9 23:7 25:21
fifth 39:10,18	23:15 29:9,23	gist 43:18	guest 21:10	26:1 36:10 66:12
figured 43:9	30:1 32:14 33:3	give 4:21 21:13	guided 98:18,22	host 83:19
file 6:7,10,16 23:18	43:19 44:21 46:23	52:22 63:13 80:4	guideline 84:4	hour 67:25 68:1,3,6
65:25	47:5,13 48:16,22	86:17 87:18 97:9	guidelines 61:13	hours 21:25 68:7,11
find 65:14,17 72:15	52:11,12,23,23,24	given 21:2 35:6	guy 43:21	Howard 2:4 22:19
findings 28:16 29:4	53:24 54:19 55:3	36:1 37:12 40:24	GYN 26:18	hypothetically 72:6
47:21 51:25 52:25	56:1 65:7,12	44:24 75:3 79:2	<u> </u>	92:20
fine 3:20 98:18	66:11 70:16 76:1	86:8 87:8 101:13	H	
finishes 5:10	78:24 79:8 81:25	giving 23:2 29:21	half 14:16,19 15:8	<u> </u>
firm 33:25 34:1,14	82:1,3 84:17	38:13	hand 5:20 103:18	ideal 83:10,12 84:6
38:22 43:19 44:13	87:10,13 91:18	glandular 19:23	Handbook 56:20	identification 3:4
103:16	92:4 93:14,15	70:6 78:21	hands-on 16:8	identified 4:1 12:16
firms 43:25 44:3,22	100:4	glass 10:5	Harley 43:22	35:6
first 3:9 10:3 17:14	front 59:5 68:13	go 5:10 9:10 24:25	having 29:1 54:21	identify 69:2 75:1
21:24 46:13 51:23	frozen 36:18	41:24 50:8 51:7	head 28:3	III 1:4
53:20 74:16 77:8	full 14:17,22,24	53:2,23 58:17	heard 91:20	illness 46:14 53:21
81:3 83:5 86:7	15:2 60:24	64:14 83:3 88:3	hectic 41:20	immunologic 83:19
87:10 103:9	full-time 15:5	93:4 95:15 99:14	held 17:17	important 67:22
five 21:8,10 26:2	function 71:7,8	God 37:8	her 21:7 40:11 47:5	75:1 89:16
30:20 31:20 32:15	further 51:25 86:12	goes 45:15 99:8	47:6 102:2	Inc 14:10
32:22,25 33:8	99:4 101:21			

Page 6

I				I
inception 91:19	involved 34:24	K	late 87:24 88:23	85:25 86:2 95:11
includes 12:17 62:4	36:17 61:4 66:17	Kaisi 1:12,15 3:2,7	later 88:5 93:13	limitations 72:16
including 14:21,22	66:17	3:12,16,19,20,21	latter 47:22	limited 69:13
14:24 39:1 40:23	involvement 16:8	103:9 104:2	law 33:25 34:14	101:17
inconsistently	52:14,20 53:1	Kampinski 36:24	38:22 44:13,22	line 46:5
90:19	54:14 55:12,15	Katherine 28:4	lawyer 38:18 40:10	lingering 55:2
increasing 42:5	59:19 60:9 82:1	keep 34:16 41:2	43:19	lining 70:2 76:1
INDEX 104:1	involves 31:11	kidding 14:20	lawyers 39:22 40:1	78:24 79:8
indicated 51:17	Iraq 17:1	kind 24:3 34:25	40:8 43:14 44:21	linings 69:11
indicates 88:22	issue 13:19 21:3	47:11 48:10 51:23	65:13 90:21,22	list 34:23 35:1 45:1
indicating 8:18	33:11 35:5 46:2	61:17	101:6,7	59:2
indication 52:23	issues 23:24 31:11	knew 60:22 66:11	lead 43:10 51:25	listed 25:24
indicators 29:2	37:19,20 38:4		leading 48:20	literature 60:23
indirect 94:11	64:15	know 4:11 8:1,15	least 43:16 44:11	64:13 88:21 92:7
infiltrate 50:15	issuing 97:5	8:21 9:2 10:16,23	51:23 59:14 65:22	92:10,11 93:15
influence 60:25	item 21:20	20:24 28:8 33:5	95:22	litigation 36:3
62:7	i.e 19:19	35:23 37:7 38:21	leave 24:24 72:11	little 14:13,20 20:23
influenza 53:14		44:18 46:10,12	101:24	67:11 86:15 91:14
information 29:22	J	47:18,18 48:19	lecture 23:6	live 29:3
34:25 57:21 61:8	J 1:4	50:13 51:8 54:19	lectures 21:1,10,12	living 72:14
61:9 64:4 80:13	January 7:25 8:1	55:4,7 57:6 62:22	21:12,19 25:20	local 78:7
95:5 97:10 99:12	9:3 45:14,20 46:4	62:23,23 65:6	30:3	located 70:9
initial 98:15	47:8,16,19,24	66:3,7,10,21 67:3	led 34:10	location 70:11
input 28:14 98:21	48:6 49:2,11,13	67:5,6,19 68:7	left 27:22 48:1	locations 21:22
intend 12:24 13:9	50:3,6 51:2,5	70:16,19,24 71:1	1	
45:18 46:1 64:19		71:18,20 73:23	80:15 87:15	long 14:11 16:14
85:21 86:1	52:7,14 54:18,19	74:21 76:11,19	left-hand 8:11,25	29:2 36:8 41:14
	54:24 55:3,3,6,11	80:1,22,23 81:6	lesion 52:4 58:12	46:10 67:13 76:12
intending 13:5	55:16,17,22 73:19	81:13 82:16 83:17	lesions 27:12	76:19 77:2 80:25
interact 67:9	80:19 94:16 95:12	84:1 85:17 86:9	less 41:21 56:9 58:5	84:5,16 85:14
interest 27:5,9,15	95:23 96:1,14	87:12,17 92:11,22	58:10,16 59:16,23	87:16,19
interested 103:15	. 99:18	99:17 100:7	60:6,8 66:24 67:1	longer 62:19 76:24
internal 15:15	Jim 40:6	knowing 81:5 86:9	94:7 99:18	look 9:5 19:3,8,25
interpret 27:13	journal 64:20,21	knowledge 16:20	let 4:21 9:12 32:12	21:5 25:4,17 27:7
interpretation	65:1,2	62:25 65:17 72:16	54:3 57:23 81:2	38:16 41:15 47:5
16:18 33:2,6,11	Judge 1:7	73:23 82:16 84:23	90:20,21,22	53:23 54:1 64:4,7
36:19	July 17:12 94:19	known 3:16 49:22	lethal 91:6	64:14 94:3 96:13
interpreting 36:22	95:13,25 96:2,19	67:13	letter 9:18,20 10:3	97:25 98:13,20
interruption 6:6,13	99:19	knows 71:5	10:10	looked 48:14 97:1
interval 87:10	juncture 90:4	kodachrome 22:15	letters 9:10	looking 6:3,7 7:18
intervals 74:4	June 103:24	23:5	let's 6:14 37:2	9:9 13:8 15:25
intrinsic 62:3 83:16	junior 28:1	kodachromes 22:12	56:22 100:1	28:9,10,13 48:25
invade 69:15 70:13	just 4:21 6:22 7:21	23:3	Levitan 66:7,8,19	56:3 57:20 81:13
77:19	8:9 10:23 11:11		67:17	86:9 96:1 98:7,9
invaded 56:14	14:3,20 20:23	L	Levitan's 11:17,22	looks 19:2 23:12
69:25	21:7 24:21 25:1	L 1:18 103:8,22	life 88:24	24:10
invades 70:7	33:8 41:4 43:9	lab 33:3	light 96:25	lot 63:12 64:7 82:18
invading 58:10,11	44:16 47:5 54:3	language 32:13	like 17:18 19:11	82:22 83:4 87:25
invasion 58:14 69:8	55:8 58:16 59:12	large 61:15 76:5,22	22:19 23:12 24:10	89:15 93:10 94:11
invasive 51:24	62:13,24 66:13	77:23 78:1	24:18 33:9 38:17	98:4,5 100:3
76:16	72:15 75:16 86:15	larger 75:24 99:21	41:4,18 44:19	lots 89:20
invited 21:9,14 25:3	87:18 94:3 95:20	last 12:10 16:7	66:25 83:6 84:15	low 62:6 90:24 91:7
30:3	97:24 99:5 101:8	24:10 26:12 33:19	94:12,12,21	91:10,12 92:14,18
involve 33:6		45:10	likely 61:19 72:2	lower 8:11,25 79:18
		40.10	79:7 81:16 85:11	84:25

Page 7

			1	1
lumen 77:20	31:15 45:24 46:7	means 62:15 66:21	mets 48:8 80:20,24	motion 66:1
lump 75:11	46:11,21,25 48:18	79:15 85:18	82:5,7 101:4	move 4:22,25 30:1
lung 13:19 16:9	52:21 53:5 54:7	meant 60:22	microscope 19:2	Mt 36:16
18:2,11,14 20:19	54:15,24 55:13,18	mediastinum 58:11	96:23 97:12	much 23:14,17
21:12,13,19 24:2	55:21,24,25 66:4	72:25 73:1,5	microscopic 94:14	27:23 67:23 68:1
25:9,11,15,19,22	81:5 85:23	81:25	Midland 2:13	68:4 76:11 85:19
26:5,17 27:7,10	manual 57:4 59:25	medical 10:9,12,15	might 42:11	101:20
27:16,17,19 28:3	60:19 61:14	15:24 16:23,25	millimeter 22:17	multiple 73:2,8
28:9,20,21 30:4	many 4:9 14:14	19:25 23:6 30:22	millimeters 82:11	myself 14:24
37:23 41:9,11	17:10 25:20 30:19	30:25 31:12 39:1	95:16,22 96:4,19	mystery 18:1,4
45:14,20 47:9,16	31:21 32:16 38:1	45:12 48:23 61:2	million 70:20	M.D 1:8,12,15 3:7
49:4 51:6,12,15	38:15 39:6 40:5	61:4 64:4,10,13	mind 40:9 46:6	3:12 103:9 104:2
51:18 56:4 57:5,9	40:16,23 41:16,24	72:12 73:18 74:17	65:8	
57:12,15,22,25	42:22 46:16,24	82:3,6 88:21	minutes 14:5	<u>N</u>
58:4,18 59:3 60:4	68:7 71:2,6 78:21	90:20 99:23	Mishkind 2:3,4	Nadia 1:12,15 3:7
60:13,21 61:5,10 61:20 62:8,17	84:12 86:8 89:7 93:9	100:11	3:13 17:4 21:6	3:12,16,16 103:9
63:2,18 64:22	93:9 Marilena 40:12	medical/legal 30:8	22:19 24:18,21	104:2
68:23 70:25 71:15	mark 73:4	30:24 32:10 33:13 34:17,23	25:1 53:25 101:20	name 3:14 5:19
74:3,24 75:6,8,10	marked 3:3 5:18	34:17,23 medicine 15:15	104:3	34:13 35:2,3
75:20 76:25 77:9	104:5	meet 31:9	misleading 90:10	36:14,23 40:2,11
77:15 80:23 81:16	Marymount 15:12	meet 51:9 meeting 22:2,12,14	missing 7:22 mix 23:7	44:18,24 45:1
82:16,19 84:15	mass 52:4 71:12,13	22:14	mix 25:7 modalities 16:3	named 36:20 37:3,5
85:22 86:2,7 87:1	84:14 100:6	meetings 21:15,17	98:24	37:8,10 103:9
87:4 88:16,17,23	match 23:8	memory 47:6 53:24	moderately 20:20	names 15:1 40:8 43:13 44:2
89:9 91:17,18	material 6:3,8 9:13	mention 53:9,12	modifications	national 21:15,17
92:2 99:25 100:4	9:16,25 11:2,4,12	54:6,8,16 55:14	68:16	22:2
lungs 76:3 88:13	11:13 12:11,16,18	mentioned 17:7	molecular 72:7	nature 22:9 52:4
lymph 52:20 59:21	12:22,24 13:2,6	47:2 58:7 84:19	97:17,24	58:16
78:7	22:7,20 23:2,10	85:8 95:1	moment 26:13	necessarily 20:13
lymphatics 70:9	23:13,17,19 24:4	merkel 19:12	48:13	24:4 58:8 70:14
	24:5 27:12,19	Mester 43:21	month 53:16,17	83:25
<u> </u>	33:7,12 36:22	met 4:19 87:16 92:4	74:4	necessary 26:23
made 7:2 12:8	99:2	metaplastic 75:25	months 66:25	65:24
28:22 45:1,24	matter 34:3 41:5	metastasis 60:10	more 6:14 20:22	neck 48:2 52:19,25
68:16	matters 35:3	69:7 81:20,22	28:1 29:21 33:9	72:25 73:7 80:16
mail 8:5	may 5:5 20:1 21:6	85:12 100:16,20	36:5 50:11 54:1	81:24 87:14,15
main 53:13 55:1	23:16 28:19,23	100:22	57:7 58:1 65:12	100:20
major 57:11 77:12	29:3 32:10 33:10	metastasize 69:19	66:22,25 68:11	necrosis 83:14
make 6:19,22,24,25	48:13 51:25 62:22	70:11,13,15,17,18	71:10 72:2 73:25	need 50:11 68:16
8:9 21:7 24:6	62:23,23 65:5	71:11 79:17,21	75:9,13 78:22,25	needed 50:4
28:17 32:12 68:17	74:25 78:2,5,6	80:12 84:24 85:4	79:9,15 90:25	needle 98:18,19,22
75:7 80:9 92:9,19	86:13 96:15,16	87:10 88:5 91:9,9	91:6,14 92:8 97:9	negative 59:21
99:15 101:9	98:9 100:25 101:3	metastasized 78:6	99:7,25 100:8	negligence 30:23
malaise 101:4	101:3	79:13,22 80:3,6	Moskovitz 36:12	31:1,12
Malone 40:4,6	maybe 11:21 19:17	metastasizing 77:6	most 67:22 71:14	neuroendocrine
malpractice 31:18	39:24 41:18 42:25	metastatic 47:9,16	75:21 77:8,9,11	19:13 25:13
32:9,24 36:16 39:1	44:15 75:13	49:3,4,21,24 50:3	78:16 79:7 81:15	never 4:19 44:16
manage 99:12	ma'am 12:19 36:8	50:6,11,18 51:6	85:25 86:2 89:16	45:6 101:6
manage 99:12 manner 94:11	mean 5:7 18:4	53:10,12 54:8	93:12 98:17	new 38:16 41:15
Mansnerus 1:8 4:2	29:11 30:24 39:3 47:17 49:18 76:8	55:17,22 56:2	mostly 15:12 21:15	newer 61:18
13:10,15 31:3,8	77:2 78:12 81:21	71:4 72:24 73:5 81:16 85:22 86:2	24:1 25:22 32:2	next 4:25 7:3 35:11
****************	99:20,21	87:20 89:7 95:6	37:20 67:11 77:19	35:23
		07.20 09.7 99.0	80:8 90:1	

Page 8

				1
nice 61:14	Nurenberg 43:17	oncologist 15:24	origin 75:24 90:12	palpation 84:9
nodal 52:13 53:1	44:1	51:16 99:4	original 24:22	PAP 33:3
54:8,13,17 55:12	nutrients 83:12	oncologists 72:12	originated 78:11	paper 8:22
55:14 59:18 60:8		82:22	79:5,7	papers 64:5
node 52:20	0	oncology 15:18,21	originates 70:4	paragraph 45:11
nodes 59:21 73:2,6	object 5:5	15:23	75:22	parenthesis 21:25
73:8 78:7 84:15	objection 5:7,10	one 6:14 14:17,19	origination 75:19	Parma 1:21,22 14:6
nodules 73:2,8	7:23 47:4 49:5	15:6 19:2,3,5	other 5:3 12:15,18	15:9,11,12 29:14
none 41:8 59:24	50:8 51:7,13,21	20:5 21:23,25	12:22 14:14 15:1	67:8,14
nonetheless 95:8	53:2,22 55:19,23	22:4 23:7 26:5	15:6,11,25 19:6	part 14:17 15:22
noninvasive 69:3,5	57:3 63:6 65:21	27:17,25 32:23	28:16 30:5 31:24	23:5 27:23 31:18
76:9,20	68:25 71:17 77:1	33:1 34:4 36:4,6	32:8 33:4,5 37:3	48:20 54:19 61:14
nonsmall 18:2,8,11	83:3 89:14 93:4	36:24 38:1 39:8	37:6,12 38:17,25	participants 22:11
18:17,20,23,24	95:14	40:4,7,18 41:18	39:22,24,25 40:8	22:13 23:2
19:6,9,19 20:2,11	objects 5:9	42:11 44:11,15	40:19 43:21,25	particular 28:20
20:14,18 21:4	observations 84:11	56:23,24 58:3	44:1,4 50:1 55:6	65:2
25:8 29:19 37:23	84:11	61:1 64:3,9,15	56:16 58:8,20	parts 69:12
41:8 60:4,13	obstruction 77:21	66:25 67:7,22	59:24 60:9 62:3	party 36:3 103:15
61:10,20 62:17	obstructive 58:22	84:12 86:13 92:2	63:13 66:6 68:14	passing 66:13
63:2,18 64:22 70:12,25 71:15	77:21 obtained 44:19	98:7 100:5	68:15 69:12 71:24	past 42:8,8
74:7 75:6,9,11,16	\$	ones 18:19 41:3	76:17,25 83:17	pathologic 27:12
77:9,10 79:19	52:7	43:20 51:8 70:16	84:8 88:25 89:8	33:6 62:20 96:9
89:12,22,24 92:1	obvious 33:3 55:7 56:1	70:18 77:18	89:15 90:20 94:14	99:2
92:22 93:16,21	obviously 13:24	one-third 75:11	94:25 98:23 101:2	pathological 33:12
99:6	49:19 50:11 52:2	only 5:25 8:8 41:18	otherwise 19:13	72:22
non-small 75:12	59:22	54:21 56:11 61:25 75:4 84:3 85:6	37:9 103:15	pathologically
normal 90:18	occasion 36:6 38:24	95:21 96:19	out 15:20 16:17	57:24 59:22 61:22
normally 10:19	66:14	op 100:11	32:23 36:21 43:9	94:23
28:10 87:24 90:5	Occasionally 5:5	operate 71:25	51:5 62:17 64:9	pathologist 3:23
Notary 1:19 103:8	occasions 81:9	opinion 13:14 29:8	65:17 72:15 outcome 13:21	14:8 17:17 27:3
103:22	occurred 36:17	29:18 34:9 46:1	34:11 94:17	44:23 60:2 90:9 98:7,8,12
note 47:4 53:2,22	OCTOBER 1:13	50:21 60:11 61:6	outlined 17:19	
65:21	off 17:4,5 35:18,19	61:19 64:23 78:9	outside 18:16,19	pathologists 14:14 15:5 21:16 22:2
notes 6:4,9,9,11,16	35:21 43:24	79:25 81:4,15	44:8 58:17 60:7	23:20 28:1 82:23
6:19,24,25 7:2	101:17	85:10,20 86:3,25	76:23 77:6 97:6	90:19 99:11
12:8 53:10 54:7	office 2:5 8:6,13	87:9,19 92:24	over 14:13 23:13	pathology 14:10
55:2	103:18	95:19,21 96:17	42:2 74:3 98:13	15:22,23 16:21,22
nothing 36:21 60:7	offices 1:21	100:12,15	Overall 41:22	17:7,15 26:24
101:21 103:10	often 67:9 92:8	opinions 4:14 5:23	overlapping 5:3	27:4,7,7,8,10,16
noticed 7:21	Ohio 1:2,20,23 2:7	11:5,7 12:24 13:9	98:5	27:17,19 28:3,10
notify 65:23	2:14 3:8 43:2	13:20,25 64:1	oversight 10:24	29:12 36:22 37:19
November 35:13,17	103:3,8,19,23	68:20 101:10,12	own 43:9	37:20 38:4 52:2,6
52:25 64:18	okay 5:3,4,11,12	101:15	o'clock 1:23	85:3 94:11
103:19	10:6 24:9 30:9,10	opportunity 8:8		patient 16:9,10
nowhere 8:17	35:9,10 50:20	65:24 101:13	<u> </u>	28:24 29:2,8,23
nuclei 91:3	65:4 66:1,2 70:22	opposed 8:12 16:3	P 1:5	34:5,6 46:11,20
number 22:4 25:5,6	75:18 85:15 96:6	29:22 32:24 42:24	page 21:8,10,18,20	48:5,6 49:15,18
25:18,18 26:3,8	old 61:17 90:11	87:24 88:23,25	24:13,15,15,22	49:23 50:6,10
26:10 39:14 71:7	omission 68:14	89:12	25:2 26:2,3,8,10	51:18 52:18 53:6
71:11 94:2,4	omitted 10:23	order 50:1	26:12	55:5,9,18 60:4
numbness 48:1	once 31:23 66:22,25	ordered 51:10	pages 24:23	61:21 62:2 80:14
49:17 52:19 80:15	70:7 71:2	organs 57:10 89:8	pain 101:1,5,6	80:18,20,21 85:12
				93:18 99:1,3,7,13
			1	L

October 28, 2003

Page 9

I	1		I	1
101:2	plan 65:12,14	80:15 85:10 87:14	provided 3:8 27:13	range 41:15 62:12
patients 16:4,5	PLEAS 1:1	presenters 22:4	83:12	63:4,20 80:2,6
29:16 62:14,16,16	please 3:14	presents 50:13	provides 13:1	rate 32:3 63:19
63:15 64:16 66:16	pleura 58:11,14,23	press 86:15	providing 13:20	74:14,17 83:14,21
71:14,19,22 74:3	Plevin 43:17 44:1	presume 38:21	28:14	85:7 88:8
84:12 88:17 92:8	pneumonia 45:24	96:23	proximal 77:11	rates 82:17
92:13,14 93:20,22	49:17 53:13 54:22	pretty 23:14,17	proximate 37:21	rather 47:23 71:7
patient's 28:15	77:21	85:19 89:25	38:3	71:11 75:17
50:12	pneumonitis 56:15	previous 49:22	Public 1:19 103:8	read 5:15 11:25
PC 7:1	58:22	primary 18:7 49:24	103:22	12:2,4 50:15
peer 25:6 26:7	point 20:5 22:8,17	73:12 87:1	publications 25:7	101:22,25
people 100:7	45:16 69:24 79:10	principle 96:13	26:3	really 30:25 33:4
per 41:13,21 68:1	100:18	printed 23:10,13,19	published 64:6	42:7 44:2 57:8
percent 38:11	polygonal 98:3	24:4,5	pulmonary 21:21	61:12 63:13 71:6
62:13 63:4,11,20	poorly 19:18 20:11	prints 8:22	21:24 26:4,19	74:21 76:11 83:7
71:21 94:7,7	20:13,16,19 29:19	prior 12:11,22	pulmonologists	84:5 86:12 87:12
percentage 63:14	74:11 77:24 78:2	22:14 46:25	27:21	89:16 90:1,9,18
75:7	88:19 90:3,7,16	privileges 45:7	pure 78:18,22	90:25 94:2 97:25
percentages 71:18	91:13	probability 45:12	purpose 51:10	99:24 100:4
perfect 101:7	position 14:7 17:13	73:18 79:12	65:16 97:5	reason 50:17 55:6
performed 74:2	positions 17:18	probable 85:11	purposes 3:4 10:1	84:12 93:10 94:25
perhaps 8:12 57:19	possession 22:25	92:25	75:5,5	reasonable 45:12
94:22 98:16	possible 4:23 45:13	probably 4:10 8:3,5	purse 97:13	73:18
period 46:21 77:3	45:19 68:24 69:4	33:8,8 34:10	pursuant 1:20	reasonably 63:25
80:1 92:23	94:16	39:13,21 40:25	put 10:19 37:2	reasons 62:22 95:1
periodically 23:12	potential 13:20	41:25 44:3 63:22	57:23 68:8 91:13	recall 44:1 46:12
periods 76:7,25	70:10,15 78:5	63:23 66:24 68:11	96:22	53:19 63:23 97:8
peripheral 77:13	potentially 16:2	76:20 80:2,24,25	Putting 35:22	received 9:13,16
77:14 78:2,22	65:24 69:18,18	81:24,25 82:11	p.m 1:23 102:5	10:4 11:2,12,14
periphery 76:17	power 22:8,16	85:13 86:11 87:16	*****	11:16,19,21 12:13
peritoneum 100:2	Powers 1:22	95:16 96:3,18,21	Q	receives 61:22
person 14:19 27:20	practice 17:8,10	100:19	qualified 60:2,11	recognize 36:14
61:1	29:11	Procedure 3:9	61:2,5 96:11	recognizing 9:6
personality 91:19	precautions 4:22	proceed 5:8 98:24	101:12 103:9	recommendations
person's 86:13,14	prefer 3:18	process 65:19	quarrel 63:4	61:13
perusal 6:10	preferably 69:3	professional 66:15	question 4:25 5:1,6	reconvene 65:25
phenomenon 71:4	preparation 64:11	prognoses 61:3	5:8,9,11,13 7:3	record 3:15 11:11
71:21	prepare 7:8,14 9:23	prognosis 28:15	16:6 45:8 49:8	17:4,5 21:8 24:7
physically 16:11	prepared 7:12,19	60:3,12,20 61:10	60:16 70:21 72:11	24:21 35:21 41:2
physician 31:18	9:8 10:17	62:8,8,9 64:23	76:18 96:11	43:24
48:4,6 50:10	preparing 9:14,17	93:6,7,18,22	questions 4:12,13	records 9:9 10:9,12
98:25	10:25 11:13	prognostic 29:1	14:4 27:21 30:9	10:15 20:1 34:16
physicians 27:21	presence 58:21,22	62:12 75:5	67:22 81:2	47:5 48:23 49:8
64:6	58:23 95:5	progress 7:12	quicker 89:23	49:10,12 51:1
pinpoint 79:10	present 89:7 92:11	progressed 29:9,23	quickly 25:17	52:12,16,22,24
pitfalls 84:2	presentation 22:3,6	progression 32:3	quote 64:25	53:23 54:2 56:1
place 8:14 16:24	22:17,21 23:4	74:14,17		68:2 82:4,6
92:6 103:14	47:20,25 51:19	protocol 57:24	<u> </u>	reduced 103:11
placed 8:12,15	52:17 80:14,25	protocols 60:25	radiation 72:9	refer 7:16 32:10
plaintiff 1:6,17 2:2	85:13	provide 12:25 13:5	radiologic 84:17,18	59:2 60:18 65:5
31:12 42:23,25	presentations 2.2:8	13:9 22:7,11,13	radiological 16:18	75:16 83:6,9
plaintiff's 5:19	30:3,4	24:3,7 29:8,18	radiology 16:18,20	97:15 98:1
43:14,25 44:5	presented 23:19	31:7 34:22 60:11	16:22	reference 54:13
	24:11 38:15 49:16	98:21 99:10,11		

October 28, 2003

Page 10

	T	1	1	
referenced 10:1	8:21,23 9:5,7,7,14	46:23 47:7 48:16	Seacrist 40:14,15	85:9 87:13
12:17 21:2	9:17,23 10:1,2,14	51:14 52:11 54:20	40:17	similar 93:23
references 20:1	10:17,25 11:7,8	85:3 97:10	seal 103:18	Sinai 36:16
23:16 25:16	11:13 13:8 29:15	reviewed 6:18 7:11	Seattle 22:2	since 67:14 97:4
referrals 44:21	45:10 50:16 68:13	7:15 9:25 10:13	second 10:10 77:16	single 61:1
referred 3:18 20:6	68:15,17,19 73:13	12:10,18 25:6	section 36:18 64:20	sit 12:21 13:3 94:5
99:4	97:5,6	26:7 39:24 40:5	65:2	site 75:21
referring 51:9 55:2	reported 25:13	40:16 42:2,14,22	see 6:4,8 16:5 20:1	sites 78:8 84:8 95:6
74:21 78:14 99:21	63:19	43:8,14 44:4,8	20:5 21:11 48:18	situ 69:10,13 76:8
refers 58:4 60:19	reporter 1:19 5:6	68:10 80:18 97:4	50:4 52:23 54:16	76:12,15
69:8 91:22	reporting 103:16	97:4	55:10 56:22 57:15	situations 37:14
regard 13:10,18	reports 7:7 8:4	reviewing 12:22	72:7,8,20 76:15	83:10 84:6
regarding 33:2	10:12,13,20	18:10 27:19 49:15	90:5 97:2,11	six 21:10 38:19
regardless 58:12,24	100:11	51:1 68:2	100:10	40:22 41:13 86:17
59:10 60:14 91:23	representing 32:19	reviews 68:3	seeing 16:10 48:4,6	sixth 39:10,18
91:24 92:23	38:5,12 42:23,24	revoked 45:7	seen 46:6,13,17,24	size 56:4,14 58:25
regimen 61:23	represents 8:2 9:3	right 3:22 4:20	63:17,22 80:18	71:12 73:11,19
regions 58:15	request 24:6 34:22	12:21 13:3 31:6	81:5,9 82:18,21	80:9 82:9 84:16
Registered 1:18	38:5,11,25	41:6,7 48:11	85:23 98:2,3	85:8 91:24 92:15
regular 66:19,21	required 72:9	54:25 57:17 59:5	seminars 21:14	95:2,9,23,24,25
relate 13:20 25:22	research 64:10	86:13 92:6,6 94:5	25:4	99:18,22
related 15:23 21:11	resect 99:14	Rob 21:6 24:18	sending 11:1	skin 69:12
21:13 29:5 37:21	resectable 72:3,6	ROBERT 2:12	sent 9:11	Skylight 2:5
49:24 95:6 101:3	resection 98:15,19	ROGER 1:8	sentence 45:15	slide 22:8
relates 15:22 16:20	resemblance 90:11	roughly 87:5	75:17	slides 10:5,5,8
26:4 57:14 64:21	resemble 90:15,17	routine 4:11	separated 32:23	12:18 15:25 18:10
relationship 46:8	resident 16:13	routinely 16:6	separately 25:24	19:21,22 22:15
46:13 53:21 66:15	36.15,17	Rozman 67:2,3	serial 84:18	24:5 48:14 68:2
relative 103:15	resources 63:24	rule 51:5 103:17	serve 38:24 39:7	72:8 85:3 86:9
relevance 23:23	respiratory 48:1	Rules 3:8	Services 14:10	94:14 96:22 97:4
25:8,10	49:16	Russo 1:7	serving 38:2	97:11 98:14
relevant 12:23 21:3	respond 74:25	<u> </u>	set 1:24 22:12,15	slower 77:19
reliable 57:1,5,21	response 83:19	<u> </u>	35:23 103:11,18	small 18:22 88:6
61:7 63:25 64:24	responsibilities	same 21:7,9 23:14	seven 26:3,8	89:3,4,12,19 99:3
65:11,15,20	26:1	23:17 32:13 54:12	several 19:7 21:21	smaller 82:12 95:10
remember 33:1,4,7	responsibility	55:23 62:20 73:2	27:18 56:16 66:6	95:12,17 96:1,4
33:25 34:3,13	27:25	73:8 74:9 90:4	74:3	96:18 99:21
37:24 40:2,11,21	responsiveness	92:15,15,16,16,17	shape 97:23,25	smears 33:3
41:1 43:12,13,18 44:2 46:16,22	89:17	98:9 100:19	shaped 97:2,16	smoothly 4:23
47:3 52:15 57:8	result 84:14	saw 53:6,11,20	sheet 59:4,6	Society 21:16 22:1
57:11 59:1,7 68:9	retained 32:18	54:15 55:18,21	short 14:20 15:6	23:20
94:2	33:16 34:1 36:2	56:2 94:13 96:19	shortly 13:25	solely 22:5 51:19
Reminger 2:11,11	37:15	saying 13:14 30:25	show 94:1	some 9:13 11:2 14:4
38:22,22 39:3,3	retrospect 47:17 48:2 80:16	35:8 81:7 85:20 96:11	side 73:3,8	23:23 25:10 28:14
39:23,23,25,25	retrospectively		Signature 102:6	29:1 30:9 38:17
40:20,20	48:12 81:7,14	says 45:11 scan 78:14,15	signed 8:4	39:25 42:14,19
render 46:1 101:12	return 54:24	schedule 41:20	significance 11:6 56:5	44:10,13 55:6
rendering 61:6	returned 54:18,21	scheduled 35:11,24	significant 69:6	56:5 57:10,19
repeat 55:20 94:20	55:6,9,9	55:5,8	88:10 94:23 96:5	60:19 61:5 62:18
rephrase 5:15	revealed 47:13	school 16:24,25	96:16	62:19,21,22 64:5
report 5:21,25 7:1	review 7:13 10:8,8	23:6	significantly 95:10	65:19 70:23 71:1 74:1 76:17 84:8
7:4,9,12,14,16,17	10:15 41:14,24	scientific 91:15	signs 20:15 47:20	93:20 100:8,9,10
7:19,20 8:11,17	44:17,23 45:11	いっかいれいははない ノス・ミン	50:12 52:20 56:2	<i>93.20</i> 100.0,9,10
	· · · · · · · · · · · · · · · · · · ·		50.12 52.20 50.Z	

Page 11

I		1	1	
somebody 35:8	75:25 76:4,21	statistic 63:5,17	surgeons 67:8	100:21
someone 7:6 8:12	77:9,11,13,17,25	statistically 29:3	surgery 72:10 99:9	teaching 25:25
22:19 29:18 49:21	78:3,10,19,20,23	63:2 89:10	surgical 17:15 27:4	Telephone 6:6,13
50:9	79:4 87:23 88:4,8	statistics 63:1 92:1	27:8 28:11,13,17	tell 4:9 5:14 7:18
something 22:24	88:12,17 89:1,6	93:25	61:25 71:16,19,23	9:7 11:20 14:21
25:18 34:19 35:5	89:24 90:5,13,16	status 52:8	98:14	15:1 25:17 42:22
65:6,10,14,20	90:18 98:4 99:6	statute 1:17	surprised 100:10	46:23 65:8 73:17
97:16	SS 103:4	stay 76:5,24 77:2	surrounding 69:16	74:15 78:16 79:12
sometime 10:14	staff 17:16	stays 76:12,19	70:8	79:21 80:4 81:19
sometimes 15:13	stage 28:21 29:9,9,9	steady 42:7,9	survival 60:12 61:3	82:3,8 87:13,17
37:20 83:14,20	29:10,18,24,24	Steele 67:19	61:15,20 63:3,10	93:5,25 94:6,13
89:19	32:2 57:5,24	Steele's 11:23	63:19 89:11 92:9	94:22 97:11 99:13
sorry 24:16 32:11	58:24 60:5,10,12	Steinetz 15:7,11	92:12,12,13,25	tells 84:4
55:20 60:21 81:11	61:10,21 62:8,11	stenotypy 103:11	93:1,22 94:7,8	temporal 46:7
97:14	62:17,21 63:1,9	still 27:7 28:5 91:25	survive 62:14,18	ten 41:17 42:2,10
sort 20:7,23 59:4	63:18 69:2,3,9,13	92:8	survivor 94:1	term 74:16,17,20
62:12 66:13	69:17,23 71:15,22	stoma 69:17 70:8	suspect 48:7 49:18	74:22 81:7 90:8,9
source 57:1,5,21	72:2,5,5,18,19,22	stop 45:16	50:17	90:23 91:11,13,16
64:3	76:8,9,12,15,20	Street 2:6	suspended 45:7	91:18,20 99:23,23
spaces 79:1 span 88:24	81:19 86:2,5,10	strike 46:4 75:15	suspicion 16:9	99:24 100:6
	88:5 89:17 92:3,3	structure 28:16	Sutherland 67:20	terms 4:12 6:10,23
speaking 32:13 56:18 57:18 58:4	92:15,16,21,24	72:8 79:3 97:1,17	Sutherland's 11:23	16:8,23 18:6 19:4
59:19 87:5	93:2,7,8,12,13,17		sworn 3:10 103:10	20:2 23:10 28:19
specialists 61:4	93:21,24 94:1,8 95:18,24 99:8	structures 56:15 studies 47:14 48:24	symptoms 47:20	38:9 46:6 54:12
90:20	stages 60:20 62:10	1	48:1 49:16,17,23	58:3 61:9 62:12
specialty 26:25	staging 13:19 16:2	50:5,22 51:4 60:24 61:16 63:20	50:12 81:14,25	63:1,9,18 75:6,19
27:4 51:17	21:3 28:20,20	74:2 93:15 99:4	82:2 85:9 87:14	82:23 93:18 96:7
specific 19:20 25:12	29:5 56:20 57:2,4	4	87:15 95:6 101:2	97:22 100:8
29:16 63:15,15,16	57:16,22 58:3	study 17:23,24 subcategories	system 83:19 S-T-E-I-N-E-T-Z	test 51:23,24
65:1 97:10 100:18	59:3 61:8,9 64:22	19:10	15:7	testified 30:11,16
specifically 52:15	96:7,8,9,12,17	subject 23:8 34:3	15.7	30:21 31:16,21,22
63:23 64:12 93:6	stamp 8:10,14,15	57:18	T	31:25 32:5,9,16 32:17 33:19 35:4
specifics 14:4 59:1	8:21	subjectivity 98:5	T 58:24	35:7 37:22
97:8	stand 13:13 64:18	subsets 60:24	take 5:6 16:16 19:8	testify 8:9 33:17
specified 103:14	standard 13:15	subspecialties 27:6	21:5 37:18 38:16	34:1 35:12,23
specify 86:12	31:4,9 52:2	subspeciality 27:1	45:6 62:16 64:18	45:18 60:3 64:19
specimen 28:17	standpoint 11:5	substitute 25:2	71:2 87:8	68:4 85:21 86:1
specimens 16:1	16:1 47:13 65:12	Sue 40:13,14,15	taken 1:18 4:6,18	103:10
28:11,13	70:17 92:5 100:4	suffice 10:16	30:13 51:9 103:14	testifying 12:23
spectrum 42:10	start 5:2 21:20 69:9	sufficient 72:21	takes 71:6 83:7	32:24,25 38:4,9
83:2 86:20 87:7	69:11 76:22	sufficiently 12:4	84:5,15	testimony 8:10
speculating 87:18	started 27:15 41:17	suggest 92:7	taking 13:13 83:13	37:13 38:10,14
spread 59:12,18	67:14 78:17 79:10	suggestive 50:16	83:15,18,21	40:24 41:25 43:11
60:6 69:19 70:11	starts 21:19 70:3	53:1 55:17	talk 4:3 8:8 13:24	53:15 103:11,12
70:24 87:24 88:8	state 1:20 3:14 43:1	Suite 2:5	20:22,23 37:13	tests 51:25 99:8
88:22 89:5,23	85:2 103:3,8,23	supply 83:16	48:13	thank 37:8 46:3
90:4,5 91:6	stated 54:4 59:24	support 64:1	talked 30:5 42:17	66:3 101:20
spreading 76:7,23	statement 6:15	sure 25:20 31:2	66:16 67:16 93:16	their 12:6 61:6,14
77:4,5	13:22 47:22,23	32:12 34:25 54:5	talking 18:1 23:24	61:15 71:8,9,10
squamous 19:5,11	65:9 69:1 74:12	62:11 81:12 92:19	38:20 41:22 63:14	78:4 82:17 88:14
19:14,21 20:8,15	74:23 80:5 87:21	101:9	86:16,17 88:16	themselves 99:16
69:10 70:5 74:10	statements 68:10	surgeon 98:22,25	91:12 94:10 97:7	therapy 72:10
74:14 75:14,15,20		99:13		~ `
L				

Page 12

	I			1
thing 48:12	84:2,3,5,16 85:13	tree 77:12,20 78:12	79:16,18 80:12	unfortunate 37:4
things 84:15 89:10	85:14 86:6 87:16	78:25 79:9	83:9 84:5,14,22	University 17:9
think 7:15 10:3,24	92:6,16,16,23	trial 34:8 42:19	88:25 90:15 91:2	23:6 25:21 26:1
11:10 12:7,13	95:2 98:16,22	45:18 65:18 68:5	91:3,5,7,8,8,8,10	36:9 44:22 66:12
19:16 20:5 21:6	99:19 100:18,19	85:21	92:13,14 93:10,23	unless 8:20 13:1
21:20 26:10,22	100:25 103:14	tried 44:15	97:7 100:2	63:14
30:6 32:7 35:15	times 4:9,10,18	true 9:3,4,18 11:2	twice 31:23 46:18	unlikely 49:20
38:7 41:10,12,17	30:12,19,20 31:20	11:18 12:8,9	48:18	until 4:24 5:1,9
41:21 44:10 47:2	31:21,24 32:4,8	13:11,16,17 14:1	two 15:1,5 19:16	26:13 65:7 84:6,7
49:21 52:17 53:9	32:15,17,22,23,25	15:15,16 17:2	26:8 32:23 33:5	100:25
53:12,18,19 58:20	35:25 37:12,25	18:8 20:12 23:21	41:18 43:16,20	updated 23:16
61:4 63:22 64:25	39:6,9 41:24	24:12 28:11,24	46:19 65:19 66:25	upgrade 58:23
65:3 68:18 71:5	46:16,24 73:16	29:24,25 30:12	80:8 81:9 86:16	upgraded 57:7
72:11 73:1,15,21	78:21 82:19,24	33:17 37:16 42:15	two-thirds 75:13	upstages 59:25
74:5 75:9 78:15	89:7	46:8 50:7 51:6	type 7:7 19:3 26:5	use 22:16 23:5
79:11 80:19 81:6	tissue 17:25 36:19	52:9,10 57:22	28:22 29:6 44:25	57:24 74:16 86:19
86:5 94:24,25	52:3 69:16 90:12	61:11 81:17 85:24	62:5 63:16 71:8	90:8,24 91:11,13
97:19 101:8,16,19	title 18:17	89:13 95:13 96:2	74:1 75:2 83:11	91:16,17 97:23
thinking 100:22	today 4:3 6:4 12:12	96:20 103:12	84:22 87:8 88:22	100:7
though 4:17 23:11	14:6 26:6 41:6	trust 102:2	89:2 95:3,4	used 23:3 51:11
25:12 33:10 50:13	65:17 67:24 94:4	truth 103:10,10,10	typed 6:9,16,25 7:5	81:6 90:19 91:20
51:16 62:20 63:17	. 97:13	try 4:22 5:14 6:14	7:16	97:16 99:25 100:1
77:8 90:8 95:21	today's 65:21	19:8 64:8 91:14	types 18:24 19:1,16	using 74:22 82:24
96:15,16	together 12:11	trying 19:4 73:4	74:6,6,8,24 76:25	100:5
thought 53:5 65:18	75:12	97:19	98:2	usually 7:7 8:3,22
65:19 75:25	told 48:17 74:5	TUESDAY 1:13	typically 29:7 51:18	10:7 23:7 44:22
three 14:13,16,17	94:15,21,23	tumor 18:7 19:9,19	76:24 97:16 98:14	51:11,22 59:2
14:22,24 15:8,10	101:11	20:18 26:5,9 29:6	T1 56:10,12 58:4,19	60:18 61:15 69:9
19:17 21:25 32:8	Tom 43:20	29:15 32:3,3	60:1	70:3,8 73:25
40:25 42:8 44:4	topic 25:8,19 30:4	45:14 52:4,8 56:4	T1-N0 59:20	75:23 76:22 77:19
56:9 58:5,10,17	total 14:16 21:10	56:9,12,14,17	T2 59:14	77:23 78:23 79:16
59:10,13,16,23	42:21	58:5,9,16,24 59:9	T4 56:17 58:12	80:12 83:9 85:1
60:6,8 67:15 80:9	touch 30:4	59:13,16,18,23,25	¥7	88:23 89:6 91:4
86:17,19,20,21	touching 25:19	60:1,5 62:1,4,5,6	<u> </u>	98:2,17 99:3
through 6:3,7 19:25	Tower 2:5	69:22 70:3,8,10	UH 15:13 17:13	100:1
25:4,17 41:3	tracheobronchial	70:25 71:3,13	27:13,17,23 28:1	.
throw 94:3	77:12,20 78:25	72:2 73:9,11,12	28:2,5 41:19	<u>V</u>
time 6:14,18 12:10	79:8	73:19,24,24 74:9	66:20 98:13	vague 74:20 90:9
12:13 14:17,17,22	training 27:2 84:24	76:16,18 78:17,18		90:19
14:25 15:2 16:7	93:15	78:20 79:14,14,16	undated 10:2	variables 88:20
22:11,16 24:10	transcribed 103:12	79:20,22 80:2,10	under 1:17 19:2	89:16,21
26:22,23 27:14	transcript 101:23	82:9 83:7,8,10,13	25:25 26:7 96:22	varies 61:24
33:1,19 34:7 36:4	transcription	83:15,18,20,22	103:16	various 17:17 18:24
36:15 37:6 38:1	103:12	84:2,3,20 85:4,7	understand 4:3,15	18:25
39:19 46:5,13,21	transfer 27:24	87:2,8,10 89:2	5:13,14 8:7 30:25	verify 54:3
47:18 48:2,3,8,14	transparencies	90:11,15 91:2,22	31:2,5 56:3 62:24	version 21:9
50:17,19,23 51:3	22:18 treat 51:18 00:1	91:23 95:2,4,10	64:17 85:19 92:19	versus 53:14 88:9
52:9,17,20 53:6	treat 51:18 99:1	95:11,23,24,25	95:19 96:10	88:13 90:24 92:13
53:20 54:9 56:5 59:3 73:10,25	treating 16:3,8	96:1,2,9,18 98:2	understanding 13:4	92:17 95:24
76:7 77:22 78:5	treatment 16:2	98:20 99:14,17	63:9	very 25:17 27:11,24
78:16 80:1,2,10	28:23 60:14,15,17	100:3,9	undifferentiated	41:19,20 59:14
80:13,24,25 82:5	60:25 61:9,12,23	tumors 25:12,14	19:12	64:6 65:22 67:11
82:7,12 83:5,7	63:16 75:1,2,4 91:24 92:17 98:24	27:11 69:9 74:3	unequivocal 6:23	75:1 84:5,5,16,16
00.1,1400.0,1	71.24 72.17 70.24	77:23 78:1,22		

Page 13

85:11 90:10,11	well 5:16 9:12	worry 35:8	1400 2:13	4:10 102:5
91:3 101:20	15:12,13 16:5,19	wouldn't 35:4 50:4	15 4:10,18 30:12	44113 2:7
vessels 70:9	18:5,9 20:20,20	100:5	35:25	44115 2:14
visible 84:7	21:19 22:5 25:10	write 26:19,23	17 21:2,10	457639 1:7
visit 55:11	27:11 33:1 36:4	written 6:5,9,16	19th 9:21,23 10:11	
vitro 74:1 83:11	37:7 38:10 54:3	22:7 29:15	1986 17:12,14	5
Vivian 1:18 5:15	54:15 56:11 57:23	wrong 56:8	1986-87 16:15	5th 56:24 57:6,14
103:8,22	60:16 61:12,24	wrote 26:14	1987 17:15 36:10	50 71:21 94:7,7
volume 83:6,8 84:3	63:12 65:9 70:20		1994 22:3 23:11	,·
voluminous 25:16	71:5 72:1 74:1,20	X	1995 87:5,8	6
vs 1:7	75:5 77:8,15,18	X 62:13	1997 87:5,8	6th 55:3,6,11 57:8
	78:2 79:4,18,25	x-ray 47:21 50:14	1998 24:12	57:14,19,20
W	80:9 83:4,5 85:8	51:9,11,14,20,22	1999 24:13 45:23	60 63:3,10,20
W 2:6	85:9 89:15 90:7	52:5 84:8,13	46:15,25 47:1	660 2:5
wait 4:24 5:1,9	90:14,21 95:4	02.0 0 1.0,10	50:15 54:7,17	687-1311 2:15
waive 102:3	97:3,19 98:25	Y	81:17,20 82:10	007-1511 2.15
waived 102:6	99:24 100:7 101:2	yeah 99:10	86:22 95:7	7
wall 58:12,15	went 41:3 44:16	year 17:14 23:15,15	00.444 73.1	7007 1:22
want 6:22 8:9 9:10	48:20 100:25	33:22 34:4 38:15	2	10011.22
14:3 20:25 35:1	were 3:3 11:14 17:2	38:19 41:13,19,21	2 3:3 5:19 7:5 10:2	8
37:13 45:15,16	19:21,22 22:4,17	42:6,10,11 57:7	12:17 29:9 104:5	8 103:24
47:5 54:2 62:24	25:13 31:17 32:4			
63:13 64:17 72:15		years 14:13 17:10	2nd 2:6	80 63:3,11,20
88:19 90:7 92:19	32:5,6,7,9,23	21:22 23:13 27:18	20th 35:17	9
	33:12 35:9 37:3	27:22 41:16,17	2000 17:12 45:15	
95:20 97:9 101:9	38:1,2,4 41:8,11	42:3,8,9 61:16,17	45:20 47:19,24	9 8:1 9:3 47:1
101:22,25	41:21 43:1,4,16	62:14,19 67:15	48:7,20 49:2,11	9th 7:25 10:4 46:18
wanted 22:20 55:9	43:20 44:3,12	76:20 86:8,11,21	49:13 52:14 54:24	53:7,20 54:7,10
wants 53:24	47:14 49:10,12	86:21	55:3 80:10,19	54:11 81:4
Warner 2:12 5:5,22	50:23,25 51:2,4	younger 27:25	86:24 87:11 94:17	95 87:11
7:23 8:19 9:11,13	52:25 57:20 66:19	Youngstown 44:11	95:3	99 49:14 100:13
9:17 10:4,11 11:1	74:11 92:6 104:5		2002 9:21,23	
13:1,4 24:6,7,20	WHEREOF 103:18	<u> </u>	2003 1:13 7:25 8:1	
24:24 35:16,19	while 38:20 95:9	\$300 68:3	9:3 103:19	
38:17,21 39:1,6	98:3	\$400 67:25 68:6	2004 103:24	
39:20 40:23 47:4	white 48:23		241-2600 2:8	
49:5 50:8 51:7,13	whole 103:10	1	25 41:25 42:1,13,21	
51:21 53:2,22	WILLIAM 1:4	1 3:3 14:1 25:2 29:9	28 1:13	
55:19,23 57:3	wind 36:11	60:5,10,12 61:10	28(D) 103:17	
63:6 65:23 68:25	witness 1:15 3:7	61:21 62:8,11,17		
71:17 77:1 79:23	10:13 30:22 35:17	63:1,9,18 71:15	3	
83:3 89:14 93:4	37:15 102:1	71:22 72:5 92:4	3 29:9,24	
95:14 101:24	103:18	92:21,24 93:3,17	3rd 103:19	
102:2	woman 40:10	94:1,8 104:5	3:13 104:3	
Warner's 8:6,13	words 50:1	1:30 1:23	3:3 104:5	
41:5	work 7:12 15:8,10	10 25:18	30th 46:18 54:17	
way 27:15 30:2	worked 40:20	100 38:10 62:16,18	81:4	
43:10 57:23 66:3	working 66:11	11 21:20 24:15,22	35 22:17	[
72:7 86:19 98:10	67:14	25:18 37:25		
101-5 19	works 15:11 67:11	12 4:10,18 24:13,15	4	
101:5,18		24:22 25:2 30:11	4 29:10,18,24 72:19	
ways 74:25	workshop 21:21,24			
	24:11			
ways 74:25	24:11	35:25	72:22 86:2,5 93:8	
ways 74:25 week 54:21 66:23	· · ·			